Note: Descriptions are shown in the official language in which they were submitted.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-1-
INSOLi?SL$ COMPOSITIONS FO1Z CONTROLLING BLOOD GLUCOS$
Background of the Inveation
1. Field of the Invention. This invention is in
the field of human medicine. More particularly, this
invention is in the field of pharmaceutical treatment of the
diseases of diabetes and hyperglycemia.
2. Description of Related Art. It has long been
a goal of insulin therapy to mimic the pattern of endogenous
insulin secretion in normal individuals. The daily
physiological demand for insulin fluctuates and can be
separated into two phases: (a) the absorptive phase
requiring a pulse of insulin to dispose of the meal-related
blood glucose surge, and (b) the post-absorptive phase
requiring a sustained delivery of insulin to regulate
hepatic glucose output for maintaining optimal fasting blood
glucose.
Accordingly, effective therapy for people with
diabetes generally involves the combined use of two types of
exogenous insulin formulations: a rapid acting meal time
insulin provided by bolus injections and a long-acting, so-
called, basal insulin, administered by injection once or
twice daily to control blood glucose levels between meals.
An ideal basal insulin will provide an extended and "flat"
time action - that is, it will control blood glucose levels
for at least 12 hours, and preferably for 24 hours or more,
without significant risk of hypoglycemia. Furthermore, an
ideal basal insulin should be mixable with a soluble meal-
time insulin, and should not cause irritation or reaction at
the site of administration. Finally, basal insulin
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/2~299
-2-
- to be readily, and uniformly resuspended by the patient
prior to administration.
As is well understood by those skilled in this
art, long-acting insulin formulations have been obtained by
formulating normal insulin as microcrystalline suspensions
for subcutaneous injection. Examples of commercial basal
insulin preparations include NPH (Neutral Protamine
Hagedorn) insulin, protamine zinc insulin (PZI), and
ultralente (UL) .
Early versions of present-day commercial NPH
insulin that contained a surplus of protamine were developed
in the 1930's by Scott, et a1. [J. Pharmacol. Exp. Ther.
58:78, et seq. (1936)] and Hagedorn, et al. [J. Am. Med.
Assoc. 106:177-180 (1936)]. In 1946, NPH insulin having
isophane proportions of insulin and protamine, together with
zinc, were developed by Krayenbuhl, et al. [Rep. Steno Mem.
Hosp. Nord. Insulinlab. 1:60, et seq. (1946)]. These
workers found that when insulin and protamine were combined
in so-called isophane proportions at a neutral pH, in the
presence of zinc and a phenolic compound, that an amorphous
precipitate formed, and that upon standing the amorphous
precipitate was transformed into oblong, tetragonal crystals
having pyramidal shaped ends. These crystals have been
described as rod-like. The isophane ratio of insulin and
protamine sulfate is observed to be about 0.09 mg of
protamine sulfate per mg of insulin. Zinc is needed in an
amount of at least about 3.5 ~g per mg of insulin, and a
phenolic compound at a concentration higher than about 0.1%.
Insulin NPH is the most widely-used insulin
preparation, constituting from 50 to 70 per cent of the
insulin used worldwide. It is a suspension of a
microcrystalline complex of insulin, zinc, protamine, and
one or more phenolic preservatives. NPH insulin
preparations are commercially available incorporating human
insulin, pork insulin, beef insulin, or mixtures thereof.
Also, NPH-like preparations of a monomeric insulin analog,
LysB298,ProB29-human insulin analog, are known in the art
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-3-
- [abbreviated herein as "NPL": De Felippis, M. R., U.S.
Patent No. 5,461,031, issued 24 October 1995; De Felippis,
M. R., U.S. Patent No. 5,650,486, issued 22 July 1997; and
De Felippis, M. R., U.S. Patent No. 5,747,642, issued 5 May
19981. It is widely accepted that insulin NPH provides
extended control of blood glucose compared with regular
insulin because insulin must first dissolve from the insulin
NPH microcrystals before it can be absorbed. With regular
insulin, there is no dissolution needed prior to absorption.
For insulin NPH, dissolution is the rate-controlling step in
determining the pharmacodynamics and pharmacokinetics.
NPH insulin microcrystals possess a distinctive
rod-shaped morphology of typical dimensions about 5 microns
long by 1 micron thick and 1 micron wide. The extended
duration of action of NPH insulin microcrystals results from
their slow absorption from the subcutaneous injection site.
Therapy using currently-available NPH insulin
preparations fails to provide the ideal °flat"
pharmacokinetics necessary to maintain optimal fasting blood
glucose for an extended period of time between meals.
Consequently, treatment with NPH insulin can result in
undesirably high levels of insulin in the blood, which may
cause life-threatening hypoglycemia.
In addition to failing to provide an ideal flat
pharmacokinetic profile, the duration of action of NPH
insulin also is not ideal. In particular, a major problem
with NPH therapy is the "dawn phenomenon" Which is
hyperglycemia that results from the loss of effective
glucose control overnight while the patient is sleeping.
These deficiencies in glycemic control contribute to serious
long-term medical complications of diabetes and impose
considerable inconvenience and quality-of-life disadvantages
to the patient.
Protamine zinc insulin (PZI) has a composition
similar to NPH, but contains higher levels of protamine and
zinc than NPH. PZI preparations may be made as
intermediate-acting amorphous precipitates or long-acting
CA 02315300 2000-06-20
WO 99!32116 PCT/US98IZ7299
-4-
crystalline material. PZI, however, is not an ideal basal
insulin pharmaceutical because it is not mixable with a
soluble meal-time insulin, and the high zinc and protamine
can cause irritation or reaction at the site of
administration.
Human insulin ultralente is a microcrystalline
preparation of insulin having higher levels of zinc than
NPH, and not having either protamine or a phenolic
preservative incorporated into the microcrystal. Human
ultralente preparations provide moderate time action that is
not suitably flat, and they do not form stable mixtures with
insulin. Furthermore, they are difficult to resuspend.
There have been attempts to address the perceived
inadequacies of known insulin suspensions. Fatty acid-
acylated insulins have been investigated for basal control
of blood glucose [Havelund, S., et al., WIPO publication
W095/07931, 23 March 1995]. Their extended time action is
caused by binding of the fatty acyl portion of these
molecules to serum albumin. The fatty acyl chain lengths of
these molecules is such as to take advantage of the fatty
acid binding capability of serum albumin. The fatty acid
chains used in fatty acid-acylated insulins are typically
longer than about ten carbon atoms, and chain lengths of
fourteen and sixteen carbon atoms are optimal for binding to
serum albumin and extending time action.
Unlike NPH insulin, which is insoluble, the
aforementioned fatty acid-acylated insulins are soluble at
the usual therapeutic concentrations of insulin. However,
the time action of these preparations may not be
sufficiently long enough, or flat enough, to provide ideal
basal control, and they are less potent than insulin,
thereby requiring administration of greater amounts of the
drug agent [Radziuk, J., et al., Diabetologia 41:116-120,
489-490 (1998) ] .
Whittingham, J. L., et al. [Biochemistry 36:2826-
2831 (1997)] crystallized B29-NE-tetradecanoyl-des(B30)-
human insulin analog as a hexamer complex with zinc and
CA 02315300 2000-06-20
WO 99/32116 PCT/US98I27299
_5_
- phenol for the purpose of structural studies by X-ray
crystallography. The hexamer was found to be in the R6
conformation, and to have certain properties different from
hexamers of human insulin. Whittingham, et al. do not
disclose any pharmaceutical or pharmacological properties of
the crystal that was formed, nor do they suggest that such a
crystal would have any advantageous properties for treating
diabetes or hyperglycemia. It is not possible to predict
from Whittingham, et aI. whether protamine-containing
10~ crystals of the NPH type could be formed with derivatized
insulins and insulin analogs, or what the pharmacokinetics
or pharmacodynamic response of such crystals would be.
Thus, there remains a need to identify insulin
preparations that have flatter and longer time action than
NPH insulin, that are mixable with soluble, meal-time
insulins, that can be readily resuspended, and that do not
pose risk of irritation or reaction at the site of
administration. I discovered quite surprisingly that these
properties are provided by insoluble compositions that
include a derivatized protein, an un-derivatized protein,
zinc, protamine, and a phenolic preservative. In addition
to the properties mentioned above, the insoluble
compositions provide flexibility of control over the
duration and shape of the glucodynamic response profile.
They are thought to function as controlled release
compositions, wherein, the release rate is controlled by the
proportion and nature of the derivatized protein. Thus, one
aspect of the present invention is an insoluble composition
comprising an un-derivatized protein, a derivatized protein,
a complexing compound, a hexamer-stabilizing compound, and a
divalent metal cation. Other aspects of this invention that
relate to the preparation, formulation, and use of such
compositions will be discussed herein.
There are no examples known to me of mixtures of
derivatized and un-derivatized insulins, as those terms are
to be understood in the context of the present disclosure.
Crystals comprised of proinsulin and insulin [Steiner, D.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-6-
F., Nature 243:528-530 (1973); Low, B. W., et al., Nature
248:339-340 (1974)] and crystals comprised of a insulin or
an insulin analog having approximately the same isoelectric
point as insulin and an insulin analog having additional
basic amino acids [Dorschug, M., et al., U.S. Patent No.
5,028,587, issued 2 July 1991] are known.
Steiner produced crystals comprised of proinsulin
and insulin with mole ratios of about 1:11, 1:5, 1:2, and
1:1, respectively (i.e., 0.5, 1, 2, and 3 moles of
proinsulin per 6 moles total insulin and proinsulin) in
0.095 M sodium citrate, pH 6.0, 0.03 M NaCl, 0.012 M ZnCl2,
and 16% acetone. The proportion of proinsulin greatly
affected the rate of crystallization. The crystals differed
greatly from those of pure insulin under the same
conditions, and were characterized as rhombohedral crystals
with rounded borders. There was great variability within
and between preparations. The utility ascribed to
crystallizing proinsulin and insulin was that it facilitated
isolating small amounts of proinsulin and related structures
from pancreatic extracts. The author speculated that
crystallization may occur between precursor and product
peptides, and among other closely related proteins.
Low, B. W., et a1. produced very large crystals
comprised of equimolar proportions of beef or pork insulin
and their respective proinsulins, wherein the proinsulin and
insulin were formed into homogenous hexamers prior to
crystallization. Analysis by X-ray crystallography and
quantitative electrophoresis supported a conclusion that the
unit cell in the crystals was formed of twelve insulin
hexamers and twelve proinsulin hexamers. It was
specifically stated that no studies were known to suggest
that insulin and proinsulin form mixed dimers and hexamers
in solution.
DBrschug, M., et a1. disclosed crystals comprised
of insulin, des(Phe81) insulin, des(ThrB30) human insulin,
or des(AlaB30) beef insulin, and at least one insulin having
a basic modification at the C-terminal end of the B chain
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-7_
- ("modified insulin"). Such modified insulins are disclosed,
for example, in European Patent Application No. 132,769.
Globin or protamine sulfate were stated to be auxiliary
compounds that could be used in the crystal preparations.
There are no examples of the use of protamine, nor any
suggestion that the.inventors appreciated the effect of
adding such compounds. Furthermore, the modified insulins
used in DBrschug, et al. are different than the derivatives
used in the present invention.
As mentioned above, I have unexpectedly observed
that when a protein selected from insulin, an insulin
analog, and proinsulin is made less soluble in an aqueous
solvent or more lipophilic by derivatizing one or more of
its reactive side groups, the derivatized protein and an un-
derivatized protein selected from insulin, an insulin
analog, and proinsulin can be incorporated into insoluble
precipitates and into NPH-like crystals with protamine.
When such proteins are jointly precipitated or crystallized
to form insoluble compositions, the rate at which the
proteins dissolve from the insoluble composition is greatly
reduced compared with the rate at which physically similar
insoluble compositions comprised of un-derivatized protein
dissolve.
I have furthermore discovered that both amorphous
precipitates and microcrystals comprised of derivatized
protein, protein, a complexing compound, a divalent metal
cation, and a hexamer-stabilizing compound provide flatter
and longer time action than do physically similar
microcrystals comprised solely of un-derivatized protein.
Additionally, I have surprisingly discovered that the
benefits of flatter and longer time action can be obtained
even from amorphous precipitates comprised of one of the
proteins and a derivatized protein.
Summary Of The Iaveation
Accordingly, in its broadest aspect, the present
invention provides insoluble compositions comprising a
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-g_
- derivatized protein selected from the group consisting of
insulin derivatives, insulin analog derivatives, and
proinsulin derivatives, a protein selected from the group
consisting of insulin, insulin analogs, and proinsulins, a
complexing compound, a hexamer-stabilizing compound, and a
divalent metal cation. The derivatized protein is either
less soluble in an aqueous solvent than is the un-
derivatized protein, is more lipophilic than un-derivatized
insulin, or produces a complex with zinc and protamine that
is less soluble than the corresponding complex with the un-
.derivatized protein. The insoluble compositions of the
present invention may be in the form of amorphous
precipitates, or more preferably, in the form of
microcryatals. The microcrystals may be either rod-shaped
or irregular in morphology. These insoluble compositions
are useful for treating diabetes and hyperglycemia, and
provide the advantages of having flatter and longer time
action than NPH insulin. The insoluble compositions are
mixable in a formulation with soluble protein or with
soluble derivatized protein, or both. Furthermore, by
varying the ratio between protein and derivatized protein,
the extent of protraction of the time action can be finely
controlled over a very great range of time-action, from that
nearly the same as NPH insulin to much greater than that of
NPH insulin.
More specifically, the present invention provides
insoluble compositions of proteins and fatty acid-acylated
proteins that are useful for treating diabetes and
hyperglycemia. These compositions are comprised of fatty
acid-acylated protein selected from the group consisting of
fatty acid-acylated insulin, fatty acid-acylated insulin
analog, and fatty acid-acylated proinsulin, protein selected
from the group consisting o.f insulin, insulin analogs, and
proinsulin, protamine, a phenolic preservative, and zinc.
The present invention is distinct from previous fatty acid-
acylated insulin technology in that the extension of time
action of the present invention does not rely necessarily on
CA 02315300 2000-06-20
WO 99/32116 PCTNS98/Z7299
_g_
albumin-binding, though albumin binding may further protract
the time action of certain of the compositions of the
present invention.
The invention provides a microcrystal comprising a
protein selected from the group consisting of insulin,
insulin analog, and proinsulin, a derivatized protein
selected from the group consisting of derivatized insulin,
derivatized insulin analog, and derivatized proinsulin, a
complexing compound a divalent metal cation, and a hexamer-
stabilizing compound. The microcrystals of the present
invention are useful for treating diabetes and for
controlling blood glucose in a patient in need thereof.
The invention provides an amorphous precipitate
comprising a protein selected from the group consisting of
insulin, insulin analog, and proinsulin; a derivatized
protein selected from the group consisting of derivatized
insulin, derivatized insulin analog, and derivatized
proinsulin, a complexing compound a divalent metal cation,
and a hexamer-stabilizing compound. The amorphous
precipitates of the present invention are useful for
treating diabetes and for controlling blood glucose in a
patient in need thereof. They are also useful as
intermediates in the formation of the microcrystals of the
present invention.
The invention provides aqueous suspension
formulations comprising an insoluble composition and an
aqueous solvent. One such aqueous suspension formulation is
comprised of a microcrystalline composition of the present
invention and an aqueous solvent. Another such aqueous
suspension formulation comprises an amorphous precipitate of
the present invention and an aqueous solvent. The soluble,
aqueous phase of the present suspension formulations may
optionally be comprised of a protein, such as human insulin,
or a soluble analog of human insulin, such as a monomeric
insulin analog, that control blood glucose immediately
following a meal, and may additionally or alternatively be
comprised of a derivatized protein. The formulations of the
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-10-
- present invention have superior pharmacodynamics compared
with human insulin NPH, and their time-action can be
purposefully selected over a wide range, from just slightly
extended compared with human insulin NPH to very greatly
extended compared with human insulin NPH.
The invention also provides processes for
preparing hybrid hexamers, mixed hexamers, the amorphous
precipitates, and the co-crystals of the present invention,
The invention provides a method of treating
diabetes or hyperglycemia comprising, administering to a
patient in need thereof a sufficient quantity of an
insoluble composition of the present invention to regulate
blood glucose levels in the patient.
The invention includes hybrid hexamer compositions
comprising a protein selected from the group consisting of
insulin, insulin analog, and proinsulin; a derivatized
protein selected from the group consisting of derivatized
insulin, derivatized insulin analogs, and derivatized
proinsulins, and zinc. The hybrid hexamers of the present
invention are useful for treating diabetes and for
controlling blood glucose in a patient in need thereof.
They are also useful as intermediates in the formation of
the insoluble compositions of the present invention, which
are themselves useful for treating diabetes and for
controlling blood glucose in a patient in need thereof.
Hybrid hexamers are believed to be formed when a protein and
a derivatized protein are first mixed together under
conditions that strongly favor dissolution into lower states
of aggregation than the hexameric state, and second, the
conditions are changed to strongly favor the hexameric
aggregation state.
The invention includes mixed hexamer compositions,
comprised zinc hexamers of a protein selected from the group
consisting of insulin, an insulin analog, or proinsulin and
zinc hexamers of a derivatized protein selected from the
group consisting of a derivatized insulin, derivatized
insulin analog, or a derivatized proinsulin. The mixed
CA 02315300 2000-06-20
WO 99132116 PCT/US98/27299
-11-
- hexamers of the present invention are useful for treating
diabetes and for controlling blood glucose in a patient in
need thereof. They are also useful as intermediates in the
formation of the insoluble compositions of the present
invention, which are themselves useful fox treating diabetes
and for controlling blood glucose in a patient in,need
thereof. Mixed hexamers are believed to be formed when a
protein and a derivatized protein are first separately
dissolved under conditions that favor the hexameric
aggregation state, and then are mixed together under
conditions that continue to strongly favor the hexameric
aggregation state.
The invention includes the use of an insoluble
composition of the present invention to prepare a medicament
for the treatment of diabetes or hyperglycemia.
Brief Description of the Draaring
Figure 1 depicts the dissolution over a five-hour
period of co-crystals of the present invention having ratios
of human insulin to B29-NE-octanoyl-human insulin of 3:1 (~
~ ~), 1:1 (-), and 1:3 (~). compared with the
dissolution of a preparation of human insulin-protamine
crystals (....) .
Figure 2 depicts dissolution data from the same
experiments as depicted in Figure 1, but with the time axis
extended to show data for the 1:3 co-crystal up to about
13.5 hours. Dissolution of co-crystals of the present
invention having ratios of human insulin to B29-NE-octanoyl-
human insulin of 3:1 (~ ~ ~), 1:1 (-), and 1:3 (~) are
compared with the dissolution of a preparation of human
insulin-protamine crystals (....).
Figure 3 depicts the dissolution of co-crystals of
the present invention having ratios of human insulin to B29-
NE-octanoyl-human insulin of 1:1 ( ) and 1:3 (-),
compared with the dissolution of with microcrystals
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7299
-12-
comprised only of B29-NE-octanoyl-human insulin (~), or a
preparation of human insulin-protamine crystals (....).
Figure 4 depicts the dissolution of co-crystals of
the present invention having a 1:3 ratio of human insulin to
B29-Ns-octanoyl-human insulin (~), compared with
preparations of human insulin-protamine crystals (....),
human insulin ultralente ( ) and beef ultralente (-).
Descriptioa Of The Inveatioa
The term "mixed hexamers" refers to a mixture of
protein hexamers and derivatized protein hexamers, wherein
the protein hexamers are comprised of zinc and a protein
selected from the group consisting of insulin, insulin
analogs, and proinsulins, and wherein the derivatized
protein hexamers are comprised of zinc and a derivatized
protein selected from the group consisting of derivatized
insulin, derivatized insulin analogs, and derivatized
proinsulins. The level of zinc actually incorporated into a
hexamer is between about 2 and about 4 atoms of zinc per
hexamer.
The term "hybrid hexamer" refers to a hexamer
comprised of six monomers and zinc, wherein at least one
monomer is selected from the group consisting of insulin,
insulin analogs, and proinsulins, and at least one monomer
is selected from the group consisting of derivatized
insulin, derivatized insulin analogs, and derivatized
proinsulins. The level of zinc actually incorporated into a
hexamer is commonly known to be between about 2 and about 4
atoms of zinc per hexamer.
As used herein, the term "co-crystal" means a
microcrystal of the present invention.
The term "insoluble composition" refers to matter
in either a microcrystalline state or in an amorphous
precipitate state. The presence of microcrystals or
amorphous precipitate can be ascertained by visual and
microscopic examination. Solubility depends on solvent, and
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-13-
- a particular composition may be insoluble in one solvent,
but soluble in another.
The term "microcrystal" means a solid that is
comprised primarily of matter in a crystalline state,
wherein the individual crystals are predominantly of a
single crystallographic composition and are of a microscopic
size, typically of longest dimension within the range 1
micron to 100 microns. The term "microcrystalline" refers
to the state of being a microcrystal.
The term "rod-like" means the distinctive
microcrystal morphology that is also described as pyramidal-
tipped tetragonal rods. The morphology of microcrystals of
the present invention are easily determined by microscopic
examination.
The term "irregular morphology" is a
characterization of microcrystals whose morphology, as
determined by microscopic examination, is not readily
classified into any of the well-known crystal types, is not
a single type of crystal morphology, or is not readily
determinable because the size of the crystals is too small
for certain classification.
The term "amorphous precipitate" refers to
insoluble material that is not crystalline in form. The
person of ordinary skill can distinguish crystals from
amorphous precipitate. The amorphous precipitates of the
present invention have advantageous pharmacological
properties in their own right, and also are intermediates in
the formation of the microcrystals of the present invention.
The term "protein" may have its common meaning,
that is, a polymer of amino acids. The term "protein," as
used herein, also has a narrower meaning, that is, a protein
selected from the group consisting of insulin, insulin
analogs, and proinsulins. The term "un-derivatized protein"
also refers to a protein selected from the group consisting
of insulin, insulin analogs, and proinsulins.
As used in the claims, and elsewhere as the
context dictates, the term "total protein" refers to the
CA 02315300 2000-06-20
wo 99r~z i i 6 rcr~s9am299
-14-
combined amount of protein (insulin, an insulin analog, or a
proinsulin) and derivatized protein (derivatized insulin, a
derivatized insulin analog, or a derivatized proinsulin).
Although protamine and other known complexing compounds are
also proteins in the broadest sense of that term, the term
"total protein" does not include them.
The term "derivatized protein" refers to a protein
selected from the group consisting of derivatized insulin,
derivatized insulin analogs, and derivatized proinsulin that
is derivatized by a functional group such that the
derivatized protein is either less soluble in an aqueous
solvent than is the un-derivatized protein, is more
lipophilic than un-derivatized insulin, or produces a
complex with zinc and protamine that are less soluble than
the corresponding complex with the un-derivatized protein.
The determination of either the solubility or lipophilicity
of proteins and derivatized proteins is well-known to the
skilled person. The solubility of derivatized proteins and
protein in complexes with zinc and protamine can be readily
determined by well-known procedures [Graham and Pomeroy, J.
Pharm. Pharmacol. 36:427-430 (1983), as modified in
DeFelippis, M. R. and Frank, B., EP 735,048], or the
procedure used herein.
Many examples of such derivatized proteins are
known in the art, including benzoyl, p-tolyl-sulfonamide
carbonyl, and indolyl derivatives of insulin and insulin
analogs [Havelund, S., et al., W095/07931, published 23
March 1995]; alkyloxycarbonyl derivatives of insulin
[Geiger, R., et al., U.S. Patent No. 3,684,791, issued 15
August 1972; Brandenberg, D., et al., U.S. 3,907,763, issued
23 September 1975]; aryloxycarbonyl derivatives of insulin
[Brandenberg, D., et al., U.S. 3,907,763, issued 23
September 1975]; alkylcarbamyl derivatives [Smyth, D. G.,
U.S. Patent No. 3,864,325, issued 4 February 19?5; Lindsay,
D. G., et al., U.S. Patent No. 3,950,517, issued 13 April
1976]; carbamyl, O-acetyl derivatives of insulin [Smyth, D.
G., U.S. Patent No. 3,864,325 issued 4 February 1975];
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7299
-15-
cross-linked, alkyl dicarboxyl derivatives fBrandenberg, D.,
et al., U.S. Patent No. 3,907,763, issued 23 September
1975]; N-carbamyi, O-acetylated insulin derivatives [Smyth,
D. G., U.S. Patent No. 3,868,356, issued 25 February 1975];
various O-alkyl esters [Markussen, J., U.S. Patent No.
4,343,898, issued 10 August 1982; Morihara, K., et al., U.S.
Patent No. 4,400,465, issued 23 August 1983; Morihara, K.,
et al., U.S. Patent No. 4,401,757, issued 30 August 1983;
Markussen, J., U.S. Patent No. 4,489,159, issued 18 December
1984; Obermeier, R., et al., U.S. Patent No. 4,601,852,
issued 22 July 1986; and Andresen, F. H., et al., U.S.
Patent No. 4,601,979, issued 22 July 1986]; alkylamide
derivatives of insulin [Balschmidt, P., et al., U.S. Patent
No. 5,430,016, issued 4 July 1995]; various other
derivatives of insulin [Lindsay, D. G., U.S. Patent No.
3,869,437, issued 4 March 1975]; and the fatty acid-acylated
proteins that are described herein.
The term "acylated proteins as used herein refers
to a derivatized protein selected from the group consisting
of insulin, insulin analogs, and proinsulin that is acylated
with an organic acid moiety that is bonded to the protein
through an amide bond formed between the acid group of an
organic acid compound and an amino group of the protein. In
general, the amino group may be the a-amino group of an N-
terminal amino acid of the protein, or may be the E-amino
group of a Lys residue of the protein. An acylated protein
may be acylated at one or more of the three amino groups
that are present in insulin and in most insulin analogs.
Mono-acylated proteins are acylated at a single amino group.
Di-acylated proteins are acylated at two amino groups. Tri-
acylated proteins are acylated at three amino groups. The
organic acid compound may be, for example, a fatty acid, an
aromatic acid, or any other organic compound having a
carboxylic acid group that will form an amide bond with an
amino group of a protein, and that will lower the aqueous
solubility, raise the lipophilicity, or decrease the
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7299
-16-
solubility of zinc/protamine complexes of the derivatized
protein compared with the un-derivatized protein.
The term "fatty acid-acylated protein" refers to a
an acylated protein selected from the group consisting of
insulin, insulin analogs, and proinsulins that is acylated
with a fatty acid that is bonded to the protein through an
amide bond formed between the acid group of the fatty acid
and an amino group of the protein. In general, the amino
group may be the a-amino group of an N-terminal amino acid
of the protein, or may be the s-amino group of a Lys residue
of the protein. A fatty acid-acylated protein may be
acylated at one or more of the three amino groups that are
present in insulin and in most insulin analogs. Mono-
acylated proteins are acylated at a single amino group. Di-
acylated proteins are acylated at two amino groups. Tri-
acylated proteins are acylated at three amino groups. Fatty
acid-acylated insulin is disclosed in a Japanese patent
application 1-254,699. See also, Hashimoto, M., et al.,
Pharmaceutical Research, 6:171-176 (1989), and Lindsay, D.
G., et al., Biochemical J. 121:737-745 (1971). Further
disclosure of fatty acid-acylated insulins and fatty
acylated insulin analogs, and of methods for their
synthesis, is found in Baker, J. C., et a1, U.S. 08/342,931,
filed 17 November 1994 and issued as U.S. Patent No.
5,693,609, 2 December 1997; Havelund, S., et al.,
W095/07931, published 23 March 1995, and a corresponding
U.S. Patent No. 5,750,497, 12 May 1998; and Jonassen, I., et
al., W096/29342, published 26 September 1996. These
disclosures are expressly incorporated herein by reference
for describing fatty acid-acylated insulins and fatty acid-
acylated insulin analogs and for enabling preparation of the
same.
The term °fatty acid-acylated protein" includes
pharmaceutically acceptable salts and complexes of fatty
acid-acylated proteins. The term "fatty acid-acylated
protein" also includes preparations of acylated proteins
CA 02315300 2000-06-20
WO 99/32116 PGT/US98r17299
-17-
- wherein the population of acylated protein molecules is
homogeneous with respect to the site or sites of acylation.
For example, NE-mono-acylated protein, B1-Na-mono-acylated
protein, A1-Na-mono-acylated protein, A1,B1-Na-di-acylated
protein, Ns,Ai-Na,di-acylated protein, N8,B1-Na,di-acylated
protein, and NE,A1,B1-Na,tri-acylated protein are all
encompassed within the term "fatty acid-acylated protein"
for the purpose of the present invention. The term also
refers to preparations wherein the population of acylated
protein molecules has heterogeneous acylation. In the
latter case, the term "fatty acid-acylated protein" includes
mixtures of mono-acylated and di-acylated proteins, mixtures
of mono-acylated and tri-acylated proteins, mixtures of di-
acylated and tri-acylated proteins, and mixtures of mono-
acylated, di-acylated, and tri-acylated proteins.
The term "insulin" as used herein, refers to human
insulin, whose amino acid sequence and special structure are
well-known. Human insulin is comprised of a twenty-one
amino acid A-chain and a thirty-amino acid B-chain which are
cross-linked by disulfide bonds. A properly cross-linked
insulin contains three disulfide bridges: one between
position 7 of the A-chain and position 7 of the B-chain, a
second between position 20 of the A-chain and position 19 of
the B-chain, and a third between positions 6 and 11 of the
A-chain.
The term "insulin analog" means proteins that have
an A-chain and a B-chain that have substantially the same
amino acid sequences as the A-chain and B-chain of human
insulin, respectively, but differ from the A-chain and B-
chain of human insulin by having one or more amino acid
deletions, one or more amino acid replacements, and/or one
or more amino acid additions that do not destroy the insulin
activity of the insulin analog.
"Animal insulins" are analogs of human insulin,
and therefore, are insulin analogs, as defined herein. Four
such animal insulins are rabbit, pork, beef, and sheep
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-18-
insulin. The amino acidsubstitutions
that
distinguish
these animal i nsulins insulin are presented below
from human
for the reader 's convenience.
ino ci osi ion
9 U U
human insulin Thr Ser Ile Thr
rabbit insulin Thr Ser Ile Ser
pork insulin Thr Ser Ile Ala
beef insulin Ala Ser Val Ala
sheep insulin Ala Gly Val Ala
Another type of insulin analog, "monomeric insulin
analog" is well-known in the art. Monomeric insulin analogs
are structurally very similar to human insulin, and have
activity similar or equal to human insulin, but have one or
more amino acid deletions, replacements or additions that
tend to disrupt the contacts involved in dimerization and
hexamerization which results in their having less tendency
to associate to higher aggregation states. Monomeric
insulin analogs are rapid-acting analogs of human insulin,
and are disclosed, for example, in Chance, R. E., et al.,
U.S. patent No. 5,514,646, 7 May 1996; Brems, D. N., et al.
Protein Engineering, 5:527-533 (1992); Brange, J. J. V., et
al., EPO publication No. 214,826, published 18 March 1987;
Brange, J. J. V., et al., U.S. Patent No. 5,618,913, 8 April
1997; and Brange, J., et al., Current Opinion in Structural
Biology 1:934-940 (1991). An example of monomeric insulin
analogs is described as human insulin wherein Pro at
position B28 is substituted with Asp, Lys, Leu, Val, or Ala,
and wherein Lys at position B29 is Lys or is substituted
with Pro, and also, A1a826-human insulin, des(B28-B30)-human
insulin, and des(B27)-human insulin. The monomeric insulin
analogs employed as derivatives in the present crystals, or
employed un-derivatized in the solution phase of suspension
formulations, are properly cross-linked at the same
positions as is human insulin.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7299
-19-
- Another group of insulin analogs for use in the
present invention are those wherein the isoelectric point of
the insulin analog is between about 7.0 and about 8Ø
These analogs are referred to as "pI-shifted insulin
analogs." Examples of such insulin analogs include
ArgB3l,ArgB32-human insulin, G1yA21,ArgB3l,ArgB32-human
insulin, ArgAO,ArgB3l,ArgB32-human insulin, and
ArgAO,GlyA2l,ArgB3l,ArgB32-human insulin.
Another group of insulin analogs consists of
insulin analogs that have one or more amino acid deletions
that do not significantly disrupt the activity of the
molecule. This group of insulin analogs is designated
herein as "deletion analogs." For example, insulin analogs
with deletion of one or more amino acids at positions B1-B3
are active. Likewise, insulin analogs with deletion of one
or more amino acids at positions 828-B30 are active.
Examples of "deletion analogs" include des(B30)-human
insulin, desPhe(B1)-human insulin, des(B27)-human insulin,
des(B28-B30)-human insulin, and des(B1-B3)-human insulin.
The deletion analogs employed as derivatives in the present
crystals, or employed un-derivatized in the solution phase
of suspension formulations, are properly cross-linked at the
same positions as is human insulin.
Amidated amino acids, and particularly asparagine
residues in insulin, are known to be chemically unstable
[Jorgensen, R. H., et a1. U.S. Patent No. 5,008,241, issued
16 April, 1991; Dorschug, M., U.S. Patent No. 5,656,722,
issued 12 August, 1997]. Particularly, they are prone to
deamidation and various rearrangement reactions under
certain conditions that are well-known. Therefore,
optionally, an insulin analog may be insulin or an insulin
analog that has one or more of its amidated residues
replaced with other amino acids for the sake of chemical
stability. For example, Asn or Gln may be replaced with a
non-amidated amino acid. Preferred amino acid replacements
for Asn or Gln are Gly, Ser, Thr, Asp or Glu. It is
preferred to replace one or more Asn residues. In
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-20-
particular, AsnAl8, AsnA2l, or AsnB3, or any combination of
those residues may be replaced by Gly, Asp, or Glu, for
example. Also, G1nA15 or GlnB4, or both, may be replaced by
either Asp or Glu. Preferred replacements are Asp at B21,
and Asp at B3. Also preferred are replacements that do not
change the charge on the protein molecule, so that
replacement of Asn or Gln with neutral amino acids is also
preferred.
The term "proinsulin" means a single-chain peptide
molecule that is a precursor of insulin. Proinsulin may be
converted to insulin or to an insulin analog by chemical or,
preferably, enzyme-catalyzed reactions. In proinsulin,
proper disulfide bonds are formed as described herein.
Proinsulin comprises insulin or an insulin analog and a
connecting bond or a connecting peptide. A connecting
peptide has between 1 and about 35 amino acids. The
connecting bond or connecting peptide connects to a terminal
amino acid of the A-chain and to a terminal amino acid of
the B-chain by an a-amide bond or by two a-amide bonds,
respectively. Preferably, none of the amino acids in the
connecting peptide is cysteine. Preferably, the C-terminal
amino acid of the connecting peptide is Lys or Arg.
Proinsulin may have the formula X-B-C-A-Y or may have the
formula X-A-C-B-Y, wherein X is hydrogen or is a peptide of
from 1 to about 100 amino acids that has either Lys or Arg
at its C-terminal amino acid, Y is hydroxy, or is a peptide
of from 1 to about 100 amino acids that has either Lys or
Arg at its N-terminal amino acid, A is the A-chain of
insulin or the A-chain of an insulin analog, C is a peptide
of from 1 to about 35 amino acids, none of which is
cysteine, wherein the C-terminal amino acid is Lys or Arg,
and B is the B-chain of insulin or the B-chain of an insulin
analog.
A "pharmaceutically acceptable salt" means a salt
formed between any one or more of the charged groups in a
protein and any one or more pharmaceutically acceptable,
non-toxic cations or anions. Organic and inorganic salts
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7299
-21-
include, for example, those prepared from acids such as
hydrochloric, sulfuric, sulfonic, tartaric, fumaric,
hydrobromic, glycolic, citric, malefic, phosphoric, succinic,
acetic, nitric, benzoic, ascorbic, p-toluenesulfonic,
benzenesulfonic, naphthalenesulfonic, propionic, carbonic,
and the like, or for example, ammonium, sodium, potassium,
calcium, or magnesium.
The verb "acylate" means to form the amide bond
between a fatty acid and an amino group of a protein. A
protein is "acylated" when one or more of its amino groups
is combined in an amide bond with the acid group of a fatty
acid.
The term "fatty acid" means a saturated or
unsaturated, straight chain or branched chain fatty acid,
having from one to eighteen carbon atoms.
The term "C1 to C18 fatty acid" refers to a
saturated, straight chain or branched chain fatty acid
having from one to eighteen carbon atoms.
The term "divalent metal cation" refers to the ion
or ions that participate to form a complex with a
multiplicity of protein molecules. The transition metals,
the alkaline metals, and the alkaline earth metals are
examples of metals that are known to form complexes with
insulin. The transitional metals are preferred. Zinc is
particularly preferred. Other transition metals that may be
pharmaceutically acceptable for complexing with insulin
proteins include copper, cobalt, and iron.
The term "complex" has two meanings in the present
invention. In the first, the term refers to a complex
formed between one or more atoms in the proteins that form
the complex and one or more divalent metal cations. The
atoms in the proteins serve as electron-donating ligands.
The proteins typically form a hexamer complex with divalent
transition metal cations. The second meaning of "complex"
in the present invention is the association between the
complexing compound and hexamers. The "complexing compound"
is an organic molecule that typically has a multiplicity of
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-22-
- positive charges that binds to, or complexes with hexamers
in the insoluble composition, thereby stabilizing them
against dissolution. Examples of complexing compounds
suitable in the present invention include protamine, surfen,
various globin proteins [Brange, J. , Galenics of Insulin,
Springer-Verlag, Berlin Heidelberg (1987)], and various
polycationic polymer compounds known to complex with
insulin.
The term "protamine" refers to a mixture of
strongly basic proteins obtained from fish sperm. The
average molecular weight of the proteins in protamine is
about x,200 [Hoffmann, J. A., et al., Protein Expression and
Purification, 1:127-133 (1990)]. "Protamine" can refer to a
relatively salt-free preparation of the proteins, often
called "protamine base." Protamine also refers to
preparations comprised of salts of the proteins. Commercial
preparations vary widely in their salt content.
Protamines are well-known to those skilled in the
insulin art and are currently incorporated into NPH insulin
products. A pure fraction of protamine is operable in the
present invention, as well as mixtures of protamines.
Commercial preparations of protamine, however, are typically
not homogeneous with respect to the proteins present. These
are nevertheless operative in the present invention.
Protamine comprised of protamine base is operative in the
present invention, as are protamine preparations comprised
of salts of protamine, and those that are mixtures of
protamine base and protamine salts. Protamine sulfate is a
frequently used protamine salt. All mass ratios referring
to protamine are given with respect to protamine free base.
The person of ordinary skill can determine the amount of
other protamine preparations that would meet a particular
mass ratio referring to protamine.
The term "suspension" refers to a mixture of a
liquid phase and a solid phase that consists of insoluble or
sparingly soluble particles that are larger than colloidal
size. Mixtures of NPH microcrystals and an aqueous solvent
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-23-
form suspensions. Mixtures of amorphous precipitate and an
aqueous solvent also forms a suspension. The term
"suspension formulation" means a pharmaceutical composition
wherein an active agent is present in a solid phase, for
example, a microcrystalline solid, an amorphous precipitate,
or both, which is finely dispersed in an aqueous solvent.
The finely dispersed solid is such that it may be suspended
in a fairly uniform manner throughout the aqueous solvent by
the action of gently agitating the mixture, thus providing a
reasonably uniform suspension from which a dosage volume may
be extracted. Examples of commercially available insulin
suspension formulations include, for example, NPH, PZI, and
ultralente. A small proportion of the solid matter in a
microcrystalline suspension formulation may be amorphous.
Preferably, the proportion of amorphous material is less
than 10%, and most preferably, less than 1% of the solid
matter in a microcrystalline suspension. Likewise, a small
proportion of the solid matter in an amorphous precipitate
suspension may be microcrystalline.
"NPH insulin" refers to the "Neutral Protamine
Hagedornn preparation of insulin. Synonyms include human
insulin NPH a.nd insulin NPH, among many others. Humulin N
is a commercial preparation of NPH insulin. A related term
is "NPL" which refers to an NPH-like preparation of
LysB28,ProB29-human insulin analog. The meaning of these
terms, and the methods for preparing them will be familiar
to the person of ordinary skill in the insulin formulation
art.
The term "aqueous solvent" refers to a liquid
solvent that contains water. An aqueous solvent system may
be comprised solely of water, may be comprised of water plus
one or more miscible solvents, and may contain solutes. The
more commonly-used miscible solvents are the short-chain
organic alcohols, such as, methanol, ethanol, propanol,
short-chain ketones, such as acetone, and polyalcohols, such
as glycerol.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-24-
An qisotonicity agent" is a compound that is
physiologically tolerated and imparts a suitable tonicity to
a formulation to prevent the net flow of water across cell
membranes that are in contact with an administered
formulation. Glycerol, which is also known as glycerin, is
commonly used as an isotonicity agent. Other isotonicity
agents include salts, e.g., sodium chloride, and
monosaccharides, e.g., dextrose and lactose.
The insoluble compositions of the present
invention contain a hexamer-stabilizing compound. The term
"hexamer-stabilizing compound" refers to a non-
proteinaceous, small molecular weight compound that
stabilizes the protein or derivatized protein in a hexameric
aggregation state. Phenolic compounds, particularly
phenolic preservatives, are the best known stabilizing
compounds for insulin and insulin derivatives. Hexamer-
stabilizing compounds stabilize the hexamer by binding to it
through specific inter-molecular contacts. Examples of
hexamer-stabilizing agents include: various phenolic
compounds, phenolic preservatives, resorcinol, 4'-
hydroxyacetanilide, 4-hydroxybenzamide, and 2,7-
dihyroxynaphthalene. Multi-use formulations of the
insoluble compositions of the present invention will contain
a preservative, in addition to a hexamer-stabilizing
compound. The preservative used in formulations of the
present invention may be a phenolic preservative, and may be
the same as, or different from the hexamer-stabilizing
compound.
The term "preservative" refers to a compound added
to a pharmaceutical formulation to act as an anti-microbial
agent. A parenteral formulation must meet guidelines for
preservative effectiveness to be a commercially viable
mufti-use product. Among preservatives known in the art as
being effective and~acceptable in parenteral formulations
are benzalkonium chloride, benzethonium, chlorohexidine,
phenol, m-cresol, benzyl alcohol, methylparaben,
chlorobutanol, o-cresol, p-cresol, chlorocresol,
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7299
-25-
- phenylmercuric nitrate, thimerosal, benzoic acid, and
various mixtures thereof. See, e.g., Wallh$usser, K.-H.,
Develop. Biol. Standard, 24:9-28 (1974) (S. Krager, Basel).
The term "phenolic preservative" includes the
compounds phenol, m-cresol, o-cresol, p-cresol,
chlorocresol, methylparaben, and mixtures thereof. Certain
phenolic preservatives, such as phenol and m-cresol, are
known to bind to insulin-like molecules and thereby to
induce conformational changes that increase either physical
or chemical stability, or both [Birnbaum, D. T., et al.,
Pharmaceutical. Res. 14:25-36 (1997); Rahuel-Clermont, 5.,
et al., Biochemistry 36:5837-5845 (1997)].
The term "buffer" or "pharmaceutically acceptable
buffer" refers to a compound that is known to be safe for
use in insulin formulations and that has the effect of
controlling the pH of the formulation at the pH desired for
the formulation. The pH of the formulations of the present
invention is from about 6.0 to about 8Ø Preferably the
formulations of the present invention have a pH between
about 6.8 and about 7.8. Pharmaceutically acceptable
buffers for controlling pH at a moderately acidic pH to a
moderately basic pH include such compounds as phosphate,
acetate, citrate, arginine, TRIS, and histidine. "TRIS"
refers to 2-amino-2-hydroxymethyl-1,3,-propanediol, and to
any pharmacologically acceptable salt thereof. The free
base and the hydrochloride form~are two common forms of
TRIS. TRIS is also known in the art as trimethylol
aminomethane, tromethamine, and
tris(hydroxymethyl)aminomethane. Other buffers that are
pharmaceutically acceptable, and that are suitable for
controlling pH at the desired level are known to the chemist
of ordinary skill.
The term "administer" means to introduce a
formulation of the present invention into the body of a
patient in need thereof to treat a disease or condition.
The term "treating" refers to the management and
care of a patient having diabetes or hyperglycemia, or other
CA 02315300 2000-06-20
WO 99/32116 PCT/US981Z7299
-26-
condition for which insulin administration is indicated for
the purpose of combating or alleviating symptoms and
complications of those conditions. Treating includes
administering a formulation of present invention to prevent
the onset of the symptoms or complications, alleviating the
symptoms or complications, or eliminating the disease,
condition, or disorder.
As mentioned above, the present invention provides
insoluble compositions that have properties similar to NPH
insulin in certain respects, and superior to NPH insulin in
other respects. They are similar to NPH insulin in respect
to their physical properties, as described hereafter. A
light microscope equipped with an oil immersion objective
and a crossed polarizer was utilized to examine
microcrystals comprised of B29-Ns-octanoyl-human insulin,
insulin, zinc, protamine, and phenol prepared according to
the present invention. Examination at 1000x magnification
showed that these microcrystals were single and rod-like,
exhibiting a uniform crystal morphology. The sizes of these
microcrystals fell generally within the range of
approximately 2 microns long to 8 microns long. A direct
comparison using this microscope showed that the morphology
of these microcrystals appeared to be similar to that of
commercially manufactured pork NPH microcrystals, which has
elsewhere been described as rod-like. The size range of
these microcrystals was also similar to that of commercially
manufactured NPH microcrystals, which generally have an
average length of about 5 microns. The commercial
manufacturing specification for the mean.length of NPH
microcrystals is from 1 micron to 40 microns.
The microcrystals of the present invention are,
however, unexpectedly and unpredictably different from NPH
insulin crystals in their dissolution properties, and in
their time action. In particular, the microcrystals of the
present invention dissolve much more slowly under conditions
that simulate physiologic conditions than do NPH insulin
crystals, and provide a longer and flatter profile of blood
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-27-
glucose control than does NPH insulin. This was
demonstrated by the following experiments.
Certain derivatized proteins, in soluble form,
were found to have time actions not significantly different
from regular human insulin. Three groups of animals were
used. Each animal in the first group received a dose (0.75
nmol/kg) of Humulin~ R (soluble human insulin), each animal
in the second group received a dose (0.75 nmol/kg) of
soluble B29-Ns-octanoyl-human insulin ("C8-hI"), and each
animal in the third group received a dose (0.75 nmol/kg) of
soluble B29-NE-decanoyl-human insulin ("C10-hI"). The
experiments were carried out essentially as described in
Example 5, with five dogs per group. The proteins were
administered subcutaneously. Blood glucose concentrations
were determined, and are presented in the table below.
Table 1. Blood glucose concentrations before and after
administration of Humulin~ R, soluble B29-Ns-octanoyl-human
insulin ("C8-hI"), or soluble B29-Ns-decanoyl-human insulin
("C10-hI") in normal dogs simultaneously administered
somatostatin to create a transient diabetic state. Values
are mean ~ standard error.
Btooo. Glucose
oncen ra
ion mg
ime umu in o a a o a
(h) C8-hI C10-hI
t t t
t t t
t SU t
t f t
t t t
t f f
t t t
t t t
t t t
t t
t U t t
~ t t
f t t
These data clearly show that soluble B29-NE-
octanoyl-human insulin and B29-N8-decanoyl-human insulin,
administered subcutaneously to normal dogs in a transient
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-28-
- diabetic state, provide glucose lowering roughly comparable
to that obtained with soluble human insulin. Most notably,'
soluble B29-NE-octanoyl-human insulin shows a.quicker onset,
and shorter time action than does human insulin.
In a second experiment, the dissolution rate of
co-crystals of insulin and B29-NE-octanoyl-human insulin
prepared in accordance with the present invention was found
to be markedly longer than that of a commercially
manufactured NPH-pork insulin. This was most unexpected in
view of the data above. The rate of dissolution may be
measured using well-known procedures (Graham and Pomeroy, J.
Pharm. Pharmacol. 36:427-430 (1983), as modified in De
Felippis, M. R. and Frank, B., BP 735,048], or the procedure
used herein.
The dissolution rate of pork insulin NPH
microcrystals was measured by placing 5 microliters of 0100
pork insulin NPH into 3 mL of Dulbecco's phosphate buffered
saline (without calcium or magnesium) in a 1 cm path length
square quartz cuvette at a temperature of 22°C. This
solution was stirred at a constant rate using a magnetic
cuvette stirrer. Absorbance measurements at 320 nm were
taken at 1 minute intervals. The absorbance at 320 nm
corresponds to the light scattered by the insoluble
particles present in the aqueous suspension. Consequently,
as the microcrystals dissolve, the absorbance approaches
zero. Pork insulin NPH microcrystals were completely
dissolved after about 20 minutes.
The dissolution rate of protamine-zinc crystals of
human insulin containing no co-crystallized acylated human
insulin was also found to be about 20 minutes by the
procedure used above. These crystals of NPH-human insulin
were prepared essentially by the procedure of Preparation
#1, below, except that no acylated protein was used, and 7
parts of human insulin were used. The data generated from
this experiment are presented in Figure 1 as the dashed
line.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-29-
Co-crystals of the present invention comprised of
human insulin and B29-Ns-octanoyl-LysB29 human insulin were
prepared as described in Preparations #2, 4, and 5, below.
In these preparations, human insulin and the acylated
insulin were used in pre-crystallization mass ratios of 3:1,
1:1, and 1:3, respectively.
A procedure as described above was followed to
measure the dissolution rate of these co-crystals. In
summary, a volume of 12 microliters of each protamine-zinc-
B29-NE-octanoyl-LysB29 human insulin-human insulin co-
crystalline suspension (containing no more than 50 U/mL) was
placed into 3 mL of Dulbecco~s phosphate buffered saline
(without calcium or magnesium) in a 1 cm path length square
quartz cuvette. This solution was stirred at the same
constant rate and at the same temperature of 22°C. The data
generated from this experiment are presented in Figure 1,
and show that the 3:1 co-crystals required more than 100
minutes to dissolve, that the 1:1 co-crystals required more
than 150 minutes to dissolve, and that the 1:3 co-crystals
required did not completely dissolve even after 400 minutes.
The time required for the absorbance during
dissolution to reach half way from the starting absorbance
value to the final absorbance value is defined as the tl~z
value. The tl~avalues for these preparations are presented
below in Table 2.
Table 2. Dissolution tl~svalues for Iletin NPH, Human
Insulin NPH, and co-crystals of B29-octanoyl-human insulin
and human insulin
icten~ity ~ ~ l~z va ue
octanoyl- insulin porcine (minutes)
human insulin
insulin
Iletin NPH 0 0 100 6
Human NPH 0 100 0 7
3:1 co-crystal 25 75 0 38
1:1 co-crystal 50 50 0 117
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7299
-30-
1:3 co-crystal 75 25 ~ 0 >400
These experiments establish that, in Dulbecco's
phosphate buffered saline (without calcium and magnesium), a
solution that mimics the interstitial fluid in certain
aspects, the rate of dissolution of the 3:1, 1:1, and 1:3
co-crystals is significantly slower than that of pork NPH
microcrystals. These experiments also establish that the
rate of dissolution of protamine-zinc-human insulin
microcrystals is very similar to that of pork NPH insulin
(Iletin NPH). These results further establish that the rate
of dissolution of protamine-zinc-B29-Ns-octanoyl-LysB29
human insulin-human insulin co-crystals depends on the ratio
of human insulin to B29-NE-octanoyl-LysB29 human insulin
present in the co-crystals, and, in particular, the rate of
dissolution of protamine-zinc-B29-Ns-octanoyl-LysB29 human
insulin-human insulin co-crystals decreases as the
proportion of human insulin decreases.
Another dissolution method, based on HPLC
determination of dissolved protein and derivatized protein,
was used to compare the dissolution rate of the 1:3
microcrystals described above with commercial preparations
of human insulin NPH, human insulin ultralente, and beef
ultralente, and also to study the effects on dissolution
rate of varying the ratio of protein to derivatized protein.
A volume (0.5 mL) of a U100 formulation was
suspended in 200 mL of Dulbecco's phosphate buffered saline
adjusted to pH 7.4 in a water-jacketed dissolution apparatus
maintained at 25°C. The dissolution buffer also contained 1
mg/mL human serum albumin to prevent adsorption losses of
dissolved insulins. The dissolution medium was stirred at a
constant rate of 180 rpm. At regular intervals, 3.5 mL of
this solution was taken out and filtered through a 0.22 ~.m,
low protein-binding filter. The first 0.5 mL of the
filtrate was discarded and the next 1.5 mL of the filtrate
was acidified with 4 mL of 5 N HC1 and subjected to HPLC
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-31-
analysis. The concentrations of the dissolved insulins were
determined based on HPLC peak areas and the results were
expressed as the percent dissolved as a function of time,
with 100% being the total area of insulins in unfiltered
samples. If the total area in unfiltered samples decreased
slightly as a function of time, a linearly corrected value
was used as 100%, for computation of percent dissolved at
each time point. The results of these studies are presented
in Figures 3 and 4.
The data of Figure 3 show that the greater the
fraction of derivatized protein incorporated into the
microcrystal, the slower the dissolution rate. The data of
Figure 4 show that the 1:3 microcrystal of human insulin and
B29-octanoyl human insulin dissolves significantly more
slowly than both human insulin NPH and human insulin
ultralente. Most significantly, the 1:3 microcrystal has a
dissolution rate very similar to that of beef ultralente.
Beef ultralente has long been considered a nearly ideal
long-acting insulin preparations, both because of its very
long protraction of biological activity, and because of the
flatness of the pharmacodynamic response after its
administration. It is thus predicted that these
microcrystals may approach or exceed beef ultralente in
their ability to provide control of basal glucose output for
very long time periods.
Because the time action profile of NPH
preparations is related strongly to the rate of dissolution
of the microcrystals in the subcutaneous interstitial fluid,
it is concluded from these experiments that the
microcrystalline compositions of the present invention
possess a more protracted duration of action when
administered subcutaneously to diabetic patients than
existing commercial NHP insulin preparations. Importantly,
these results also establish that the present invention
makes it possible to control, and even to optimize, the
duration of action in patients by manipulating the ratio of
protein to derivatized protein.
CA 02315300 2000-06-20
WO 99/32116 PCTNS98/27299
-32-
This ability to manipulate the duration of action
by simply varying the ratios of protein and derivatized
protein is most significant when viewed against the
historical backdrop. Historically, a major obstacle to the
development of insulin formulations for controlling basal
glucose output has been that their time-action has been
inflexibly linked to the inherent molecular properties of
the protein, for example, albumin-binding affinity,
isoelectric point, or solubility. The consequence was that
only a single time-action was possible for each molecule or
formulation, and the only recourse for improving the
pharmacokinetics was a further modification of the molecule.
A long sought goal has been to develop controlled-
release delivery systems where the pharmacokinetics can be
precisely and conveniently adjusted by manipulating the
formulation matrix. Much academic and industrial research
in this area has been directed towards insulin over the past
15 years, however, the goal of controlled release has proven
particularly elusive because of the extremely narrow
therapeutic index of insulin, its chronic-use requirement,
as well as economic considerations which bias against
sophisticated and expensive processes and formulations.
A major advantage of the present invention is that
it is a controlled release system where the pharmacokinetics
of insulin release can be more conveniently controlled than
other proposed controlled release technologies. That is, an
insoluble composition comprised of a protein insulin with a
derivatized protein provides a convenient means to adjust
the dissolution rate and hence make controlled-release
possible. While not intended to be limiting, it is believed
that the pharmacological efficacy of the insoluble
compositions of the present invention is based on the slow
release of a consistent proportion of protein and
derivatized protein from the composition. It is further
believed, without limiting the invention, that a significant
underlying feature of this invention is the complete or
nearly complete homogeneity of the insoluble composition.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7299
-33-
For microcrystals, it is believed that every individual
microcrystal in the suspension is comprised of very nearly
the same ratio of protein and derivatized protein. This
ratio closely reflects the ratio of protein to derivatized
protein combined in solution prior to crystallization. It
is also believed that, as the microcrystals dissolve, a
consistent and predetermined proportion of protein and
derivatized protein is released throughout the entire
duration of dissolution. The significance of this behavior
is considerable because it results in a constant, but
reduced rate of release of the two active molecules from the
site of injection to the bloodstream. In order to achieve
this object, particular attention must be given to the
process for preparing the compositions.
The present discovery that it is possible to
crystallize protein with derivatized protein, and thereby
obtain a homogeneous co-crystal, was a surprising finding in
view of the complexity of the parameters affecting protein
crystallization: specific and non-specific inter-molecular
interactions, such as, hydrogen-bonding, electrostatic
interactions, hydrophobic interactions, van der Waals
forces, excluded volume effects, solubility, and steric
bulk. Although the fundamental understanding of small
molecule crystallization is relatively advanced, for complex
macromolecules it is still largely a qualitative science and
current practice consists of empirically applying large
arrays of crystallization recipes.
The hydrophobic effect has been proposed as a
major driving force for protein association [Chothia, C. et
al., Nature 256:705-708 (1975)]. Furthermore, strong
correlation between surface hydrophobicity and protein-
protein contacts have been noted [Young, L., et al., Protein
Science 3:717-729 (1994)]. Yet, in view of the complexity
of protein crystallization, the finding that derivatized
insulins can co-crystallize with un-derivatized protein in a
manner that is isomorphous, or nearly isomorphous to normal
insulin, is surprising.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-34-
The co-crystallization of two related therapeutic
proteins for the purpose of modifying therapeutic behavior
is a new concept. To a large extent this is because the
vast majority of protein crystallization work is motivated
by the goal of obtaining single, large, homogeneous crystals
suitable for x-ray diffraction structural analysis.
Although protein co-crystals are known, such co-crystal
systems are characterized as host-substrate complexes e.g. a
protein and its receptor, protein-DNA complexes, and protein
receptor-drug complexes. These host-substrate complex co-
crystals are fundamentally different than the co-crystals of
the present invention because there is no complex formed
between the protein and derivatized protein.
The predictability of the proportions of protein
and derivatized protein and the homogeneity of the insoluble
compositions of the present invention were demonstrated by
measuring (by HPLC) the concentrations of protein and
derivatized protein during dissolution studies using two
preparations of microcrystals that were prepared with known
quantities of human insulin (protein) and B29-oc.tanoyl-human
insulin (derivatized protein). In the first preparation,
the mass proportion of protein added to derivatized protein
added was 1:3. In the second preparation, the proportion
was 55:45. For the 1:3 microcrystals, B29-octanoyl-human
insulin constituted between about 73% and 76% of the total
protein for 14 measurements over 10 hours during dissolution
under conditions as described for the dissolution test
above. No trend in the data was observed. For the 55:45
microcrystals, B29-octanoyl-human insulin constituted
between about 43% and 47% of the total protein for 9
measurements taken over a period of about 3.75 hours during
dissolution under conditions as described for the
dissolution test above. Again, no trend in the data was
observed.
The insoluble compositions of the present
invention may be crystals with rod-like morphology or with
an irregular morphology, or they may be amorphous
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-35-
- precipitates. Preferred insoluble compositions are
comprised of acylated insulin or acylated insulin analog,
zinc ions, which are present at about 0.3 to about 0.7 mole
per mole of total protein, a phenolic preservative selected
from the group consisting of phenol, m-cresol, o-cresol, p-
cresol, chlorocresol, methylparaben, and mixtures thereof
and is present in sufficient proportions with respect to
total protein to stabilize the T3R3 or R6 hexamer
conformation, and protamine, which is present at about 0.15
to about 0.7 mole per mole of total protein.
A preferred group of insulin analogs for preparing
derivatized insulin analogs used to form the present
insoluble compositions consists of animal insulins, deletion
analogs, and pI-shifted analogs. A more preferred group
consists of animal insulins and deletion analogs. Deletion
analogs are yet more preferred.
Another preferred group of insulin analogs for use
in the microcrystals of the present invention consists of
the monomeric insulin analogs. Particularly preferred are
those monomeric insulin analogs wherein the amino acid
residue at position B28 is Asp, Lys, Leu, Val, or Ala, the
amino acid residue at position B29 is Lys or Pro, the amino
acid residue at position B10 is His or Asp, the amino acid
residue at position B1 is Phe, Asp or deleted alone or in
combination with a deletion of the residue at position B2,
the amino acid residue at position B30 is Thr, Ala, Ser, or
deleted, and the amino acid residue at position B9 is Ser or
Asp; provided that either position B28 or B29 is Lys.
Another preferred group of insulin analogs for use
in the present invention consists of those wherein the
isoelectric point of the insulin analog is between about 7.0
and about 8Ø These analogs are referred to as "pI-shifted
insulin analogs." Examples of pI-shifted insulin analogs
include, for example, ArgB3l,ArgB32-human insulin,
G1yA21,ArgB3l,Arg832-human insulin, ArgAO,ArgB3l,ArgB32-
human insulin, and ArgA0,G1yA21,ArgB3l,ArgB32-human insulin.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7299
-36-
- Another preferred group of insulin analogs
consists of LysB28,Pro829-human insulin (B28 is Lys; B29 is
Pro); AspB28-human insulin (B28 is Asp), AspBl-human
insulin, ArgH3l,ArgB32-human insulin, ArgAO-human insulin,
AspBl,G1uB13-human insulin, AlaB26-human insulin, G1yA21-
human insulin, des(Thr830)-human insulin, and
G1yA21,ArgB3l,ArgB32-human insulin.
Especially preferred insulin analogs include
LysB28,ProB29-human insulin, des(ThrB30)-human insulin,
AspB28-human insulin, and AlaB26-human insulin. Another
especially preferred insulin analog is G1yA21, ArgB3l,
ArgB32-human insulin [Dorschug, M., U. S. Patent No.
5,656,722, 12 August 1997). The most preferred insulin
analog is LysB28,ProB29-human insulin.
The preferred derivatized proteins are acylated
proteins, and the preferred acylated proteins for the
microcrystals and formulations of the present invention are
fatty acid-acylated insulin, and fatty acid-acylated insulin
analogs. Fatty acid-acylated human insulin is highly
preferred. Fatty acid-acylated insulin analogs are equally
highly preferred.
The particular group used to derivatize insulin,
an insulin analog, or a proinsulin (collectively, protein)
may be any chemical moiety that does not significantly
reduce the biological activity of the protein, is not toxic
when bonded to the protein, and most importantly, reduces
the aqueous solubility, raises the lipophilicity, or
decreases the solubility of zinc/protamine complexes of the
derivatized protein.
One preferred group of acylating moieties consists
of fatty acids that are straight chain and saturated. This
group consists of methanoic acid (C1), ethanoic acid (C2),
propanoic acid (C3), n-butanoic acid (C4), n-pentanoic acid
(C5), n-hexanoic acid (C6), n-heptanoic acid (C7), n-
octanoic acid (C8), n-nonanoic acid (C9), n-decanoic acid
(C10), n-undecanoic acid (Cil), n-dodecanoic acid (C12), n-
tridecanoic acid (C13), n-tetradecanoic acid (C14), n-
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7299
-37-
- pentadecanoic acid (C15), n-hexadecanoic acid fCl6), n-
heptadecanoic acid (C17), and n-octadecanoic acid (C18).
Adjectival forms are formyl (C1), acetyl (C2), propionyl
(C3), butyryl (C4), pentanoyl (C5), hexanoyl (C6), heptanoyl
(C7), octanoyl (C8), nonanoyl (C9), decanoyl (C10),
undecanoyl (C11), dodecanoyl (C12), tridecanoyl (C13),
tetradecanoyl (C14) or myristoyl, pentadecanoyl (C15),
hexadecanoyi (C16) or palmitic, heptadecanoyl (C17), and
octadecanoyl (C18) or stearic.
A preferred group of fatty acids for forming the
fatty acid-acylated proteins used in the microcrystals of
the present invention consists of fatty acids having an even
number of carbon atoms - that is , C2 , C4 , C6, C8 , C10 , C12 ,
C14, C16, and C18 saturated fatty acids.
Another preferred group of fatty acids for forming
the fatty acid-acylated proteins used in the microcrystals
of the present invention consists of fatty acids having an
odd number of carbon atoms - that is, C1, C3, C5, C7, C9,
C11, C13, C15, and C17 saturated fatty acids.
Another preferred group of fatty acids for forming
the fatty acid-acylated proteins used in the microcrystals
of the present invention consists of fatty acids having more
than 5 carbon atoms - that is, C6, C7, C8, C9, C10, C11,
C12, C13, C14, C15, C16, C17, and C18 saturated fatty acids.
Another preferred group of fatty acids for forming
the fatty acid-acylated proteins used in the microcrystals
of the present invention consists of fatty acids having less
than 9 carbon atoms - that is, C1, C2, C3, C4, C5, C6, C7,
and C8 saturated fatty acids.
Another preferred group of fatty acids for forming
the fatty acid-acylated proteins used in the microcrystals
of the present invention consists of fatty acids having
between 6 and 8 carbon atoms - that is, C6, C7, and C8,
saturated fatty acids.
Another preferred group of fatty acids for forming
the fatty acid-acylated proteins used in the microcrystals
of the present invention consists of fatty acids having more
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-38-
than between 4 and 6 carbon atoms - that is, C4, C5, and C6,
saturated fatty acids.
Another preferred group of fatty acids for forming
the fatty acid-acylated proteins used in the microcrystals
of the present invention consists of fatty acids having more
than between 2 and 4 carbon atoms - that is, C2, C3, and C4,
saturated fatty acids.
Another preferred group of fatty acids for forming
the fatty acid-acylated proteins used in the microcrystals
of the present invention consists of fatty acids having less
than 6 carbon atoms - that is, C1, C2, C3, C4, and C5
saturated fatty acids.
Another preferred group of fatty acids for forming
the fatty acid-acylated proteins used in the microcrystals
of the present invention consists of fatty acids having less
than 4 carbon atoms - that is, C1, C2, and C3 saturated
fatty acids.
Another preferred group of fatty acids for forming
the fatty acid-acylated proteins used in the microcrystals
of the present invention consists of fatty acids having more
than 9 carbon atoms - that is, C10, C11, C12, C13, C14, C15,
C16, C17, and C18 saturated fatty acids.
Another preferred group of fatty acids for forming
the fatty acid-acylated proteins used in the microcrystals
of the present invention consists of fatty acids having an
even number of carbon atoms and more than 9 carbon atoms -
that is, C10, C12, C14, C16, and C18 saturated fatty acids.
Another preferred group of fatty acids for forming
the fatty acid-acylated proteins used in the microcrystals
of the present invention consists of fatty acids having 12,
14, or 16 carbon atoms, that is, C12, C14, and C16 saturated
fatty acids.
Another preferred group of fatty acids for forming
the fatty acid-acylated proteins used in the microcrystals
of the present invention consists of fatty acids having 14
or 16 carbon atoms, that is, C14 and C16 saturated fatty
acids. Fatty acids with 14 carbons are particularly
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-39-
preferred. Fatty acids with 16 carbons are also
particularly preferred.
Another preferred group of fatty acids for forming
the fatty acid-acylated proteins used in the microcrystals
of the present invention consists of saturated fatty acids
having between 4 and 10 carbon atoms, that is C4, C5, C6,
C7, C8, C9, and C10 saturated fatty acids.
Another preferred group of fatty acids for forming
the fatty acid-acylated proteins used in the microcrystals
of the present invention consists of saturated fatty acids
having an even number of carbon atoms between 4 and 10
carbon atoms, that is C4, C6, C8, and C10 saturated fatty
acids.
Another preferred group of fatty acids for forming
the fatty acid-acylated proteins used in the microcrystals
of the present invention consists of fatty acids having
between 6, 8, or 10 carbon atoms. Fatty acids with 6
carbons are particularly preferred. Fatty acids with 8
carbons are also particularly preferred. Fatty acids with
10 carbons are particularly preferred.
The skilled person will appreciate that narrower
preferred groups are made by combining the preferred groups
of fatty acids described above.
Another preferred group of acylating moieties
consists of saturated fatty acids that are branched. A
branched fatty acid has at least two branches. The length
of a "branch" of a branched fatty acid may be described by
the number of carbon atoms in the branch, beginning with the
acid carbon. For example, the branched fatty acid 3-ethyl-
5-methylhexanoic acid has three branches that are five, six,
and six carbons in length. In this case, the "longest"
branch is six carbons. As another example, 2,3,4,5-
tetraethyloctanoic acid has five branches that are 4, 5, 6,
7, and 8 carbons long. The "longest" branch is eight
carbons. A preferred group of branched fatty acids are
those having from three to ten carbon atoms in the longest
branch.
CA 02315300 2000-06-20
WO 99/32116 PCTNS98/Z7299
-40-
A representative number of such branched,
saturated fatty acids will be mentioned to assure the
reader's comprehension of the range of such fatty acids that
may be used as acylating moieties of the proteins in the
present invention: 2-methyl-propioinic acid, 2-methyl-
butyric acid, 3-methyl-butyric acid, 2,2-dimethyl-propionic
acid, 2-methyl-pentanoic acid, 3-methyl-pentanoic acid, 4-
methyl-pentanoic acid, 2,2-dimethyl-butyric acid, 2,3-
dimethyl-butyric acid, 3,3-dimethyl-butyric acid, 2-ethyl-
butyric acid, 2-methyl-hexanoic acid, 5-methyl-hexanoic
acid, 2,2-dimethyl-pentanoic acid, 2,4-dimethyl-pentanoic
acid, 2-ethyl-3-methyl-butyric acid, 2-ethyl-pentanoic acid,
3-ethyl-pentanoic acid, 2,2-dimethyl-3-methyl-butyric
acid,2-methyl-heptanoic acid, 3-methyl-heptanoic acid, 4-
methyl-heptanoic acid, 5-methyl-heptanoic acid, 6-methyl-
heptanoic acid, 2,2-dimethyl-hexanoic acid, 2,3-dimethyl-
hexanoic acid, 2,4-dimethyl-hexanoic acid; 2,5-dimethyl-
hexanoic acid, 3,3,-dimethyl-hexanoic acid, 3,4-dimethyl-
hexanoic acid, 3,5-dimethyl-hexanoic acid, 4,4-dimethyl-
hexanoic acid, 2-ethyl-hexanoic acid, 3-ethyl-hexanoic acid,
4-ethyl-hexanoic acid, 2-propyl-pentanoic acid, 2-ethyl-
hexanoic acid, 3-ethyl-hexanoic acid, 4-ethyl-hexanoic acid,
2-(1-propyl)pentanoic acid, 2-(2-propyl)pentanoic acid, 2,2-
diethyl-butyric acid, 2,3,4-trimethyl-pentanoic acid, 2-
methyl-octanoic acid, 4-methyl-octanoic acid, 7-methyl-
octanoic acid, 2,2-dimethyl-heptanoic acid, 2,6-dimethyl-
heptanoic acid, 2-ethyl-2-methyl-hexanoic acid, 3-ethyl-5-
methyl-hexanoic acid, 3-(1-propyl)-hexanoic acid, 2-(2-
butyl)-pentanoic acid, 2-(2-(2-methylpropyl))pentanoic acid,
2-methyl-nonanoic acid, 8-methyl-nonanoic acid, 6-
ethyl-octanoic acid, 4-(1-propyl)-heptanoic acid, 5-(2-
propyl)-heptanoic acid, 3-methyl-undecanoic acid,2-pentyl-
heptanoic acid, 2,3,4,5,6-pentamethyl-heptanoic acid, 2,6-
diethyl-octanoic acid, 2-hexyl-octanoic acid, 2,3,4,5,6,7-
hexamethyl-octanoic acid,. 3,3-diethyl-4,4-diethyl-hexanoic
acid, 2-heptyl-nonanoic acid, 2,3,4,5-tetraethyl-octanoic
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-41-
acid, 2-octyl-decanoic acid, and 2-(1-propyl)-3-(1-propyl)-
4,5-diethyl-6-methyl-heptanoic acid.
Yet another preferred group of acylating moieties
consists of cyclic alkyl acids having from 5 to 24 carbon
atoms, wherein the cyclic alkyl moiety, or moieties, have 5
to 7 carbon atoms. A representative number of such cyclic
alkyl acids will be mentioned to assure the reader's
comprehension of the range of such acids that may be used as
acylating moieties of the proteins in the present invention:
cyclopentyl-formic acid, cyclohexyl-formic acid, 1-
cyclopentyl-acetic acid, 2-cyclohexyl-acetic acid, 1,2-
dicyclopentyl-acetic acid, and the like.
A preferred group of derivatized proteins for use
in the insoluble compositions of the present invention
consists of mono-acylated proteins. Mono-acylation at the
E-amino group is most preferred. For insulin, mono-
acylation at LysB29 is preferred. Similarly, for certain
insulin analogs, such as, LysB28,ProB29-human insulin
analog, mono-acylation at the s-amino group of LysB28 is
most preferred. Mono-acylation at the a-amino group of the
B-chain (Bl) is also preferred. Mono-acylation at the a-
amino group of the A-chain (A1) is also preferred.
Another preferred group of acylated proteins for
use in the insoluble compositions of the present invention
consists of di-acylated proteins. The di-acylation may be,
for example, at the E-amino group of Lys and at the a-amino
group of the B-chain, or may be at the E-amino group of Lys
and at the a-amino group of the A-chain, or may be at the a-
amino group the A-chain and at the a-amino group of the B-
chain.
Another preferred group of acylated proteins for
use in the insoluble compositions of the present invention
consists of tri-acylated proteins. Tri-acylated proteins
are those that are acylated at the E-amino group of Lys, at
the a-amino group of the B-chain, and at the a-amino group
of the A-chain.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-42-
It is also preferred to use acylated proteins that
are a mixture of mono-acylated and di-acylated proteins.
It is likewise preferred to use acylated proteins
that are a mixture of mono-acylated and tri-acylated
proteins.
Another preferred group of acylated proteins
consists of a mixture of di-acylated and tri-acylated
proteins.
Also preferred is to use acylated proteins that
are a mixture of mono-acylated, di-acylated, and tri-
acylated proteins.
Certain fatty acid-acylated proteins used in the
present microcrystals will be mentioned to assure the
reader's comprehension of the scope of the present
invention. The list is illustrative, and the fact that a
particular fatty acid-acylated protein is not mentioned does
not mean that a microcrystal containing it is not within the
scope of the present invention.
B29-NE-Formyl-human insulin.
B1-Na-Formyl-human insulin.
Al-Na-Formyl-human insulin:
B29-NE-Formyl-,B1-Na-formyl-human insulin.
B29-NE-Formyl-, A1-Na-formyl-human insulin.
Al-Na-Formyl-,B1-Na-formyl-human insulin.
B29-Ns-Formyl-, A1-Na-formyl-, B1-Na-formyl-human insulin.
B29-NE-Acetyl-human insulin.
B1-Na-Acetyl-human insulin.
A1-Na-Acetyl-human insulin.
B29-Ns-Acetyl-, B1-Na-acetyl-human insulin.
B29-NE-Acetyl-, A1-Na-acetyl-human insulin.
A1-Na-Acetyl-, B1-Na-acetyl-human insulin.
B29-NE-Acetyl-, A1-Na-acetyl-, B1-Na-acetyl-human insulin.
B29-Ng-Propionyl-human insulin.
B1-Na-Propionyl-human insulin.
A1-Na-Propionyl-human insulin.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-43-
B29-Ns-Propionyl-,B1-Na-propionyl-human insulin.
B29-NE-Propionyl-,A1-Na-propionyl-human insulin.
A1-Na-Propionyl-,B1-Na-propionyl-human insulin.
B29-NE-Propionyl-, A1-Na-propionyl-, B1-Na-propionyl-human
insulin.
B29-Ns-Butyryl-human insulin.
B1-Na-Butyryl-human insulin.
A1-Na-Butyryl-human insulin.
B29-NE-Butyryl-,B1-Na-butyryl-human insulin.
B29-NE-Butyryl-,A1-Na-butyryl-human insulin.
A1-Na-Butyryl-,B1-Na-butyryl-human insulin.
B29-Ns-Butyryl-, A1-Na-butyryl-,B1-Na-butyryl-human insulin.
B29-N8-Pentanoyl-human insulin.
B1-Na-Pentanoyl-human insulin.
A1-Na-Pentanoyl-human insulin.
B29-Ns-Pentanoyl-,B1-Na-pentanoyl-human insulin.
B29-NE-Pentanoyl-,A1-Na-pentanoyl-human insulin.
A1-Na-Pentanoyl-,B1-Na-pentanoyl-human insulin.
B29-NE-Pentanoyl-, Al-Na pentanoyl-,B1-Na-pentanoyl-human
insulin.
B29-NE-Hexanoyl-human insulin.
B1-Na-Hexanoyl-human insulin.
A1-Na-Hexanoyl-human insulin.
B29-NE-Hexanoyl-,B1-Na-hexanoyl-human insulin.
B29-Ns-Hexanoyl-,A1-Na-hexanoyl-human insulin.
A1-Na-Hexanoyl-,B1-Na-hexanoyl-human insulin.
B29-Ns-Hexanoyl-, A1-Na-hexanoyl-,B1-Na-hexanoyl-human
insulin.
B29-Ne-Heptanoyl-human insulin.
B1-Na-Heptanoyl-human insulin.
A1-Na-Heptanoyl-human insulin.
B29-NE-Heptanoyl-,B1-Na-heptanoyl-human insulin.
B29-N8-Heptanoyl-,A1-Na-heptanoyl-human insulin.
A1-Na-Heptanoyl-,B1-Na-heptanoyl-human insulin.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-44-
B29-Ns-Heptanoyl-, A1-Na-heptanoyl-,B1-Na-heptanoyl-human
insulin.
B29-NE-Octanoyl-human insulin.
B1-Na-Octanoyl-human insulin.
A1-Na-Octanoyl-human insulin.
B29-NE-Octanoyl-,B1-Na-octanoyl-human insulin.
B29-NE-Octanoyl-,A1-Na-octanoyl-human insulin.
A1-Na-0ctanoyl-,B1-Na-octanoyl-human insulin.
B29-Ns-Octanoyl-, A1-Na-octanoyl-,B1-Na-octanoyl-human
insulin.
B29-Ns-Nonanoyl-human insulin.
B1-Na-Nonanoyl-human insulin.
Al-Na-Nonanoyl-human insulin.
B29-Ns-Nonanoyl-,B1-Na-nonanoyl-human insulin.
B29-Ns-Nonanoyl-,A1-Na-nonanoyl-human insulin.
A1-Na Nonanoyl-,B1-Na-nonanoyl-human insulin.
B29-NE Nonanoyl-, A1-Na-nonanoyl-,B1-Na-nonanoyl-human
insulin.
B29-Ns-Decanoyl-human insulin.
B1-Na-Decanoyl-human insulin.
A1-Na-Decanoyl-human insulin.
B29-NE-Decanoyl-,B1-Na-decanoyl-human insulin.
B29-NE-Decanoyl-,A1-Na-decanoyl-human insulin.
A1-Na-Decanoyl-,B1-Na-decanoyl-human insulin.
B29-NE-Decanoyl-,A1-Na- decanoyl-,B1-Na-decanoyl-human
insulin.
B29-NE-Undecanoyl-human insulin.
B1-Na-Undecanoyl-human insulin.
A1-Na-Undecanoyl-human insulin.
B29-Ns-Dodecanoyl-human insulin.
B1-Na-Dodecanoyl-human insulin.
A1-Na-Dodecanoyl-human insulin.
B29-NE-Tridecanoyl-human insulin.
B1-Na-Tridecanoyl-human insulin.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-45-
A1-Na-Tridecanoyl-human insulin.
B29-Ns-Tetradecanoyl-human insulin.
B1-Na-Tetradecanoyl-human insulin.
A1-Na-Tetradecanoyl-human insulin.
B29-NE-Pentadecanoyl-human insulin.
B1-Na-Pentadecanoyl-human insulin.
A1-Na-Pentadecanoyl-human insulin.
B29-Ns-Hexadecanoyl-human insulin.
Bl-Na-Hexadecanoyl-human insulin.
A1-Na-Hexadecanoyl-human insulin.
B29-NE-Heptadecanoyl-human insulin.
B1-Na-Heptadecanoyl-human insulin.
A1-Na-Heptadecanoyl-human insulin.
B29-NE-Octadecanoyl-human insulin.
B1-Na-Octadecanoyl-human insulin.
A1-Na-Octadecanoyl-human insulin.
B28-Ns-Formyl-LysB28,ProB29-human insulin analog.
B1-Na-Formyl-LysB28,ProB29-human insulin analog.
A1-Na-Formyl-LysB28,ProB29-human insulin analog.
B28-Ns-Formyl-,B1-Na-formyl-LysB28,ProB29-human insulin
analog.
B28-Ns-Formyl-, A1-Na-formyl-Lys828,ProB29-human insulin
analog.
A1-Na-Formyl-,B1-Na-formyl-LysB28,ProB29-human insulin
analog.
B28-NE-Formyl-, A1-Na-formyl-, B1-Na-formyl-LysB28,ProB29-
human insulin analog.
B28-NE-Acetyl-LysB28,ProB29-human insulin analog.
B1-Na-Acetyl-LysB28,ProB29-human insulin analog.
A1-Na-Acetyl-LysB28,ProB29-human insulin analog.
B28-Ns-Acetyl-, B1-Na-acetyl-LysB28,ProB29-human insulin
analog.
B28-NE-Acetyl-, A1-Na-acetyl-LysB28,ProB29-human insulin
analog.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7299
-46-
A1-Na-Acetyl-, B1-Na-acetyl-LysB28,ProB29-human insulin
analog.
B28-Ns-Acetyl-, A1-Na-acetyl-, B1-Na-acetyl-LysB28,ProB29-
human insulin analog.
B28-NE-Propionyl-LysB28,ProB29-human insulin analog.
Bl-Na-Propionyl-LysB28,ProB29-human insulin analog.
A1-Na-Propionyl-LysB28,ProB29-human insulin analog.
B28-Ns-Propionyl-,B1-Na-propionyl-LysB28,ProB29-human
insulin analog.
B28-Ns-Propionyl-,A1-Na-propionyl-LysB28,Pro829-human
insulin analog.
A1-Na-Propionyl-,B1-Na-propionyl-LysB28,ProB29-human insulin
analog.
828-Ns-Propionyl-, A1-Na propionyl-, B1-Na-propionyl-
LysB28,ProB29-human insulin analog.
B28-Ns-Butyryl-LysB28,ProB29-human insulin analog.
B1-Na-Butyryl-LysB28,ProB29-human insulin analog.
A1-Na-Butyryl-LysB28,ProB29-human insulin analog.
B28-Ns-Butyryl-,B1-Na-butyryl-LysB28,ProB29-human insulin
analog.
828-NE-Butyryl-,A1-Na-butyryl-LysB28,ProB29-human insulin
analog.
Al-Na-Butyryl-,B1-Na-butyryl-LysB28,ProB29-human insulin
analog.
B28-NE-Butyryl-, A1-Na butyryl-,B1-Na-butyryl-LysB28,ProB29-
human insulin analog.
B28-Ns-Pentanoyl-LysB28,ProB29-human insulin analog.
B1-Na-Pentanoyl-LysB28,ProB29-human insulin analog.
A1-Na-Pentanoyl-LysB28,ProB29-human insulin analog.
B28-Ns-Pentanoyl-,Bl-Na-pentanoyl-LysB28,ProB29-human
insulin analog.
H28-Ns-Pentanoyl-,A1-Na-pentanoyl-LysB28,ProB29-human
insulin analog.
A1-Na-Pentanoyl-,B1-Na-pentanoyl-Lys828,ProB29-human insulin
analog.
CA 02315300 2000-06-20
WO 99/32116 PCT/US9827299
-47-
B28-N8-Pentanoyl-, A1-Na pentanoyl-,B1-Na-pentanoyl-
LysB28,ProB29-human insulin analog.
B28-NE-Hexanoyl-LysB28,ProB29-human insulin analog.
B1-Na-Hexanoyl-LysB28,ProB29-human insulin analog.
A1-Na-Hexanoyl-LysB28,ProB29-human insulin analog.
B28-Ng-Hexanoyl-,B1-Na-hexanoyl-LysB28,Pro829-human insulin
analog.
B28-NE-Hexanoyl-,A1-Na-hexanoyl-LysB28,ProB29-human insulin
analog.
A1-Na-Hexanoyl-,B1-Na-hexanoyl-LysB28,ProB29-human insulin
analog.
B28-Ns-Hexanoyl-, A1-Na-hexanoyl-,B1-Na-hexanoyl-
LysB28,ProB29-human insulin analog.
B28-NE-Heptanoyl-LysB28,ProB29-human insulin analog.
B1-Na-Heptanoyl-LysB28,ProB29-human insulin analog.
A1-Na-Heptanoyl-Lys828,ProB29-human insulin analog.
B28-Ns-Heptanoyl-,B1-Na-heptanoyl-LysB28,ProB29-human
insulin analog.
B28-NE-Heptanoyl-,A1-Na-heptanoyl-Lys828,Pro829-human
insulin analog.
A1-Na-Heptanoyl-,B1-Na-heptanoyl-LysB28,ProB29-human insulin
analog.
B28-NE-Heptanoyl-, A1-Na-heptanoyl-,B1-Na-heptanoyl-
LysB28,ProB29-human insulin analog.
B28-N8-Octanoyl-LysB28,ProB29-human insulin analog.
B1-Na-Octanoyl-LysB28,ProB29-human insulin analog.
A1-Na-Octanoyl-LysB28,ProB29-human insulin analog.
B28-NE-Octanoyl-,81-Na-octanoyl-LysB28,ProB29-human insulin
analog.
B28-NE-Octanoyl-,A1-Na-octanoyl-LysB28,Pro829-human insulin
analog.
A1-Na-Octanoyl-,B1-Na-octanoyl-LysB28,ProB29-human insulin
analog.
B28-NE-~ctanoyl-, A1-Na-octanoyl-,B1-Na-octanoyl-
LysB28,ProB29-human insulin analog.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-48-
B28-Ns-Nonanoyl-LysB28,ProB29-human insulin analog.
B1-Na-Nonanoyl-LysB28,ProB29-human insulin analog.
A1-Na-Nonanoyl-LysB28,ProB29-human insulin analog.
828-Ns-Nonanoyl-,B1-Na-nonanoyl-LysB28,Pro829-human insulin
analog.
B28-N~-Nonanoyl-,A1-Na-nonanoyl-LysB28,ProB29-human insulin
analog.
A1-Na-Nonanoyl-,B1-Na-nonanoyl-LysB28,ProB29-human insulin
analog.
B28-NE Nonanoyl-, A1-Na-nonanoyl-,B1-Na-nonanoyl-
LysH28,ProB29-human insulin analog.
B28-NE-Decanoyl-LysB28,ProB29-human insulin analog.
B1-Na-Decanoyl-LysB28,ProB29-human insulin analog.
A1-Na-Decanoyl-Lys828,ProB29-human insulin analog.
828-NE-Decanoyl-,B1-Na-decanoyl-LysB28,ProB29-human insulin
analog.
B28-Ns-Decanoyl-,A1-Na-decanoyl-LysB28,ProB29-human insulin
analog.
Al-Na-Decanoyl-,B1-Na-decanoyl-LysB28,ProB29-human insulin
analog.
B28-NE-Decanoyl-,A1-Na- decanoyl-,B1-Na-decanoyl-
LysB28,Pro829-human insulin analog.
B28-NE-Undecanoyl-LysB28,ProB29-human insulin analog.
B1-Na-Undecanoyl-LysB28,ProB29-human insulin analog.
A1-Na-Ondecanoyl-LysB28,ProB29-human insulin analog.
B28-N8-Dodecanoyl-LysB28,ProB29-human insulin analog.
B1-Na-Dodecanoyl-LysB28,Pro829-human insulin analog.
A1-Na-Dodecanoyl-LysB28,ProB29-human insulin analog.
B28-NE-Tridecanoyl-Lys828,ProB29-human insulin analog.
B1-Na-Tridecanoyl-LysB28,ProB29-human insulin analog.
A1-Na-Tridecanoyl-LysB28,ProB29-human insulin analog.
B28-NE-Tetradecanoyl-LysB28,Pro829-human insulin analog.
Bl-Na-Tetradecanoyl-LysB28,Pro829-human insulin analog.
Al-Na-Tetradecanoyl-LysB28,ProB29-human insulin analog.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-49-
B28-NE-Pentadecanoyl-LysB28,ProB29-human insulin analog.
B1-Na-Pentadecanoyl-LysB28,ProB29-human insulin analog.
A1-Na-Pentadecanoyl-LysB28,ProB29-human insulin analog.
B28-Ns-Hexadecanoyl-Lys828,ProB29-human insulin analog.
B1-Na-Hexadecanoyl-LysB28,ProB29-human insulin analog.
A1-Na-Hexadecanoyl-LysB28,ProB29-human insulin analog.
B28-NE-Heptadecanoyl-LysB28,ProB29-human insulin analog.
B1-Na-Heptadecanoyl-LysB28,ProB29-human insulin analog.
A1-Na-Heptadecanoyl-LysB28,ProB29-human insulin analog.
B28-NE-Octadecanoyl-LysB28,ProB29-human insulin analog.
B1-Na-Octadecanoyl-LysB28,ProB29-human insulin analog.
A1-Na-Octadecanoyl-LysB28,Pro829-human insulin analog.
B29-Ns-Pentanoyl-G1yA21,ArgB3l,ArgB32-human insulin.
B1-Na-Hexanoyl-GlyA2l,ArgB3l,ArgB32-human insulin.
Al-Na-Heptanoyl-G1yA21,ArgB3l,ArgB32-human insulin.
B29-NE-Octanoyl-,B1-Na-octanoyl-GlyA2l,ArgB3l,ArgB32-human
insulin.
B29-N8-Propionyl-, A1-Na-propionyl-G1yA21,ArgB3l,ArgB32-human
insulin.
A1-Na-Acetyl, B1-Na-acetyl-G1yA21,ArgB3l,ArgB32-human
insulin.
B29-NE-Formyl-, A1-Na-formyl-,B1-Na-formyl-
GlyA2l,ArgB3l,ArgB32-human insulin.
B29-NE-Formyl-des(TyrB26)-human insulin.
B1-Na-Acetyl-AspB28-human insulin.
B29-Ns-Propionyl-, A1-Na-propionyl-,B1-Na-propionyl-
AspBl,AspB3,AspB21-human insulin.
A1-Na-Butyryl-AspBlO-human insulin.
B29-Ns-Pentanoyl-G1yA21-human insulin.
B1-Na-Hexanoyl-G1yA21-human insulin.
A1-Na-Heptanoyl-G1yA21-human insulin.
B29-Ns-Octanoyl-,B1-Na-octanoyl-GlyA21-human insulin.
B29-NE-Propionyl-, A1-Na-propionyl-G1yA21-human insulin.
Al-Na-Acetyl, B1-Na-acetyl-G1yA21-human insulin.
CA 02315300 2000-06-20
WO 99/3211b PCT/US98/27299
-50-
B29-NE-Formyl-, A1-Na-formyl-,B1-Na-formyl-G1yA21-human
insulin.
B29-Ns-Butyryl-des(ThrB30)-human insulin.
B1-Na-Butyryl-des(ThrB30)-human insulin.
A1-Na-Butyryl-des(ThrB30)-human insulin.
B29-NE-Butyryl-,B1-Na-butyryl-des(ThrB30)-human insulin.
B29-NE-Butyryl-,A1-Na-butyryl-des(ThrB30)-human insulin.
A1-Na-Butyryl-,B1-Na-butyryl-des(ThrB30)-human insulin.
B29-Ns-Butyryl-, A1-Na-butyryl-,B1-Na-butyryl-des(ThrB30)-
human insulin.
Aqueous compositions containing water as the major
solvent are preferred. Aqueous suspensions wherein water is
the solvent are highly preferred.
The compositions of the present invention are used
to treat patients who have diabetes or hyperglycemia. The
formulations of the present invention will typically provide
derivatized protein at concentrations of from about 1 mg/mL
to about 10 mg/mL. Present formulations of insulin products
are typically characterized in terms of the concentration of
units of insulin activity (units/mL), such as U40, U50,
U100, and so on, which correspond roughly to about 1.4,
1.75, and 3.5 mg/mL preparations, respectively. The dose,
route of administration, and the number of administrations
per day will be determined by a physician considering such
factors as the therapeutic objectives, the nature and cause
of the patient's disease, the patient's gender and weight,
level of exercise, eating habits, the method of
administration, and other factors known to the skilled
physician. In broad range, a daily dose would be in the
range of from about 1 nmol/kg body weight to about 6 nmol/kg
body weight (6 nmol is considered equivalent to about 1 unit
of insulin activity). A dose of between about 2 and about 3
nmol/kg is typical of present insulin therapy.
The physician of ordinary skill in treating
diabetes will be able to select the therapeutically most
advantageous means to administer the formulations of the
CA 02315300 2000-06-20
WO 99/32116 PCT/US98127299
-51-
- present invention. Parenteral routes of administration are
preferred. Typical routes of parenteral administration of
suspension formulations of insulin are the subcutaneous and
intramuscular routes. The compositions and formulations of
the present invention may also be administered by nasal,
buccal, pulmonary, or occular routes.
Glycerol at a concentration of 12 mg/mL to 25
mg/mL is preferred as an isotonicity agent. Yet more highly
preferred for isotonicity is to use glycerol at a
concentration of from about 15 mg/mL to about 17 mg/mL.
M-cresol and phenol, or mixtures thereof, are
preferred preservatives in formulations of the present
invention.
Insulin, insulin analogs, or proinsulins used to
prepare derivatized proteins can be prepared by any of a
variety of recognized peptide synthesis techniques including
classical (solution) methods, solid phase methods, semi-
synthetic methods, and more recent recombinant DNA methods.
For example, see Chance, R. E., et al., U.S. Patent No.
5,514,646, 7 May 1996; EPO publication number 383,472, 7
February 1996; Brange, J. J. V., et al. EPO publication
number 214,826, 18 March 1987; and Belagaje, R. M., et al.,
U.S. Patent No. 5,304,473, 19 April 1994, which disclose the
preparation of various proinsulin and insulin analogs.
These references are expressly incorporated herein by
reference.
Generally, derivatized proteins are prepared using
methods known in the art. The publications listed above to
describe derivatized proteins contain suitable methods to
prepare derivatized proteins. Those publications are
expressly incorporated by reference for methods of preparing
derivatized proteins. To prepare acylated proteins, the
protein is reacted with an activated organic acid, such as
an activated fatty acid. Activated fatty acids are
derivatives of commonly employed acylating agents, and
include activated esters of fatty acids, fatty acid halides,
activated amides of fatty acids, such as, activated azolide
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7299
-52-
derivatives [Hansen, L. B., WIPO Publication No. 98/02460,
22 January 1998], and fatty acid anhydrides. The use of
activated esters, especially N-hydroxysuccinimide esters of
fatty acids, is a particularly advantageous means of
acylating a free amino acid with a fatty acid. Lapidot, et
al. describe the preparation of N-hydroxysuccinimide esters
and their use in the preparation of N-lauroyl-glycine, N-
lauroyl-z-serine, and N-lauroyl-z-glutamic acid. The term
"activated fatty acid ester" means a fatty acid which has
been activated using general techniques known in the art
[Riordan, J. F. and Vallee, B. L., Methods in Enzymology,
XXV:494-499 (1972); Lapidot, Y., et al., J. Lipid Res.
8:142-145 (1967)]. Hydroxybenzotriazide (HOBT), N-
hydroxysuccinimide and derivatives thereof are particularly
well known for forming activated acids for peptide
synthesis.
To selectively acylate the s-amino group, various
protecting groups may be used to block the a-amino groups
during the coupling. The selection of a suitable protecting
group is known to one skilled in the art and includes p-
methoxybenzoxycarbonyl (pmZ). Preferably, the E-amino group
is acylated in a one-step synthesis without the use of
amino-protecting groups. A process for selective acylation
at the NE-amino group of Lys is disclosed and claimed by
Baker, J. C., et al., U.S. Patent No. 5,646,242, 8 July
1997, the entire disclosure of which is incorporated
expressly by reference. A process for preparing a dry
powder of an acylated protein is disclosed and claimed by
Baker, J. C., et al., U.S. Patent No. 5,700,904, 23 December
1997, the entire disclosure of which is incorporated herein
expressly by reference.
The primary role of zinc in the present invention
is to facilitate formation of Zn(II) hexamers of the protein
and derivatized protein, either separately as mixed
hexamers, or together as hybrid hexamers. Zinc facilitates
the formation of hexamers of insulin, and of insulin
CA 02315300 2000-06-20
WO 99/32116 PC1'/US98/27299
-53-
- analogs. Zinc likewise promotes the formation of hexamers
of derivatized insulin and insulin analogs. Hexamer
formation is conveniently achieved by bringing the pH of a
solution comprising protein, or derivatized protein, or both
into the neutral region in the presence of Zn(II) ions, or
by adding Zn(II) after the pH has been adjusted to the
neutral region.
For efficient yield of microcrystals or amorphous
precipitate, the molar ratio of zinc to total protein in the
microcrystal and amorphous precipitate of the present
invention is bounded at the lower limit by about 0.33, that
is, the approximately two zinc atoms per hexamer which are
needed for efficient hexamerization. The microcrystal and
amorphous precipitate compositions will form suitably with
about 2 to about 4-6 zinc atoms present when no compound
that competes with insulin for zinc binding is present.
Even more zinc may be used during the process if a compound
that competes with the protein for zinc binding, such as one
containing citrate or phosphate, is present. Excess zinc
above the minimum amount needed for efficient hexamerization
may be desirable to more strongly drive hexamerization.
Also, excess zinc above the minimum amount can be present in
a formulation of the present invention, and may be desirable
to improve chemical and physical stability, to improve
suspendability, and possibly to further extend time-action.
Consequently, there is a fairly wide range of zinc: protein
ratios allowable in the insoluble compositions, processes,
and formulations of the present invention.
In accordance with the present invention, zinc is
present in the formulation in an amount of from about 0.3
mole to about 7 moles per mole of total protein and more
preferably about from 0.3 mole to about 1.0 mole of total
protein. Yet more highly preferred is a ratio of zinc to
derivatized protein from about 0.3 to about 0.7 mole of zinc
atoms per mole of total protein. Most highly preferred is a
ratio of zinc to total protein from about 0.30 to about 0.55
mole of zinc atoms per mole of total protein. For higher
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-54-
zinc formulations that are similar to PZI preparations, the
zinc ratio is from about 5 to about 7 moles of zinc per mole
of total protein.
The zinc compound that provides zinc for the
present invention may be any pharmaceutically acceptable
zinc compound. The addition of zinc to insulin preparations
is known in the art, as are pharmaceutically acceptable
sources of zinc. Preferred zinc compounds to supply zinc
for the present invention include zinc chloride, zinc
acetate, zinc citrate, zinc oxide, and zinc nitrate.
A complexing compound is required for the
microcrystals and precipitates of the present invention.
The complexing compound must be present in sufficient
quantities to cause substantial precipitation and
crystallization of the hexamers. Such quantities can be
readily determined for a particular preparation of a
particular complexing compound by simple titration
experiments. Ideally, the complexing compound concentration
is adjusted so that there is negligible complexing compound
remaining in the soluble phase after completion of
precipitation and crystallization. This requires combining
the complexing compound based on an experimentally
determined ~isophane" ratio. This ratio is expected to be
very similar to that of NPH and NPL. However, it may be
slightly different because derivatization may affect the
nature of the protein-protamine interaction.
When protamine is the complexing compound, it is
present in the microcrystal in an amount of from about 0.15
mg to about 0.5 mg per 3.5 mg of the total protein. The
ratio of protamine to total protein is preferably from about
0.25 to about 0.40 (mg/mg). More preferably the ratio is
from about 0.25 to about 0.38 (mg/mg). Preferably,
protamine is in an amount of 0.05 mg to about 0.2 mg per mg
of the total protein, and more preferably, from about 0.05
35. to about 0.15 milligram of protamine per milligram of total
protein. Protamine sulfate is the preferred salt form of
protamine for use in the present invention. When protamine
CA 02315300 2000-06-20
WO 99/32116 PC'f/US98/27299
-55-
- sulfate, or other salt form of protamine is used, the mass
of it to be used would have to be adjusted with respect to
the mass of protamine free base that would be used for the
same application by a factor equal to the ratio of the
molecular weights of the salt form and protamine.
To further extend the time action of the
compositions of the present invention or to improve their
suspendability, additional protamine and zinc may be added
after crystallization. Thus, also within the present
invention are formulations having protamine at higher than
isophane ratios. For these formulations, the protamine
ratio is from 0.25 mg to about 0.5 mg of protamine per mg of
total protein.
A required component of the microcrystals and
precipitates of the present invention is a hexamer
stabilizing compound. The structures of three hexameric
conformations have been characterized in the literature, and
are designated T6, T3R3, and R6. In the presence of hexamer
stabilizing compound, such as various phenolic compounds,
the R6 conformation is stabilized. Therefore, it is highly
likely that hexamers are in the R6 conformation, or the T3R3
conformation in the crystals and precipitates produced in
the presence of a hexamer stabilizing compound, such as
phenol or m-cresol, among others. A wide range of hexamer
stabilizing compounds are suitable. They must be present in
sufficient proportions with respect to total protein to
stabilize the R6 hexamer conformation. To accomplish this,
at least 2 or at least 3 moles of hexamer stabilizing
compound per hexamer are required for effective hexamer
stabilization. It is preferred that at least 3 moles of
hexamer stabilizing compound per hexamer be present in the
microcrystals and precipitates of the present invention.
The presence of higher ratios of hexamer stabilizing
compound, at least up to 25 to 50-fold higher, in the
solution from which the microcrystals and precipitates are
prepared will not adversely affect hexamer stabilization.
CA 02315300 2000-06-20
WO 99/32116 PCT/US981Z7299
-56-
In formulations of the present invention, a
preservative may be present, especially if the formulation
is intended to be sampled multiple times. As mentioned
above, a wide range of suitable preservatives are known.
Preferably, the preservative is present in the solution in
an amount suitable to provide an antimicrobial effect
sufficient to meet pharmacopoeial requirements.
Preferred preservatives are the phenolic
preservatives, which are enumerated above. Preferred
concentrations for the phenolic preservative are from about
2 mg to about 5 mg per milliliter of the aqueous suspension
formulation. These concentrations refer to the total mass
of phenolic preservatives because mixtures of individual
phenolic preservatives are contemplated. Suitable phenolic
preservatives include, for example, phenol, m-cresol, and
methylparaben. Preferred phenolic compounds are phenol and
m-cresol. Mixtures of phenolic compounds, such as phenol
and m-cresol, are also contemplated and highly preferred.
Examples of mixtures of phenolic compounds are 0.6 mg/mL
phenol and 1.6 mg/mL m-cresol, and 0.7 mg/mL phenol and 1.8
mg/mL m-cresol.
The microcrystals of the present invention are
preferably oblong-shaped, also known as "rod-like", single
crystals that are comprised of a protein, a derivatized
protein, a divalent cation, and including a complexing
compound and a hexamer-stabilizing compound. The mean
length of the microcrystals of the present invention
preferably is within the range of 1 micron to 40 microns,
and more preferably is within the size range of 3 microns to
15 microns.
A preferred composition comprises from about 3 mg
to about 6 mg of protamine sulfate per 35 mg of total
protein, and from about 0.1 to about 0.4 mg zinc per 35 mg
of total protein. Another preferred composition comprises
from about 10 mg to about 17 mg of protamine sulfate per 35
mg of total protein, and from about 2.0 to about 2.5 mg zinc
per 35 mg of total protein. Another preferred composition
CA 02315300 2000-06-20
WO 99/32116 PCf/US98/27299
-57-
- comprises, per mL, protamine sulfate, 0.34-0.38 mg; zinc,
0.01-0.04 mg; and total protein, 3.2-3.8 mg.
Both an un-derivatized protein and a derivatized
protein are required for the present co-crystals and
amorphous precipitates. The ratio between the masses of
these proteins determines the degree of time extension of
the preparations. A preferred ratio of the number of moles
of the protein to the number of moles of the derivatized
protein is between about 1:100 and about 100:1. A further
preferred ratio of the number of moles of the protein to the
number of moles of the derivatized protein is between about
1:1 and about 100:1. Another preferred ratio of the number
of moles of the protein to the number of moles of the
derivatized protein is between about 1:1 and about 20:1.
Yet other preferred ratios of the number of moles of the
protein to the number of moles of the derivatized protein
are: between about 2:1 and about 20:1; between about 2:1 and
10:1; between about 2:1 and 5:1; between about 3:1 and 5:1;
between 1:1 and 1:20; between 1:1 and 1:10; between about
1:2 and about 1:20; between about 1:2 and 1:10; between
about 1:2 and 1:5; between about 1:3 and 1:5; between about
10:1 and about 1:10; between about 9:1 and about 1:9;
between about 5:1 and about 1:5; and between about 3:1 and
about 1:3.
The present invention provides processes for
preparing the compositions. Also, the use of the present
insoluble compositions to prepare medicaments for
controlling blood glucose, and for treating diabetes or
hyperglycemia is contemplated. The amorphous precipitates
and microcrystals of the present invention can be prepared
for use in medicaments, or other uses, by many different
processes.
In summary, suitable processes are comprised
generally of the steps in one of the following sequences:
solubilization (if starting with dry material),
hexamerization, homogenization, complexation, precipitation,
crystallization, and optionally formulation; or
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-58-
- solubilization (if starting with dry material),
homogenization, hexamerization, complexation, precipitation,
crystallization, and optionally formulation.
Solubilization means the dissolution of
derivatized protein and protein sufficiently to allow them
to form hexamers. Hexamerization refers to the process
wherein molecules of protein and derivatized protein bind
with zinc(II) atoms to form hexamers. Complexation denotes
the formation of insoluble complexes between the hexamers
and protamine. Precipitation results typically from the
formation of insoluble complexes. Crystallization involves
the conversion of precipitated hexamer/protamine complexes
into crystals, typically, rod-like crystals.
Solubilization is carried out by dissolving the
derivatized protein and protein in an aqueous solvent. The
aqueous solvent may be, for example, an acidic solution, a
neutral solution, or a basic solution. The aqueous solvent
may be comprised partially of a miscible organic solvent,
such as ethanol, acetonitrile, dimethylsulfoxide, and the
like. Acidic solutions may be, for example, solutions of
HC1, advantageously from about 0.01 N HC1 to about 1.0 N
HCl. Other acids that are pharmaceutically acceptable may
be employed as well. Basic solutions may be, for example,
solutions of NaOH, advantageously from about 0.01 N NaOH to
about 1.0 N NaOH, or higher. Other bases that are
pharmaceutically acceptable may be employed as well. For
the sake of protein stability, the concentration of acid or
base is preferably as low as possible while still being
effective to adequately dissolve the protein and derivatized
protein.
Most proteins (insulin, insulin analogs, and
proinsulins) and many derivatized proteins may be dissolved
to suitable concentrations at neutral pH. Solutions to
dissolve derivatized proteins at neutral pH may contain a
buffer and optionally, one or more additional solutes such
as salts, phenolic compounds, zinc, and isotonicity agents.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-59-
When hexamerization occurs before homogenization,
two populations of homogenous hexamers are formed first, and
then the populations are mixed, thereby forming mixed
hexamers. When homogenization occurs first, hexamerization
yields hybrid hexamers. As mentioned above, to prepare
insoluble compositions comprised of hybrid hexamers, protein
and derivatized protein are homogenized under conditions
favoring dissociation to monomer or dimer aggregation states
prior to hexamerization with a divalent metal cation. To
achieve the necessary dissociation, the protein and
derivatized protein may be mixed under strongly acidic or
strongly basic conditions. The degree of dissociation, and
therefore, homogenization is influenced by the solution
conditions chosen for this step. Insulin and related
proteins readily self-associate in a series of reactions
producing dimers, hexamers, and other associated forms. The
distribution of these association forms at equilibrium is
dependent on many parameters, including pH. These
association reactions are commonly thought to involve
primarily monomer-dimer-hexamer assembly. Consequently,
depending on the solution conditions chosen, homogenization
should accomplish the mixing of monomers, dimers, or a
mixture thereof. Homogenization in 1 N HC1, for example,
could involve a higher fraction of monomer mixing than in
0.1 N HC1, which would probably involve more dimer mixing.
For the preparation of compositions comprised of hybrid
hexamers, the homogenization process will be effective
provided that only a very small or negligible fraction of
homogeneous hexamers of the protein or derivatized protein
exist under the homogenization conditions employed.
Compositions comprised of mixed hexamers
incorporate predominantly two types of hexamers, namely
hexamers of the protein, and hexamers of the derivatized
protein. In this case, the homogenization step occurs after
the hexamerization step, and achieves the homogenization of
the hexamers prior to complexation with the complexing
compound. Consequently, the homogenization step is
CA 02315300 2000-06-20
WO 99/32116 PCTNS98/27299
-60-
- performed under solution conditions that stabilize the
Zn(II)-insulin hexamer. Solution conditions that stabilize
insulin hexamers are well known in the literature.
The solution conditions required for
hexamerization are those that allow the formation of the
hybrid hexamers or mixed hexamers in solution. These
conditions will be identical or very similar to the
conditions under which insulin or insulin analogs are made
to hexamerize. Typically, hexamerization requires zinc and
a neutral to slightly basic pH, which is taken to be from
about pH 6.8 to about pH 8.4. The presence of a hexamer-
stabilizing compound advantageously influences
hexamerization by promoting the R6 or the T3R3 conformations
of the derivatized protein, and in certain instances, of the
protein also. For certain monomeric insulin analogs, a
hexamer-stabilizing compound is required to form hexamers.
For compositions comprised of hybrid hexamers,
seven hexameric species are expected: P6, P5D1, P4D2, P3D3,
PZD4, P1D5, and D6, where P represents the protein monomer,
and D represents the derivatized protein monomer. The
statistical distribution of hexamers is expected to conform
to a Poisson distribution, and will be influenced by the
relative proportion of protein and derivatized protein, and
by the degree of dissociation prior to hexamerization. For
example, from a homogenized solution constituted
predominantly of dimers, four major hybrid hexamer species
are expected: P6, P4D2, PZD4, and D6. For compositions
comprised of mixed hexamers, only two hexameric species are
expected to predominate: P6 and D6.
The complexation step must involve the combination
a complexing compound with hexamer under solution conditions
where each is initially soluble. This could be accomplished
by combining separate solutions of hexamers and of
protamine, or by first forming a solution of protein,
CA 02315300 2000-06-20
wo ~r~iil6 Pc~rius9amz~
-61-
- derivatized protein, and protamine at acidic or basic pH,
and then shifting the pH to the neutral range.
During crystallization, the solution conditions
must stabilize the crystallizing species, and promote the
conversion of precipitate to solute to crystal. Thus, the
solution conditions will determine the rate and outcome of
crystallization. Crystallization likely involves a complex
equilibrium involving non-crystalline precipitate, dissolved
hexamer-protamine complexes, and crystal. To obtain
microcrystals, the conditions chosen for crystallization
must drive the equilibrium toward crystal formation. Also,
in light of the hypothesized equilibrium, the solubility of
the derivatized protein is expected to profoundly affect
crystallization rate and size because lower solubility will
likely slow the net conversion from precipitate to solution
to crystal. Furthermore, it is well-recognized that slowing
the rate of crystallization often results in larger
crystals. Thus, the crystallization rate and crystal size
are thought to depend on the size and nature of the
derivatizing moiety on the derivatized protein.
Crystallization parameters that influence the
crystallization rate and the size of crystals of the present
invention are: acyl group size and nature; temperature; the
presence and concentration of compounds that compete with
the protein and derivatized protein for zinc, such as
citrate, phosphate, and the like; the nature and
concentration of phenolic compound(s); zinc concentration;
the presence and concentration of a miscible organic
solvent; the time permitted for crystallization; the pH and
ionic strength; buffer identity and concentration; the
concentration of precipitants; the presence of seeding
materials; the shape and material of the container; the
stirring rate; and the total protein concentration.
Temperature and the concentration of competing compounds are
thought to be of particular importance.
Competing compounds, such as citrate, may affect
the rate at which crystals form, and indirectly, crystal
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-62-
size and quality. These compounds may exert their effect by
forming coordination complexes with zinc in solution, thus
competing with the relatively weak zinc binding sites on the
surface of the hexamer for zinc. Occupation of these weak
surface binding sites probably impedes crystallization.
Additionally, many derivatized proteins are partially
insoluble in the presence of little more than 0.333 zinc per
mole of derivatized protein, and the presence of competing
compounds restores solubility, and permits crystallization.
The optimum concentration of competing compound can be
determined using routine techniques for any combination of
protein and derivatized protein. As an upper limit, of
course, is the concentration at which zinc is precipitated
by the competing compound, or the concentration at which
residual competing compound would be pharmaceutically
unacceptable, such as, when it would cause pain or
irritation at the site of administration.
An example of a process for preparing the
precipitates and crystals of the present invention follows.
A measured amount of the derivatized protein and a measured
amount of the protein are dissolved in, or are combined to
form a solution in an aqueous solvent containing a hexamer-
stabilizing compound, such as a phenolic compound. To this
solution is added a solution of zinc as one of its soluble
salts, for example Zn(II)C12, to provide from about 0.3
moles of zinc per mole of derivatized insulin to about 0.7
moles, or to as much as 1.0 moles, of zinc per mole of total
protein (protein + derivatized protein). Absolute ethanol,
or another miscible organic solvent, may optionally be added
to this solution in an amount to make the solution from
about 5% to about 10% by volume organic solvent. This
solution may then be filtered through a 0.22 micron, low-
protein binding filter. A protamine solution is prepared by
dissolving a measured amount of protamine in an aqueous
solvent. This solution may be filtered through a 0.22
micron, low-protein binding filter. The solution of protein
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-63-
- and derivatized protein and the protamine solution are
combined, whereupon a precipitate forms initially. The
resulting suspension is stirred slowly at room temperature
(typically about 20-25°C), whereupon microcrystals are
formed within a period from about 4 hours to about 10 days.
The microcrystals may then be separated from the
mother liquor and introduced into a different solvent, for
storage and administration to a patient. Examples of
appropriate aqueous solvents are as follows: water for
injection containing 25 mM TRIS, 5 mg/mL phenol and 16 mg/mL
glycerol; water for injection containing 2 mg/mL sodium
phosphate dibasic, 1.6 mg/mL m-cresol, 0.65 mg/mL phenol,
and 16 mg/mL glycerol; and water for injection containing 25
mM TRIS, 5 mg/mL phenol, 0.1 M trisodium citrate, and 16
mg/mL glycerol.
In another process for preparing the insoluble
compositions of the present invention, for example, a
measured mass of dry derivatized protein and a measured mass
of dry protein are dissolved together in an acidic aqueous
solvent, such as 0.1 N - 1.0 N HC1. This solution is
stirred to insure thorough mixing of derivatized protein and
protein. The ratio of derivatized protein powder to protein
powder in this mixture is predefined to achieve a similar
ratio of derivatized protein to protein in the insoluble
composition to be produced. A separately prepared aqueous
solution comprised of a phenolic preservative and,
optionally, a pharmaceutically acceptable buffer, is
combined with the acidic solution of the proteins. The pH
of the resulting solution is then adjusted to about 6.8 to
about 8.4, preferably from about 6.8 to about 8.0, or
preferably to a pH of from about 7.2 to about 7.8, and most
preferably from about 7.4 to about 7.8. To this solution is
added a solution of zinc as one of its soluble salts, for
example Zn(II)C12, to provide from about 0.3 moles of zinc
per mole of total insulin to about 4 moles of zinc per mole
of total insulin. This solution is adjusted to a pH as
CA 02315300 2000-06-20
WO 99/32116 PCTNS98/27299
-64-
- given above, and preferably to about 7.4 -7.6, and may then
be filtered through a 0.22 micron, low-protein binding
filter. A solution of protamine is prepared by dissolving a
measured mass of protamine in an aqueous solvent. The
protamine solution may be filtered through a 0.22 micron,
low-protein binding filter. The solution of protein and
derivatized protein and the protamine solution are combined,
whereupon a precipitate forms initially. The resulting
suspension is stirred slowly at room temperature (typically
about 20-25°C), whereupon microcrystals are formed within a
period from about 4 hours to about 10 days.
In another process for preparing the insoluble
compositions of the present invention, a measured amount of
a derivatized protein is first dissolved in an aqueous
solvent containing a phenolic preservative. To this
solution is added a solution of zinc as one of its soluble
salts, for example Zn(II)C12, to provide from about 0.3
moles of zinc per mole of derivatized protein to about 4
moles of zinc per mole of derivatized protein. The pH of
the resulting solution is then adjusted to about 6.8 to
about 8.4, preferably from about 6.8 to about 8.0, or
preferably to a pH of from about 7.2 to about 7.8, and most
preferably from about 7.4 to about 7.8. A second solution
is prepared separately wherein a measured amount of a
protein selected from the group consisting of insulin,
insulin analogs, and proinsulin is dissolved in an aqueous
solvent containing a phenolic preservative. To this
solution is added a solution of zinc as one of its soluble
salts, for example Zn(II)C12, to provide from about 0.3
moles of zinc per mole of protein to about 4 moles of zinc
per mole of protein. The pH of the resulting solution is
then adjusted to about 6.8 to about 8.4, preferably from
about 6.8 to about 8.0, or preferably to a pH of from about
7.2 to about 7.8, and most preferably from about 7.4 to
about 7.8, or 7.4 - 7.6. Portions of the derivatized
protein solution and the protein solution are combined in a
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7299
-65-
- ratio that is predefined in order to achieve a similar ratio
of derivatized protein to protein in the insoluble
composition. This solution is stirred to insure thorough
mixing of derivatized protein and protein. This solution is
then adjusted to a pH of about 7.6, and may then be filtered
through a 0.22 micron, low-protein binding filter. A
protamine solution is prepared separately by dissolving a
measured amount of protamine in an aqueous solvent. This
protamine solution may be filtered through a 0.22 micron,
low-protein binding filter. The solution of protein and
derivatized protein and the protamine solution are combined,
whereupon a precipitate forms initially. The resulting
suspension is stirred slowly at room temperature (typically
about 20-25°C), whereupon microcrystals are formed within a
period from about 4 hours to about 10 days.
While not describing all of the very many types of
processes that will produce the insoluble compositions of
the present invention in any way, the following are yet
further processes of the present invention:
dissolving a protein, a derivatized protein, a
hexamer-stabilizing compound, and a divalent metal cation in
an aqueous solvent having a pH that will permit the
formation of hexamers, and adding a complexing compound;
dissolving a protein, a derivatized protein, a
hexamer-stabilizing compound, and a divalent metal cation in
an aqueous solvent having a pH that will not permit the
formation of hexamers, adjusting the pH to between about 6.8
and about 7.8, and adding a complexing compound;
dissolving a protein, a hexamer-stabilizing
compound, and a divalent metal cation in an aqueous solvent
having a pH that will permit the formation of hexamers,
separately, dissolving a derivatized protein, a hexamer-
stabilizing compound, and a divalent metal cation in an
aqueous solvent having a pH that will permit the formation
of hexamers, thoroughly mixing together these two solution,
and then adding a complexing compound;
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7299
-66-
dissolving a protein, a hexamer-stabilizing
compound, a divalent metal cation, and a complexing compound
in an aqueous solvent, wherein the resulting solution has a
pH at which precipitation does not occur, separately,
dissolving a derivatized protein, a hexamer-stabilizing
compound, a divalent metal cation, and a complexing compound
in an aqueous solvent, wherein the resulting solution has a
pH at which precipitation does not occur, thoroughly mixing
together these two solutions, and adjusting the pH of the
solution of to a value at which precipitation occurs;
dissolving a protein, a derivatized protein, a
hexamer-stabilizing compound, a divalent metal cation, and a
complexing compound in an aqueous solvent, wherein the
resulting solution has a pH at which precipitation does not
occur and adjusting the pH of the solution to a value at
which precipitation occurs;
dissolving a protein, a derivatized protein, a
hexamer-stabilizing compound, and a divalent metal cation,
in an aqueous solvent, wherein the~resulting solution has a
pH at which precipitation will not occur when a complexing
agent is added, adding a complexing compound, and adjusting
the pH of the solution of step b) to a value at which
precipitation occurs;
dissolving a protein, a hexamer-stabilizing
compound, and a divalent metal cation in an aqueous solvent,
wherein the resulting solution has a pH at which
precipitation will not occur when a complexing compound is
added, separately, dissolving a derivatized protein, a
hexamer-stabilizing compound, and a divalent metal cation in
an aqueous solvent, wherein the resulting solution has a pH
at which precipitation will not occur when a complexing
compound is added, thoroughly mixing together these two
solutions, adding complexing compound to the solution, and
adjusting the pH to a value at which precipitation occurs;
dissolving a protein, a protein derivative, a
hexamer-stabilizing compound, and a divalent metal cation in
an aqueous solvent, wherein the resulting solution has a pH
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-67-
- at which precipitation will not occur when a complexing
compound is added, adjusting the pH of the solution to a
value at which precipitation will occur when a complexing
compound is added, and adding a complexing compound to the
solution;
dissolving a protein, a hexamer-stabilizing
compound, and a divalent metal cation in an aqueous solvent,
wherein the resulting solution has a pH at which
precipitation will not occur when a complexing compound is
added, separately, dissolving a derivatized protein, a
hexamer-stabilizing compound, and a divalent metal cation in
an aqueous solvent, wherein the resulting solution has a pH
at which precipitation will not occur when a complexing
compound is added; thoroughly mixing together these two
solutions, adjusting the pH of the solution of step c) to a
value at which precipitation will occur when a complexing
compound is added, and adding a complexing compound to the
solution;
In a preferred embodiment, the microcrystals are
prepared in a manner that obviates the need to separate the
microcrystals from the mother liquor. Thus, it is preferred
that the mother liquor itself be suitable for administration
to the patient, or that the mother liquor can be made
suitable for administration by dilution with a suitable
diluent. The term diluent will be understood to mean a
solution comprised of an aqueous solvent in which is
dissolved various pharmaceutically acceptable excipients,
including without limitation, a buffer, an isotonicity
agent, zinc, a preservative, protamine, and the like.
In addition to the protein, derivatized protein,
divalent cation, complexing compound, and hexamer-
stabilizing compound, pharmaceutical compositions adapted
fQr parenteral administration in accordance with the present
invention may employ additional excipients and carriers such
as water miscible organic solvents such as glycerol, sesame
oil, aqueous propylene glycol and the like. When present,
such agents are usually used in an amount less than about
CA 02315300 2000-06-20
WO 99/32116 PCTNS98/27299
-68-
- 2.0% by weight based upon the final formulation. For
further information on the variety of techniques using
conventional excipients or carriers for parenteral products,
please see Remington~s Pharmaceutical Sciences, 17th
Edition, Mack Publishing Company, Easton, PA, USA (1985),
which is incorporated herein by reference.
In the broad practice of the present invention, it
is also contemplated that a formulation may contain a
mixture of the microcrystals and a soluble fraction of a
protein selected from insulin, derivatized insulin, insulin
analogs, and derivatized insulin analogs. Examples of such
pharmaceutical compositions include sterile, isotonic,
aqueous saline solutions of insulin, an insulin analog, a
derivatized insulin, or a derivatized insulin analog,
buffered with a pharmaceutically acceptable buffer and
pyrogen-free. Preferred for the soluble phase are insulin
or a rapid-acting insulin analog, such as, LysB28,ProB29-
human insulin, or AspB28-human insulin. Such mixtures are
designed to provide a combination of meal-time control of
glucose levels, which is provided by the soluble insulin,
and basal control of glucose levels, which is provided by
the insoluble insulin. The ratio of total protein (protein
plus derivatized protein) in the insoluble phase and total
protein in the soluble phase is in the range of about 9:1 to
about 1:9. A preferred range of this ratio is from about
9:1 to about 1:1, and more preferably, about 7:3. Other
ratios are 1:1, and 3:7.
The following preparations and examples illustrate
and explain the invention. The scope of the invention is
not limited to these preparations and examples. Reference
to parts" for solids means parts by weight. Reference to
"parts" for liquids means parts by volume. Percentages,
when used to express concentration, mean mass per volume
(x100). All temperatures are degrees Centigrade (°C).
°TRIS" refers to 2-amino-2-hydroxymethyl-1,3,-propanediol.
The 1000 part-per-million (ppm) zinc solution was prepared
by diluting 1.00 mL of a 10,000 ppm zinc atomic absorption
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-69-
standard solution [Ricca Chemical Company, zinc in dilute
nitric acid] with water to a final volume of 10.00 mL.
In many of the preparations described below, the
yield of precipitates and crystals was estimated. The yield
estimate relied on determination of the amount of total
protein in the precipitate or crystal, and on an estimate of
the amount of the same initially in solution. To determine
the amount of total protein, samples of re-dissolved
precipitate or crystal, and of the supernatant above the
precipitate or crystals, were analyzed by reversed-phase
gradient HPLC, as described below.
Briefly, the analytical system relied on a C8
reversed-phase column, at 23°C. The flow rate was 1.0
mL/min and TJV detection at 214 nm was used. Solvent A was
0.1% (vol:vol) trifluroacetic acid in 10:90 (vol:vol)
acetonitrile:water. Solvent B was 0.1% (vol:vol)
trifluroacetic acid in 90:10-(vol:vol) acetonitrile:water.
The development program was (minutes, %B): (0.1,0);
(45.1,75); (50.1,100); (55,100); (57,0); (72,0). All
changes were linear. Other analytical systems could be
devised by the skilled person to achieve the same objective.
To prepare for the HPLC analysis, aliquots of the
well-mixed suspensions were dissolved by diluting with
either 0.01 N HC1 or 0.03 N HC1. Results of HPLC analysis
of these solutions permitted calculation of total protein.
Aliquots of the suspensions were centrifuged for
approximately 5 minutes in an Eppendorf 5415C
microcentrifuge at 14,000 rpm. The decanted supernatant was
diluted with either 0.01 N or 0.1 N HC1 and analyzed by
HPLC. The precipitate was washed by re-suspending in
Dulbecco's phosphate buffered saline (without calcium or
magnesium) and re-pelleted by centrifugation. The buffer
was decanted and the solid was re-dissolved in 0.01 N HC1.
The re-dissolved precipitate was analyzed by HPLC.
HPLC was used to confirm the presence of the
expected proteins in the acidified suspension, re-dissolved
precipitate, and supernatant and also to determine protein
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-70-
concentrations. The retention times of peaks in the
chromatograms of the re-dissolved precipitates were compared
with the retention times observed for protamine and the
active compounds used to make the formulations. The
agreement between retention times was always good, showing
that protamine, protein, and derivatized proteins were
actually incorporated into the microcrystals.
Concentrations of protein and derivatized protein were
determined by comparing the appropriate peak areas to the
areas of a standard. A 0.22 mg/mL solution of derivatized
insulin was used as the standard. A standard containing
protamine was run, but only for the purpose of determining
the retention time. Protamine concentration was not
quantitated.
In many of the preparations described below, a
standard spectrophotometric assay was used to determine how
rapidly the crystals dissolved in Dulbecco's phosphate
buffered saline (pH 7.4) at room temperature. Significant
deviations from the procedure described immediately below
are noted where appropriate in the descriptions of the
preparations. A spectrophotometer suitable for measuring in
the ultraviolet range, and equipped with a 1 cm cuvette and
a magnetic cuvette stirrer was used for all the dissolution
assays. The cuvette, containing a small stir bar and 3.00
mL of phosphate buffered saline (PBS), was put into the cell
compartment of the spectrophotometer. The instrument was
set to 320 nm and zeroed against the same buffer. Then 4.0
microliters of a well suspended formulation, usually having
a total concentration approximately equivalent to a U50
formulation, or about 1.6 to 1.8 mg/mL, was added to the
cuvette. After waiting 1.0 minute for mixing, the optical
density at 320 nm was recorded. Since the proteins involved
in this work do not absorb light at 320 nm, the decrease in
optical density was due to reduction in light scattering as .
the crystals dissolved. The time for the optical density to
drop to half of its initial value is typically reported
(t1/2). As a control, 2.0 microliters of U100 Humulin~ N
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7299
-71-
- (i.e., human insulin NPH, which is also known as human NPH
insulin) was added to 3.00 mL of PBS buffer, and the optical
density at 320 nm monitored as above. The dissolution half-
time (ti/2) for the Humulin~ N formulation was about 6
minutes.
Preparatioa 1
9:1 co-crystals of humaa insulin aad HZ9-NE-octaaoyl- humaa
iasulin
A dry powder of B29-NE-octanoyl-LysB29 human
l0 insulin (0.7 parts by mass) and a dry powder of human
insulin (6.3 parts by mass) are dissolved in 1000 parts by
volume of an aqueous solvent composed of 50 mM TRIS, 0.1 M
trisodium citrate, and 10 mg/ml phenol at pH 7.6. To this
solution is added 75 parts of a 15.3 mM solution of zinc
chloride. The pH is adjusted to 7.6 with 1 N HC1 and/or 1 N
NaOH. This solution is filtered through a 0.22 micron, low-
protein binding filter. A second solution is prepared by
dissolving 7 parts by mass of protamine sulfate in 10,000
parts by volume of water then filtering through a 0.22
micron, low-protein binding filter. Equal volumes of the
solution containing insulin and acylated insulin and of the
protamine sulfate solution are combined. Initially, an
amorphous precipitate forms. This suspension is allowed to
stand for about 24 hours at room temperature (typically
about 22°C). The amorphous precipitate converts to a co-
crystalline microcrystalline solid.
Preparation 2
3:1 co-crystals of humaa iasulia aad Ba9-Ns-octaaoyl- humaa
iasulia
The procedure of Preparation 1 is followed, except
that 1.75 parts by mass of a dry powder of B29-NE-octanoyl-
LysB29 human insulin and 5.25 parts by mass of a dry powder
of human insulin are used. After equal volumes of the
solution containing insulin and acylated insulin and of the
protamine sulfate solution are combined, an amorphous
precipitate forms. This suspension is allowed to stand for
about 24 hours at room temperature (typically about 22°C}.
CA 02315300 2000-06-20
WO 99132116 PCT/US98/27299
-72-
- The amorphous precipitate converts to a co-crystalline
microcrystalline solid.
preparation 3
Formulatioa of 3:1 co-crystals of humaa iasulia aad B29-I~s-
octaaoyl-humaa iasulia
The co-crystalline microcrystals prepared by the
method of Preparation 1 are separated from the supernatant
and are recovered by conventional solid/liquid separation
methods, such as, filtration, centrifugation, or
decantation. The recovered co-crystalline microcrystals are
then suspended in a solution consisting of 25 mM TRIS, 5
mg/ml phenol, and 16 mg/ml glycerol, pH 7.8, so that the
final concentration of insulin activity is about 100 U/mL.
Preparstioa 4
lsl co-crystals of human iasulia aad Ba9-Ns-octanoyl- humaa
iasulia
The procedure of Preparation 1 is followed, except
that 3.5 parts by mass of a dry powder of B29-Ng-octanoyl-
Lys829 human insulin and 3.5 parts by mass of a dry powder
of human insulin are used. After equal volumes of the
solution containing insulin and acylated insulin and of the
protamine sulfate solution are combined, an amorphous
precipitate forms. This suspension is allowed to stand for
about 24 hours at room temperature (typically about 22°C).
The amorphous precipitate converts to a co-crystalline
microcrystalline solid.
Preparation 5
1:3 co-crystals of hvmaa fasulia aad B29-Ns-octanoyl- humaa
iasulia
The procedure of Preparation 1 is followed, except
that 5.25 parts by mass of a dry powder of B29-NE-octanoyl-
LysB29 human insulin and 1.75 parts by mass of a dry powder
of human insulin are used. After equal volumes of the
solution containing insulin and acylated insulin and of the
protamine sulfate solution are combined, an amorphous
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-73-
- precipitate forms. This suspension is allowed to stand for
about 24 hours at room temperature (typically about 22°C).
The amorphous precipitate converts to a co-crystalline
microcrystalline solid.
Preparation 6
3:1 co-crystals of human insulin and 829-NE-hexaaoyl- human
insulin
The procedure of Preparation 1 is followed, except
that 1.75 parts by mass of a dry powder of B29-NE-hexanoyl-
LysB29 human insulin and 5.25 parts by mass of a dry powder
of human insulin are used. After equal volumes of the
solution containing insulin and acylated insulin and of the
protamine sulfate solution are combined, an amorphous
precipitate forms. This suspension is allowed to stand for
about 24 hours at room temperature (typically about 22°C).
The amorphous precipitate will convert to a co-crystalline
microcrystalline solid.
8reparation 7
3:1 co-crystals of human insulin and BZ9-NE-butyrl-human
insulin
The procedure of Preparation 1 is followed, except
that 1.75 parts by mass of a dry powder of B29-NE-butyryl-
LysB29 human insulin and 5.25 parts by mass of a dry powder
of human insulin are used. After equal volumes of the
solution containing insulin and acylated insulin and of the
protamine sulfate solution are combined, an amorphous
precipitate forms. This suspension is allowed to stand for
about 24 hours at room temperature (typically about 22°C).
The amorphous precipitate will convert to a co-crystalline
microcrystalline solid.
Preparation 8
Co-crystalline mierocrystals of protamiae-ziae-
B29-Ns-octaaoyl-human insulin-human insulin
B29-Ns-octanoyl-LysB29 human insulin (20.1 mg) was
dissolved in 1 mL of a solvent composed of 0.1 N HC1. Human
insulin (19.3 mg) was dissolved in 1 mL of a solvent
CA 02315300 2000-06-20
wo ~r~z~ i 6 pcrius9smz99
-74-
composed of 0.1 N HCl. Five solutions comprising different
ratios of B29-NE-octanoyl-LysB29 human insulin to human
insulin were prepared by combining volumes of each solution
in the ratios shown below.
Table 3. Volumes of solutions of human insulin and of B29-
NE-octanoyl-human insulin used to prepare precipitates and
microcrystals.
Volume (~C1) ~ Ratio of Human Insulin to
Acylated Human Insulin
1:0 ~ 3:1 ~ 1:1 ~ 1:3 I 0:1
Human insulin solution ~ 400 ~ 300 ~ 200 ~ 100 ~ 0
B29-Ns-octanoyl-human ~ 0 ~ 100 ~ 200 ~ 300 ~ 400
insulin solution
To each of these five solutions, 1.6 mL of a
solvent composed of 50 mM TRIS buffer, 0.1 M trisodium
citrate, and 10 mg/mL phenol at pH 7.6 was added. To each
of the five solutions, 0.15 ml of a 15.3 mM solution of zinc
chloride was added. Each of the resulting five solutions
were adjusted to a pH of 7.6 with 1 N NaOH. Each of the
resulting five solutions were filtered through a 0.22
micron, low-protein binding filter. An additional solution
was prepared by dissolving 3.50 mg of protamine sulfate in
10 mL of water then filtered through a 0.22 micron, low-
protein binding filter. A volume of 1.9 mL of each of the
five solutions and 1.9 mL of the protamine sulfate solution
were combined respectively, in each of the five solutions
resulting in the immediate appearance of an amorphous
precipitate. These five solutions were allowed to stand for
24 hours at room temperature (approximately 22°C). This
procedure resulted in the formation of a white-to-off-white
microcrystalline solid in each of the five solutions.
Prnparatioa 9
9:1 co-crystals of human insulia aad 829-Ns-octaaoyl- humaa
iasulia
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7299
-75-
A dry powder of B29-Ns-octanoyl-LysB29 human
insulin (0.7 parts by mass) is dissolved in 100 parts by
volume of an aqueous solvent composed of 50 mM TRIS, 0.1 M
trisodium citrate, and 10 mg/ml phenol at pH 7.6. To this
solution is added 7.5 parts of a 15.3 mM solution of zinc
chloride. A second solution is prepared wherein a dry
powder of human insulin (6.3 parts by mass) is dissolved in
900 parts by volume of an aqueous solvent composed of 50 mM
TRIS, 0.1 M trisodium citrate, and 10 mg/ml phenol at pH
7.6. To this solution is added 67.5 parts of a 15.3 mM
solution of zinc chloride. The acylated insulin solution
and the insulin solution are combined together and stirred
to insure mixing of the two solutions. This solution is
filtered through a 0.22 micron, low-protein binding filter.
A protamine solution is prepared by dissolving 7 parts by
mass of protamine sulfate in 10,000 parts by volume of water
then filtering through a 0.22 micron, low-protein binding
filter. Equal volumes of the acylated insulin solution and
of the protamine sulfate solution are combined. An
amorphous precipitate forms. This suspension is allowed to
stand for about 24 hours at room temperature (typically
about 22°C). The amorphous precipitate will convert to a
co-crystalline microcrystalline solid.
Preparatioa 10
3i1 co-crystals of humaa iasulia aad B29-Ns-octanoyl- humaa
iasulia
A dry powder of B29-Ns-octanoyl-LysB29 human
insulin (1.75 parts by mass) is dissolved in 250 parts by
volume of an aqueous solvent composed of 50 mM TRIS, 0.1 M
trisodium citrate, and 10 mg/ml phenol at pH 7.6. To this
solution is added 18.75 parts of a 15.3 mM solution of zinc
chloride. A second solution is prepared wherein a dry
powder of human insulin (5.25 parts by mass) is dissolved in
750 parts by volume of an aqueous solvent composed of 50 mM
TRIS, 0.1 M trisodium citrate, and 10 mg/ml phenol at pH
7.6. To this solution is added 56.25 parts of a 15.3 mM
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-76-
- solution of zinc chloride. The acylated insulin solution
and the insulin solution are combined together and stirred
to insure mixing of the two solutions. This solution is
filtered through a 0.22 micron, low-protein binding filter.
A protamine solution is prepared by dissolving 7 parts by
mass of protamine sulfate in 10,000 parts by volume of water
then filtering through a 0.22 micron, low-protein binding
filter. Equal volumes of the acylated insulin solution and
of the protamine sulfate solution are combined. An
amorphous precipitate forms. This suspension is allowed to
stand for about 24 hours at room temperature (typically
about 22°C). The amorphous precipitate converts to a co-
crystalline microcrystalline solid.
Breparatioa il
1:1 co-crystals of humaa insulin and H29-Ns-octaaoyl- human
insulin
A dry powder of B29-Ns-octanoyl-LysB29 human
insulin (3.5 parts by mass) is dissolved in 500 parts by
volume of an aqueous solvent composed of 50 mM TRIS, 0.1 M
trisodium citrate, and 10 mg/ml phenol at pH 7.6. To this
solution is added 1.75 parts of a 15.3 mM solution of zinc
chloride. A second solution is prepared wherein a dry
powder of human insulin (3.5 parts by mass) is dissolved in
500 parts by volume of an aqueous solvent composed of 50 mM
TRIS, 0.1 M trisodium citrate, and 10 mg/ml phenol at pH
7.6. To this solution is added 37.5 parts of a 15.3 mM
solution of zinc, chloride. The acylated insulin solution
and the insulin solution are combined together and stirred
to insure mixing of the two solutions. This solution is
filtered through a 0.22 micron, low-protein binding filter.
A protamine solution is prepared by dissolving 7 parts by
mass of protamine sulfate in 10,000 parts by volume of water
then filtering through a 0.22 micron, low-protein binding
filter. Equal volumes of the acylated insulin solution and
of the protamine sulfate solution are combined. An
amorphous precipitate forms. This suspension is allowed to
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
_77_
stand for about 24 hours at room temperature (typically
about 22°C). The amorphous precipitate converts to a co-
crystalline microcrystalline solid.
Preparatioa la
1:3 co-crystals of humaa iasulia aad B29-NE-octaaoyl- humaa
iasulia
A dry powder of B29-Ns-octanoyl-LysB29 human
insulin (5.25 parts by mass) is dissolved in 750 parts by
volume of an aqueous solvent composed of 50 mM TRIS, 0.1 M
trisodium citrate, and 10 mg/ml phenol at pH 7.6. To this
solution is added 56.25 parts of a 15.3 mM solution of zinc
chloride. A second solution is prepared wherein a dry
powder of human insulin (1.75 parts by mass) is dissolved in
250 parts by volume of an aqueous solvent composed of 50 mM
TRIS, 0.1 M trisodium citrate, and 10 mg/ml phenol at pH
7.6, To this solution is added 18.75 parts of a 15.3 mM
solution of zinc chloride. The acylated insulin solution
and the insulin solution are combined together and stirred
to insure mixing of the two solutions. This solution is
filtered through a 0.22 micron, low-protein binding filter.
A protamine solution is prepared by dissolving 7 parts by
mass of protamine sulfate in 10,000 parts by volume of water
then filtering through a 0.22 micron, low-protein binding
filter. Equal volumes of the acylated insulin solution and
of the protamine sulfate solution are combined. An
amorphous precipitate forms. This suspension is allowed to
stand for about 24 hours at room temperature (typically
about 22 °C). The amorphous precipitate converts to a co-
crystalline microcrystalline solid.
Preparatioa 13
Co-crystals of humaa iasulia aad B29-NE-hexanoyl-humaa
fasulia
An acidic solution of B29-Ns-hexaaoyl-human
insulin was prepared by dissolving 12.3 mg of B29-Ns-
hexanoyl-human insulin in 0.3 mL of 0.1 N HCl. An acidic
solution of human insulin was prepared by dissolving 4.6 mg
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27199
_78_
of human insulin (zinc crystals) in 0.1 mL of 0.1 N HCl.
The two solutions were combined giving a total volume of 0.4
mL. This resulting solution was stirred for approximately 5
minutes. To this resulting solution was added, with
stirring, 0.150 mL of a 1000 ppm zinc(II) solution. A
crystallization diluent was prepared comprising 32 mg/mL
glycerol, 50 mM tris buffer, 10 mg/mL phenol, 100 mM
trisodium citrate, at a pH of 7.6. To the insulin solution
was added 1.6 mL of the crystallization diluent. The pH of
the solution was adjusted to 7.59 using, 1 N NaOH and 1 N
HC1. The solution was filtered through a 0.22 micron, low
protein binding filter. A protamine solution was prepared
by dissolving 7.47 mg of protamine sulfate in 10 mL of
water. Two milliliters (2 mL) of the protamine solution was
added to 2 mL of the insulin solution. The resulting
solution was allowed to stand undisturbed for 18 hours at a
controlled temperature of 25°C.
Microscopic inspection (at 18 hours) revealed that
crystallization had occurred and that the preparation
yielded uniform, single, rod-like crystals possessing
approximate average lengths of 3 microns.
Four milliliters (4 mL) of the crystal formulation
produced above after 18 hours were allowed to stand
undisturbed overnight, and the crystals sedimented
completely. The supernatant was then removed, and replaced
with 4 mL of a diluent comprising 16 mg/mL glycerol, 20 mM
tris buffer, 1.6 mg/mL m-cresol, 0.65 mg/mL phenol, 40 mM
trisodium citrate, pH 7.6. The crystals were then
resuspended, and allowed to sediment again. This procedure
was carried out three times except that on the third
occasion the supernatant was replaced with only 3 mL of
diluent.
The dissolution rate of the crystals was measured
by placing 0.005 mL of the uniformly suspended formulation
into 3 mL of Duibecco~s phosphate buffered saline (without
calcium or magnesium) in a 1 cm path length square quartz
cuvette at a temperature of 22°C. This solution was stirred
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-79-
' at a constant rate using a magnetic cuvette stirrer.
Absorbance measurements at 320 nm were taken at 1 minute
intervals. The absorbance at 320 nm corresponds to the
light scattered by the insoluble particles present in the
aqueous suspension. Consequently, as the microcrystals
dissolve, the absorbance approaches zero. The time required
for the 0.005 mL of this formulation to dissolve was greater
than 150 minutes. The time required for dissolution of a
0.005 mL sample of U100 commercial Humulin N to dissolve
when subjected to the same conditions was about 10 minutes.
The amount of total protein in the formulation was
analyzed by HPLC to quantitate the total potency. The total
potency refers to the total concentration of human insulin
and B29-NE-hexanoyl-human insulin. An aliquot (0.050 mL) of
the fully resuspended formulation was dissolved in 0.950 mL
of 0.01 N HCL, and subjected to HPLC analysis, as described
below. The total potency determined from this analysis was
4.54 mg/mL.
For HPLC analyses, the following conditions were
used: a C8-reversed phase column; constant 23°C; 1.0 mL/min,
detection at 214 nm; solvent A=10% acetonitrile (vol/vol) in
0.1% aqueous trifluoroacetic acid; solvent B=90%
acetonitrile (vol/vol) in 0.1% aqueous trifluoroacetic acid;
linear gradients (0.1 min, 0%B; 45.1 min, 75%B; 50.1 min,
100%B; 55 min 100%B; 57 min, 0%B; 72 min, 0%B). Standards
were prepared by dissolving bulk insulin and bulk aryl
insulin in 0.01 N HC1. The concentration of each standard
was determined by UV spectroscopy. A solution of 1.0 mg/ml
of human insulin in a 1 cm cuvette was assumed to have an
absorbance of 1.05 optical density units at the wavelength
maximum (approximately 276 nm). This corresponds to a molar
extinction coefficient of 6098. Acylated insulins were
assumed to have the same molar extinction coefficient as
human insulin. The solutions calibrated by UV were then
diluted to get standards at 0.220, 0.147, 0.073, and 0.022
mg/mL. The standards were run on HPLC and a standard curve
of area vs. concentration was obtained.
CA 02315300 2000-06-20
WO 99/32116 PC'f/US98/27299
-80-
- The supernatant was analyzed to determine the
total concentration of soluble human insulin and B29-Ns-
hexanoyl-human insulin present in the formulation. To 0.040
mL of the supernatant, were added 0.160 mL of 0.01 N HC1.
The acidified supernatant was analyzed by HPLC, as described
above. The concentration of soluble human insulin and B29-
NE-hexanoyl-human insulin in the supernatant was determined
to be 0.07 mg/mL.
The ratios of B29-Ns-hexanoyl-human insulin and
human insulin in the crystal were determined by sedimenting
an aliquot (0.100 mL) of the formulation using a bench-top
centrifuge, decanting the supernatant, resuspending the
crystals in 0.400 mL of Dulbecco~s phosphate-buffered
saline, recentrifuging, removing the supernatant, and
finally dissolving the crystals in 1.50 mL of 0.01 N HC1.
The HPLC analysis described above was performed. The result
of this analysis was 84.2% B29-Ns-hexanoyl-human insulin and
15.8% human insulin.
Preparation 14
Co-crystal suspension formulatioa comprisiag humaa iasulia
and H29-NE-decaaoyl-humaa insulia
An acidic solution of B29-N8-decanoyl-human
insulin was prepared by dissolving 10.4 mg of B29-NE-
decanoyl-human insulin in 0.25 mL of 0.1 N HC1. An acidic
solution of human insulin was prepared by dissolving 30.3 mg
of human insulin (zinc crystals) in 0.75 mL of 0.1 N HC1.
The two solutions were combined, giving a total volume of 1
mL. This resulting solution was stirred for approximately 5
minutes. To this solution was added, with stirring, 0.305
mL of a 1000 ppm zinc(II) solution. To the resulting
solution, was added 4 mL of a crystallization diluent (40
mg/mL glycerol, 50 mM tris buffer, 4 mg/mL m-cresol, 1.625
mg/mL phenol, 100 mM trisodium citrate, pH 7.4). The pH of
the resulting solution was adjusted to 7.58. This solution
was filtered through a 0.22 micron, low protein binding
filter. Five milliliters (5 mL) of protamine solution (37.6
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-81-
mg of protamine sulfate in 50 mL of water) was added to 5 mL
of the filtered solution. The resulting solution was
allowed to stand undisturbed for 63 hours at a controlled
temperature of 25°C.
Microscopic inspection (at 63 hours) revealed that
crystallization had occurred, and that the preparation had
yielded uniform, single, rod-like crystals possessing
approximate average lengths of 8 microns.
The dissolution rate of the crystals was measured
by placing 0.006 mL of the uniformly suspended crystal
formulation into 3 mL of Dulbecco~s phosphate buffered
saline (without calcium or magnesium) in a 1 cm path length
square quartz cuvette at a temperature of 22°C. The time
required for the 0.006 mL of this crystal formulation to
dissolve was greater than 300 minutes. The time required
for a 0.005 mL sample of U100 commercial Humulin N to
dissolve under the same conditions was about l0 minutes.
To prepare for HPLC analysis, the crystals were
sedimented by allowing the formulation to stand undisturbed.
Eight milliliters (8 mL) of the supernatant were then
removed, and were replaced with 8 mL of a diluent [16 mg/mL
glycerol, 20 mM tris buffer, 1.6 mg/mL m-cresol, 0.65 mg/mL
phenol, 40 mM trisodium citrate, pH 7.6]. The co-crystals
were then resuspended. This procedure was carried out in
the same way three times, except that on the third occasion,
the 8 mL of supernatant was replaced with 7 mL of diluent.
Potency of the crystal formulation, and in the
supernatant, was analyzed by HPLC, essentially as described
in Preparation 13. The total potency determined from this
analysis was 3.87 mg/mL. The concentration of soluble human
insulin and B29-Ns-decanoyl-human insulin in the supernatant
was determined to be 0.06 mg/mL. The proportions of human
insulin and B29-NE-decanoyl-human insulin in the crystal
phase were determined by the procedure of Preparation 13 to
be 74.3% human insulin, and 25.7% B29-NE-decanoyl-human
insulin.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-82-
A particle sizing measurement was performed on a
sample of the formulation utilizing a particle sizing
instrument (Multisizer Model IIE, Coulter Corp., Miami, FL
33116-9015). To perform this measurement, 0.25 mL of the
crystal formulation was added to 100 mL of a diluent
consisting 14 mM dibasic sodium phosphate, 16 mM glycerol,
1.6 mg/mL m-cresol, 0.65 mg/mL phenol, pH 7.4. The
instrument aperture tube orifice size was 50 microns.
Particle size data was collected for 50 seconds. This
measurement showed that the mean particle diameter of the
crystals was approximately 6 microns with an approximately
normal distribution encompassing a range of particle sizes
from approximately 2 microns to approximately 9 microns.
This result is similar to the particle size distribution of
commercial NPH determined using an analogous method
[DeFelippis, M. R., et al. J. Pharmaceut. Sci. 87:170-176
(1998) ] .
Pre aratioa 15
Co-crystal suspeasioa formulat oa comprisiag humaa iasulin
and 829-Ns-octaaoyl-human insulin
An acidic solution of B29-Ns-octanoyl-human
insulin was prepared by dissolving 30.3 mg of B29-NE-
octanoyl-human insulin in 0.75 mL of 0.1 N HC1. An acidic
solution of human insulin was prepared by dissolving 59.7 mg
of human insulin (zinc crystals) in 1.5 mL of 0.1 N HC1. An
aliquot (0.25 mL) of the human insulin solution was combined
with the 0.75 mL B29-NE-octanoyl-human insulin solution,
giving a total volume of 1 mL, which was stirred for
approximately 5 minutes. To this was added, with stirring,
0.365 mL of a 1000 ppm zinc(II) solution. To the insulin
plus zinc solution was added 4 mL of crystallization diluent
(40 mg/mL glycerol, 35 mM sodium phosphate dibasic buffer, 4
mg/mL m-cresol, 1.625 mg/mL phenol, 15 mM trisodium citrate,
pH 7.4). The pH of the resulting solution was adjusted to
7.60. The solution was filtered through a 0.22 micron, low
protein binding filter. Five milliliters (5 mL) of
protamine solution (37.9 mg of protamine sulfate in 50 mL of
CA 02315300 2000-06-20
WO 99/3Z! ! 6 PCT/US98/27299
-83-
water) was added to 5 mL of the filtered insulin plus zinc
solution. The resulting solution was allowed to stand
undisturbed for 48 hours at a controlled temperature of
2 5°C .
Microscopic inspection (at 48 hours) revealed that
crystallization had occurred and that the preparation had
yielded uniform, single, rod-like crystals possessing
approximate average lengths of 5 microns.
To prepare for HPLC analysis and dissolution
testing, the crystals were sedimented by allowing the
formulation to stand undisturbed. Eight milliliters (8 mL)
of the supernatant were then removed and replaced with 8 mL
of a diluent [16 mg/mL glycerol, 14 mM sodium phosphate
dibasic buffer, 1.6 mg/mL m-cresol, 0.65 mg/mL phenol, 6 mM
trisodium citrate, pH 7.6J. The crystals were then
resuspended. This procedure was carried out in the same way
three times, except that on the third occasion the 8 mL of
supernatant was replaced with 7 mL of diluent.
The dissolution rate was determined essentially as
described in Preparation 13, above. The approximate time
required for 0.005 mL of the present formulation to dissolve
was more than 300 minutes. The time required for a 0.005 mL
sample of U100 commercial Humulin N to dissolve under the
same conditions was about 10 minutes.
Total potency, and potency in the supernatant,
were determined by HPLC, essentially as described in
Preparation 13. The total potency was 3.44 mg/mL. The
concentration of soluble human insulin and B29-Ns-octanoyl-
human insulin in the crystal formulation was determined to
be 0.01 mg/mL. The proportions of human insulin and B29-Ns-
octanoyl-human insulin in the crystal phase were determined,
essentially by the procedure of Preparation 13, to be 25.5%
human insulin, and 74.5% B29-Ns-octanoyl-human insulin.
The mean particle diameter of the crystals,
determined as described in Preparation 14, was approximately
6 microns, with an approximately normal distribution,
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-84-
' encompassing a range of particle sizes from approximately 2
microns to approximately 12 microns. This result is similar
to the particle size distribution of commercial NPH as
reported in DeFelippis, M. R., et al. supra.
pre aratioa 16
Three co-crystal formulat oas compared arith as iasulia
formulation
An acidic solution of B29-NE-octanoyl-human
insulin was prepared by dissolving 24.18 mg of B29-Ns-
octanoyl-human insulin in 0.6 mL of 0.1 N HC1. An acidic
solution of human insulin was prepared by dissolving 41.1 mg
of human insulin (as zinc crystals) in 1 mL of 0.1 N HC1.
Four 0.4 mL solutions were prepared by combining different
volumes of the B29-NE-octanoyl-human insulin and human
insulin solutions as indicated below in Table 4.
Table 4. Preparation of formulations of microcrystals
Formulation
D C B A
Nominal Mass Percent of B29-Ns- 75 50 25 0
octanoyl-human insulin
Volume of B29-Ns-octanoyl-human 300 200 100 0
insulin solution added (~.L)
Volume of human insulin solution 100 200 300 400
added ( ~,L )
To each of the four 0.4 mL solutions, 0.15 mL of a
1000 ppm zinc(II) solution was added. To each of the four
0.55 mL solutions, 1.6 mL of a crystallization diluent (50
mM tris buffer, 10 mg/mL phenol, 100 mM trisodium citrate,
with a pH of 7.6) were added. Each of the four solutions
was adjusted to pH 7.6 with small quantities of 1 N NaOH and
0.1 N HC1. Each solution was filtered through a 0.22
micron, low protein binding filter. Two milliliters (2 mL)
of each of the four protein solutions were combined with 2
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-85-
mL of protamine solution (7.34 mg of protamine sulfate in 10
mL of water). In each case, a precipitate formed
immediately. These four 4 mL suspensions were allowed to
stand undisturbed at room temperature (approximately 22°C)
for 16 hours.
Microscopic inspection (at 16 hours) revealed that
each of the four preparations had yielded uniform, single,
rod-like crystals with approximate average lengths of about
microns.
10 Each 4 mL formulation was transferred to a test
tube and centrifuged in a bench-top centrifuge at 3000 rpm
for 20 minutes to fully sediment the crystals. For each
formulation, 3 mL of the supernatant were removed and
replaced with 3 mL of a diluent (25 mM tris buffer, 5 mg/mL
phenol, 16 mg/mL glycerol, pH 7.4). The crystals were then
resuspended. This procedure was carried out three times
except that on the third occasion the 3 mL of supernatant
was replaced with 2.5 mL of diluent for each formulation.
Each of the four formulations was analyzed by HPLC
to quantitate the total potencies of the formulations and
the compositions of the respective crystals, essentially as
described above. The total potency refers to the total
concentration of human insulin and B29-Ne-octanoyl-human
insulin. The total potency and percentage of B29-NE-
octanoyl-human insulin were determined by analyzing an
aliquot of the uniformly suspended formulation. The
supernatant was analyzed to determine the total
concentration of soluble human insulin and soluble B29-NE-
octanoyl-human insulin present in each formulation. The
results of these analyses are presented below. Dissolution
times were determined as described above in Preparation 13.
r~ormuiation
Table 5. Characteristics of formulations of microcrystals.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7299
-86-
B29-Ns-octanoyl-human 77.7 51.4 23.7 0 -
insulin in crystal (%)
Human insulin in 22.3 48.6 76.3 100 -
crystal (%)
Total potency (mg/mL) 3.21 3.48 3.38 3.43 -
Supernatant potency <0.01 <0.01 <0.01 <0.01 -
(mg/mL)
Dissolution Time (min) 300 120 50 20 10
Pre aratioa 17
Preparation of~ asoluble compositions
The following is an outline of another method that
was used to prepare precipitates and micro-crystals of the
present invention. The outline is to be read together with
the data in Table 6, below.
A measured mass of a derivatized protein, prepared
as described herein, was dissolved in 0.6 mL of 0.1 N HC1.
A measured mass of a protein was dissolved in 0.2 mL of 0.1
N HC1 (zinc crystals of human insulin or LysB28,Pro29-human
insulin analog). The two solutions were thoroughly mixed
together by stirring for five to ten minutes. A volume
(0.32 mL) of an aqueous solution containing 1000 ppm Zn(II)
and a volume (3.2 mL) of a diluent solution (about 50 mM
Tris reagent, about 10 mg/ mL phenol, about 16 mg/mL
glycerol, and about 29.5 mg/mL trisodium citrate) were added
to the mixture of the two proteins. The pH of the resulting
solution was adjusted to about 7.6 (7.55-7.64) using 1 N HC1
or 1 N NaOH. The pH-adjusted solution was filtered through
a 0.22 micron, low-protein binding filter. To four
milliliters of the filtrate was added four milliliters of a
solution of protamine in water (about 37.3 mg protamine
sulfate per 100 mL, range 37.18-37.48). Precipitate formed
immediately upon adding the protamine solution. The
preparation was allowed to stand undisturbed at 25°C.
Dissolution tests were carried out as previously described.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
_87_
- Under the same conditions, insulin NPH dissolved in about 6
minutes.
Table 6. Preparation of insoluble compositions.
Protein Lys(B28),Pro(B29)-human
insulin
analog
ro a n mass
(mg) 4.28 4.02 3.84 3.96 4.15
Lerivatizea B2g-ac
protein lated-human
insulin
y
~ermatizmg butano
rou 1 pentanoylhexanoyl nonanoyl decanoyl
Y
g
p
yerivatizea 11.90 12.1 12.08 12.13 12.20
protein mass
(mg)
Crystal shaperod-like rod-like rod-like rod-like rod-like
Yield (%) >80 >90 >90 >90 >90
~ermatizea 77.5 75.1. 77 76,5 76.6
protein in
insoluble
phase (%)
mssoiution 23-24 31 54 67 37-38
time (min)
Protein human
insulin
.ro a n mass 12.09 12.18 12.12 12.21 12.27
(mg)
Derivatized B28-acylated- A1, B28-diacylated-
protein Lys(B28),Pro(B29)-human Lys(B28),Pro(B29)-
insulin human
analog insulin
vermatiz~.ng butanoyl hexanoyl octanoyl di- di-
group
butanoyl hexanoyl
~ermatizect 4,39 4.21 4.28 4.11 4.23
protein mass
(mg)
Crystal shaperod-like rod-like rod-like rod-like rod-like
Yield (%) >80 >90 >90 >90 >90
r~ermatizea 27,6 25 27 26.8 24.1
protein in
insoluble
phase (%)
~zssolution 16-17 10-11 27-28 10-11 20-21
time (min)
- - -.
Protein human
insulin
Protein mass 4,26 4.26 4.13 4.23 12.09
(mg)
~erip~to~ein B29-acylated-human
insulin
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
_88_
Derivatizing butanoyl pentanoylhexanoyl nonanoyl tetra-
group decanoyl
~ermatizea 12.39 12.39 12:03 12.06 4.16
protein mass
(mg)
Crystal shaperod-like rod-like rod-like rod-like rod-like
Yield (%) >90 72 >90 >90 >90
~erivatizea 76,3 76.5 75 72.5 25.07
protein in
insoluble
phase (%)
mssotution 45-46 62-63 77-78 77-78 61
time (min)
Protein human insulin
ro a n mass
12
19
(mg) .
yerivatizea
protein B29-acylated-human insulin
~ermatizmg h~-decano 1
group
uerivatizea
3
99
protein mass '
(mg)
Crystal shape rod-like
Yield (%) >90
uerivatizea 24
7
protein in .
insoluble
phase (%)
Dissolution 71-72
time (min)
The following is an outline of another method that
was used to prepare precipitates and micro-crystals of the
present invention. The outline is to be read together with
the data in Table 7, below.
A measured mass of a derivatized protein, prepared
as described herein, was dissolved in 3.2 mL of diluent
solution (about 50 mM Tris reagent, about 10 mg/ mL phenol,
about 16 mg/mL glycerol, and about 29.5 mg/mL trisodium
citrate). A measured mass of a protein was dissolved in 0.6
mL of 0.1 N HC1 (zinc crystals of human insulin or
Lys828,Pro29-human insulin analog). The two solutions were
thoroughly mixed together by stirring for five to ten
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-89-
minutes. The pH of the resulting solution was adjusted to
about 7.6 (7.55-7.64) using 1 N HC1 or 1 N NaOH. The pH-
adjusted solution was filtered through a 0.22 micron, low-
protein binding filter. To a volume of the filtrate was
added an equal volume of a solution of protamine in water
(about 37.3 mg protamine sulfate per 100 mL, range 37.18-
37.48). Precipitate formed immediately upon adding the
protamine solution. The preparation was allowed to stand
undisturbed at 25°C. Dissolution tests were carried out as
previously described. Under the same conditions, insulin
NPH dissolved in about 6 minutes.
Table 7. Preparation of insoluble compositions.
Protein human
insulin
ro a n mass . . . .
(mg)
~er~vat~zea 1~1,Ba9-aiacyt-human , -a
irisu Lii a!. lfi7 liYi-
n
i
Protein diacyl- AspB28
LysB28, human
ProB29 insulin
hu~n analog
insulin
~erivaLizing ai- ai- w.- ai- octanoy
group octanoyl nonanoyl decanoyl octanoyl
eriva ze
protein masB
(mg)
rys a s pe ro - i r a ro - i r a ro - a
a a
ie >~ > > > >
~ermacizea ls.i i4.6 Z6.6 27.4 ~4.
protein in
insoluble
phase ('t)
~1B801llLlon 73-74 l5 31-32 47-48 4 -
time (min)
The following is an outline of another method that
was used to prepare precipitates and micro-crystals of the
present invention. The outline is to be read together with
the data in Table 8, below.
A measured mass of a derivatized protein, prepared
as described herein, was dissolved in a measured volume of
0.1 N HC1. A measured mass of a protein was dissolved in a
measured volume of 0.1 N HC1 (zinc crystals of human insulin
or LysB28,Pro29-human insulin analog). Measured volumes of
CA 02315300 2000-06-20
WO 99/32116 PCT/US98I27299
-90-
- each of the two solutions were thoroughly mixed together by
stirring for five to ten minutes. Measured volumes of an
aqueous solution containing 1000 ppm Zn(II) and of a diluent
solution (about 50 mM Tris reagent, about 10 mg/ mL phenol,
about 32 mg/mL glycerol, and about 30 mg/mL trisodium
citrate dihydrate, pH 8.47) were added to the mixture of the
two proteins. The pH of the resulting solution was adjusted
to about 7.6 (7.58-7.63) using 1 N HC1 or 1 N NaOH. The pH-
adjusted solution was filtered through a 0.22 micron, low-
protein binding filter. To two milliliters of the filtrate
was added two milliliters of a solution of protamine in
water (about 37.5 mg protamine sulfate per 10o mL).
Precipitate formed immediately upon adding the protamine
solution. The preparation was allowed to stand undisturbed
at 25°C. Dissolution tests were carried out as previously
described. Under the same conditions, insulin NPH dissolved
in about 6 minutes.
Table 8. Preparation of insoluble compositions.
Protein human insulin
Protein mass 11.3 11.3 33..6 33.6 16.5
(mg)
o ume o 0,57 0.57 1.68 1.68 0.83
N HC1
~erivatizea g2g-acylated-human insulin
protein
Derivatizing 2_methy- 2-ethyl-4-methyl- 3-methyl-do-
group hoyl hexanoyloctanoyl decanoyl decanoyl
uerivatizea
protein mass 6.07 6.3 6.12 2.12 6.3
(mg)
volume oz -
o.i 03 0.3 0.3 0.1 0.3
N HCl
mL of protein0.10 + 0.10 0.10 + 0.30 + 0.10 +
+
solution 0.30 0.30 0.30 0.10 0.30
combined with
mL of
derivatized
protein
solution
mL 1000 ppm 0.152 0.152 0.112 0.096 0.152
zinc
mL diluent 1.6 1.6 1.6 1.6 1.6
CA 02315300 2000-06-20
WO 99/32116 PCTNS98/2~299
-91-
a a
Crystal shaperod-like rod-like rod-like rod-like small-
irregular
Yield (%) >90 >90 >80
r~ermaL i
zea 74.1 75.5 81.9
protein in
insoluble
phase (%)
uissoiuzion 116 236 40
time (min)
Protein human insulin
ro em mass 22.3 22.3 22.3 22.3
(mg)
volume oL 1,12 1.12 1.12 1.12
0.1
N HC1
~ermam zea B29- B29- B29- H29-
protein
acylated- acylated- acylated- acylated
rabbit pork sheep beef
insulin insulin insulin insulin
Uerivatiza.ngoctanoyl octanoyl hexanoyl hexanoyl
group
r~ermauzea 6 , 21 6 6 6 . 21
protein mass . .
07 07
(mg)
volume of 0.3 0.3 0.3 0.3
o.i
N HCl
mL of protein0.1 + 0.3 0.1 0.1 0.1 + 0.3
+ +
0.3 0.3
solution
combined with
mL of
derivatized
protein
solution
mL 1000 ppm 0.152 0.152 0.152 0.152
zinc
mL diluent 1.6 1.6 1.6 1.6
added
Crystal shaperod-like rod-like small- rod-like
irregular
Yield (%) >90 >90 >90 >90
~ermamzea
protein in 74.6 74.7 75.4 75.9
insoluble
phase (%)
mssoluLion 111 >300 227 >300
time (min)
Protein human insulin
'.
ro a n mass 33.6 2.4 22.6
(mg)
CA 02315300 2000-06-20
WO 99/32116 PCT/US98l27299
-92-
- o ume o 1.68 0.1 1.12
N HCl
eriva ze g2g-acylated- B29-acylated B29-acylated-
protein
Gly(A21),Arg(b31human insulin desThr(B30)-
Arg(B32)- human insulin
human insulin analog
analog
verivatizing decanoyl 1,4- octanoyl
group dichlorophenyl-
thio-acetyl
Derivatizea
2.23 5 6
1 06
protein mass . .
(mg)
volume o=
o.i 0.1 0.3 0.3
N Hcl
mL of protein0.3 + 0.1 0.1 + 0.3 0.1 + 0.3
solution
combined with
mL of
derivatized
protein
solution
mL 1000 ppm 0.096 0.152 0.152
zinc
mL dilueat 1.6 ~ 1.6 1.6
added
Crystal shaperod-like small, irregularrod-like
crystals
Yield (%) >90 >90 >90
verivatizen
protein in 20.4 71.8 74.2
insoluble
phase (%)
vissoiuun 63 66 >300
time (min)
2.096 mL of 37.5 mg/100 mL protamine sulfate solution
were added before the diluent was added. The pH was
adjusted after adding the diluent.
Preparatioa 18
Preparatioa og as Amorphous Suspensioa
A measured mass (13.84 mg of protein) of solid
B28-tetradecanoyl-Lys(B28),Pro(B29) human insulin analog was
dissolved in 0.375 mL of 0.1 N HC1. A measured mass of zinc
human insulin (7.40 mg protein) was dissolved in 207
microliters of 0.1 N HCl. An aliquot (125 ~L) of the
insulin solution (containing 4.47 mg of human insulin) was
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7Z99
-93-
- added to the solution of B28-tetradecanoyl-
Lys(B28),Pro(B29)-human insulin analog. A volume (180 N,L)
of 1000 ppm zinc and 2.0 mL of diluent (1.6 mg/mL phenol, 4
mg/mL m-cresol, 40 mg/mL glycerol, 5 mg/mL anhydrous sodium
dibasic phosphate, 7.5 mg/mL trisodium phosphate dihydrate,
pH 7.6) were added. The pH was increased from 5.6 to 8.0
with 100 microliters of 1N NaOH and back to 7.59 with 20
microliters of 1N HC1 and 1N NaOH. The concentration of
B28-tetradecanoyl-Lys(B28),Pro(B29) human insulin analog was
4.94 mg/mL and the human insulin concentration was 1.60
mg/mL. The solution was passed through a 0.22 micron, low-
protein binding filter and refrigerated overnight. The next
morning, the solution had no precipitate present. To 2.50
mL of the solution was added 2.88 mL of a protamine solution
(0.75 mg/mL of solid protamine sulfate dissolved in water).
An amorphous precipitate formed when the protamine was
added.
After adding the protamine, the concentration of
B28-tetradecanoyl-Lys(B28),Pro(B29) human insulin analog and
human insulin in the soluble phase was again determined.
Samples for HPLC analysis were prepared promptly after the
protamine was added. From peak retention times, HPLC
analysis showed that the insoluble material in the
suspension contained protamine, B28-tetradecanoyl-
Lys(B28),Pro(B29) human insulin analog, and human insulin.
The concentration of B28-tetradecanoyl-Lys(B28),Pro(B29)
human insulin analog in the soluble phase was 2.30 mg/mL and
the concentration of human insulin was 0.74 mg/mL.
The concentrations of B28-tetradecanoyl-
Lys(B28),Pro(B29) human insulin analog and human insulin in
acidified samples of the suspension, supernatant, and
precipitate were determined and are tabulated below. They
are in reasonable agreement with expected values. Protamine
concentrations were not quantitated.
Table 9. Preparation of insoluble compositions.
concentration-ass
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-94-
mg ercen
(~k)
amp a a ra ecanoy - uman
Lys(B28),Pro(B29) human insulin
insulin analog
buspension z.si o.~9
supernatant o.ooe o.05~
Precipitate i.zy o.6o
Preparation 19
Preparation of llmorphous Suspensioas
The following is an outline of another method used
for preparing precipitates of the present invention. The
method was used to prepare formulations of amorphous
precipitates of insulin with each of three derivatized
proteins: B29-Ns-octanoyl-human insulin; B29-N8-nonanoyl-
human insulin; and B28-NE-octanoyl-LysB28,ProB29-human
insulin analog.
A measured mass of solid derivatized protein was
dissolved in 3 mL of 0.1 N HC1 to produce a solution
containing approximately 16 mg/mL derivatized protein. A
measured mass of zinc human insulin crystals (73 mg, of
which 67.17 mg was protein) was dissolved in 4.198 mL of 0.1
N HC1 to produce a solution containing approximately 16
mg/mL insulin). Three milliliters of the solution of
derivatized protein and one milliliter of the insulin
solution were combined and thoroughly mixed. Measured
volumes of a 1000 ppm zinc solution (1.137 mL) and of a
diluent (16 mL, containing, per mL: 1.625 mg phenol, 4 mg m-
cresol, 40 mg glycerol, 5 mg anhydrous sodium dibasic
phosphate, 7.5 mg trisodium citrate dehydrate, pH 7.6) were
added. The pH was adjusted to about 7.6 (7.58-7.61) using 5
N NaOH and 5 N HC1 solutions. The volume added during pH
adjustment was from 0.11 to 0.12 mL. The solution was
passed through a 0.22 micron, low-protein binding filter and
refrigerated overnight. The next morning, the solution had
no precipitate present. The solution was comprised of
protein and derivatized protein (approximately a 1:3 mass
CA 02315300 2000-06-20
WO 99/32116 PCT/US98IZ7Z99
-95-
' ratio), and the total protein concentration was equivalent
to about 85 units per milliliter. Just prior to testing in
rats, equal volumes of the solution and of a solution of
protamine sulfate (0.352 mg/mL) were combined and mixed
thoroughly. An amorphous precipitate formed immediately. A
sample of the suspension formulation containing the
amorphous precipitate was promptly injected into test
animals. After mixing with protamine, the concentration of
total protein was about 42.4 units/ml.
preparation ZO
aly (A21) ~ alrg (B31) , Arg (832 ) -Human Insulin Analog
Gly(A21)Arg(B31)Arg(B32)-human insulin was
obtained from an E. coli fermentation in which a Gly(A21)-
human proinsulin precursor molecule was overexpressed into
inclusion bodies. A portion (94.7 g) of inclusion bodies
was solubilized in 500 mL of 6 M guanidine hydrochloride
containing 0.1 M TRIS, 0.27 M sodium sulfite, and 0.1 M
sodium tetrathionate, pH 10.5 at room temperature. The pH
was quickly lowered to 8.8 with 12 N HC1. After vigorously
stirring in an open container for 45 minutes the pH was
lowered to 2.1 with phosphoric acid and the sample
centrifuged overnight at 4°C. The supernatant was decanted
and stored at 4°C for additional processing. The pellet was
re-extracted with 200 mL of additional pH 10.5 solution (see
above) and then centrifuged for 3 hours at 4°C. This and
the previously obtained supernatant were each diluted 4X
with 100 mM sodium phosphate, pH 4, precipitating the
product and other acidic components. After allowing the
precipitate to settle, most of the supernatant was decanted
and discarded. The resulting suspension was centrifuged,
followed by decanting and discarding of additional
supernatant, leaving wet pellets of the crude Gly(A21)-human
proinsulin S-sulfonate precursor. The pellets were
solubilized in 1.5 liters of 7 M deionized urea, adjusting
the pH to 8 with 5 N NaOH and stirring over several hours at
4°C. Salt (NaCl) was then added to achieve 1 M
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-96-
- concentration and the sample was loaded onto a XAD-7 column
(14 cm X 20 cm, Toso-Haas, Montgomeryville, PA), previously
flushed with 50% acetonitrile/50% 50 mM ammonium
bicarbonate, 10% acetonitrile/90% 50 mM ammonium
bicarbonate, and finally with 7 M deionized urea/1M NaCl/20
mM TRIS, pH 8. Once loaded, the column was pumped with 4.5
liters of a 7 M deionized urea/1 M NaCl/20 mM TRIS, pH 8
solution, followed by 2.8 liters of 50 mM ammonium
bicarbonate/1 M NaCl, and 6.5 liters of 50 mM ammonium
bicarbonate. The column was eluted with a linear gradient
of acetonitrile in 50 mM ammonium bicarbonate, while
monitoring .the eluant by W at 280 nm. The peak of
interest, partially purified Gly(A21)-human proinsulin S-
sulfonate precursor, was collected, lyophilized, and
subjected to a folding/disulfide bond procedure as follows.
A quantity (5.4 g) of the precursor was dissolved in 3
liters of 20 mM glycine, pH 10.5, 4°C. Then, 15 mL of 240
mM cysteine HC1 were added with stirring, while maintaining
the pH at 10.5 and the temperature at 4°C. The reaction
solution was stirred gently at 4°C for 27 hours and then
quenched by lowering the pH to 3.1 with phosphoric acid.
Acetonitrile (155 mL) was added, and the solution was then
loaded onto a 5 x 25 cm C4 reversed-phase column previously
pumped with 60% acetonitrile/40% water/0.1% TFA and
equilibrated in 10% acetonitrile/90% water/0.1% TFA. Once
loaded the column was pumped with 1 liter of 17.5%
acetonitrile/82.5% water/0.1% TFA, then eluted with a linear
gradient of acetonitrile in 0.1% TFA while monitoring at 280
nm. Selected fractions were pooled and lyophilized with a
recovery of 714 mg. For conversion of the proinsulin
precursor to the desired insulin analog, 697 mg of the
Gly(A21) human proinsulin precursor were dissolved in 70 mL
50 mM ammonium bicarbonate, then chilled to 4°C, pH 8.3. A
volume (0.14 mL) of a 1 mg/mL solution of pork trypsin
(Sigma Chemical Company, St. Louis, Mo) in 0.01 N HC1 was
added to the sample solution which was stirred gently at 4°C
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
_97_
- for about 24 hours. An additional 0.14 mL of the trypsin
solution was added to the reaction solution which was then
stirred for an additional 21 hours, 45 minutes. The
reaction was quenched by lowering the pH to 3.2 with 0.7 mL
glacial acetic acid and 0.3 mL phosphoric acid. The
quenched Gly(A21)Arg(B31)Arg(B32)-human insulin sample
solution from the tryptic cleavage reaction was diluted 4X
with 30% acetonitrile/70% 50 mM acetic acid, pH 3.1, and
loaded onto a 1 x 30 cm S HyperD F (Biosepra, Marlborough,
MA) cation exchange column previously pumped with 30%
acetonitrile/70% 50 mM acetic acid/500 mM NaCl, pH 3.3, and
equilibrated in 30% acetonitrile/70% 50 mM acetic acid.
Once loaded the column was pumped with about 50 mL of 30%
acetonitrile/70% 50 mM acetic acid, then eluted with a
linear gradient of NaCl in 30% acetonitrile/50 mM acetic
acid while monitoring the eluant at 276 nm. Selected
fractions containing the Gly(A21)Arg(B31)Arg(B32)-human
insulin were pooled, diluted 3X with purified water and
loaded onto a 2.2 x 25 cm C4 reversed-phase column (Vydac,
Hesperia, CA) previously pumped with 60% acetonitrile/40%
water/0.1% TFA, then 10% acetonitrile/90% water/0.1% TFA.
Once loaded, the column was pumped with about 200 mL of 10%
acetonitrile/90% water/0.1% TFA, then eluted with a linear
gradient of acetonitrile in 0.1% TFA. Selected fractions
were pooled and lyophilized giving a recovery of 101 mg.
Analytical HPLC revealed a purity of greater that 95% main
peak. Electrospray mass spectroscopy (ESMS) analysis of the
purified protein yielded a molecular weight of 6062.9
(6063.0, theory).
Preparatioa al
Des(830)-humaa iasulia
Des(B30)-human insulin was prepared from human
proinsulin by controlled tryptic hydrolysis. A mass (2 g)
of human proinsulin biosynthesized in recombinant E. coli
and purified by conventional methods [Frank, B. H., et al.,
in PEPTIDES: Synthesis-Structure-Function. Proceedings of
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
_98_
the Seventh American Peptide Symposium, Rich, D. H. and
Gross, E. (Eds.), Pierce Chemical Company, Rockford, pp.
729-738, 1981; also, Frank, B. H., U. S. Patent No.
4,430,266, issued 7 February 1984, each of which is
incorporated by reference] were dissolved in 400 mL of 0.1
M, pH 7.5 HEPES buffer. After addition of 8 mL of 1 M CaCl2
(in water) and pH adjustment to 7.5 with 5 N NaOH, 2 mL of a
mg/mL solution of pork trypsin (Sigma) in 0.01 N HC1 were
transferred to the sample solution while gently stirring.
10 The reaction solution was allowed to stir at ambient
temperature for 2 hours and 42 minutes, at which time it was
transferred to a 37°C environment while stirring
occasionally. After 1 hour and 45 minutes at 37°C the
enzymatic reaction was quenched by lowering the pH to 3.0
with phosphoric acid and the temperature to 4°C for storage.
Subsequently, the solution was brought to room temperature
and diluted with 50 mL acetonitrile, then to a final volume
of 500 mL with purified water, then loaded onto a 2.5 x 58
cm CG-161 (Toso-Haas) column previously pumped with 1 c.v.
(column volume) of 40% acetonitrile/60% 0.1 M ammonium
sulfate, pH 2.5, and 2 c.v. of 10% acetonitrile/90% 0.1 M
ammonium sulfate, pH 2.5. Once loaded, the column was
pumped with 1 c.v. of 10% acetonitrile/90% 0.1 M ammonium
sulfate, pH 2.5. The column was eluted with a linear
gradient of acetonitrile in 0.1 M ammonium sulfate, pH 2.5,
while monitoring the eluant at 276 nm. The peak of
interest, partially purified des(B30)-human insulin, was
collected by pooling selected fractions. This pooled sample
of partially purified des(B30)-human insulin was diluted to
1.28 liters with purified water, pH 3.5, and applied to a 1
x 29 cm S HyperD F (Biosepra) cation exchange column
previously pumped with 1 c.v. of 30% acetonitrile/70% 0.1%
TFA/0.5 M NaCl, pH 1.9, and 2 c.v. of 30% acetonitrile/70%
0.1% TFA, pH 2.3. Once loaded the column was pumped with 1
c.v. 30% acetonitrile/70% 0.1% TFA, pH 2.3, then eluted with
a linear gradient of NaCl in 30% acetonitrile/70% 0.1% TFA,
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-99_
- pH 1.9 to 2.3, while monitoring the eluant at 276 nm.
Selected fractions containing the purified des(830)-human
insulin were pooled, diluted 2.5X with purified water and
loaded onto a 35-c.c. C8 SepPak (Waters, Milford, MA)
previously cleaned and primed with 2 c.v. of acetonitrile,
2 c.v. of 60% acetonitrile/40% 0.1% TFA, and 2 c.v. of 10%
acetonitrile/90% 0.1% TFA. Once loaded the SepPak was
flushed with 3 c.v. of 10% acetonitrile/90% 0.1% TFA and
then eluted with 2 c.v. of 60% acetonitrile/40% 0.1% TFA.
The lyophilized eluant yielded 500 mg. An analytical HPLC
assay suggested greater than 95% main peak. Electrospray
mass spectroscopy (ESMS) analysis of the purified protein
yielded a molecular weight of 5706.5 (5707, theory).
Preparation Za
Rabbit Iasulin
Rabbit insulin was prepared as described in
Chance, R. E., et al. [Proinsulin, Insulin, C-Peptide, Baba,
S., et a1. (Eds.), Excerpta Medica, Amsterdam-Oxford, pp.
99-105 (1979) ] .
Prepsratioa a3
Asp(H28)-8umaa Iasulia Aaalog
Asp(B28)-human insulin was prepared and purified
essentially according to the teaching of examples 31 and 32
of Chance, R. E., et a1. (U. S. Patent No. 5,700,662, issued
23 December 1997) which is expressly incorporated herein by
reference. Des(B23-30)-human insulin [Bromer, W. W. and
Chance, R. E., Biochim. Biophys. Acta, 133:219-223 (1967),
which is incorporated herein by reference] and a synthetic
octapeptide Gly-Phe-Phe-Tyr-Thr-Asp-Lys(Tfa)-Thr were
condensed using trypsin-assisted semisynthesis, purified by
gel filtration and reversed-phased HPLC, treated with 15%
ammonium hydroxide (v/v) for four hours at ambient
temperature to remove the trifluoroacetate (Tfa) blocking
group from Lys(B29), purified by reversed-phase HPLC, and
lyophilized.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98lZ7299
-100-
pre aratioa a4
Syntheses of der vatized proteins
The following is an outline of the syntheses of
certain derivatized proteins used to prepare the
precipitates and microcrystals of the present invention.
The outline is to be read together with the data in Table
10, below.
A measured mass of purified insulin or of an
insulin analog was dissolved in a measured volume of
dimethylsulfoxide (DMSO) with stirring. Then, a measured
volume of tetramethylguanidine hydrochloride (TMG) was added
and the solution mixed thoroughly. In a separate container,
a measured mass of an N-acyl-succinimide (NAS) was dissolved
in a measured volume of DMSO. A measured volume of the
second solution was added to the first solution. The
reaction was carried out at room temperature, and the
progress of the reaction was monitored by analyzing samples
of the reaction mixture using HPLC. The reaction was
quenched by adding a measured volume of ethanolamine, and
then acidifying to pH 2-3.
The reaction mixture was then subjected to
purification using reversed-phase chromatography alone, or
using a combination of cation exchange chromatography
followed by reversed-phase chromatography. The reversed-
phase purification was carried out using an FPLC system
(Pharmacia) with W detection at 214 nm or at 280 nm, a
fraction collector, 2.2 x 25 cm or 5 x 30 cm C18 column, 2.5
or 5 mL/min flow rate, at room temperature. The liquid
phases were mixtures of Solution A [0.1% trifluroacetic acid
(TFA) in 10:90 acetonitrile:water (vol:vol)] and Solution B
[0.1% trifluroacetic acid (TFA) in 70:30 acetonitrile:water
(vol:vol)] appropriate to elute and separate the species of
interest. Typically, the column was equilibrated and loaded
while in 100% Solution A. Then, a linear gradient to some
proportion of Solution B was used to separate the reaction
products adequately. Fractions containing product were
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-101-
- pooled. The development of purification methods is within
the skill of the art.
Table 10 below provides experimental data,
according to the outline above, for the synthesis of the
derivatized proteins that were used to prepare various
embodiments of the present invention. The starting proteins
were prepared as described above, or according to
conventional methods. Conventional purification was used to
provide highly purified starting proteins for the syntheses
described below. The synthesis of insulin, insulin analogs,
and proinsulin is within the skill of the art, and may be
accomplished using recombinant expression, semisythesis, or
solid phase synthesis followed by chain combination. The
purification of synthesized proteins to a purity adequate to
prepare the derivatives used in the present invention is,
carried out by conventional purification techniques.
Molecular weight of the purified derivatives was
confirmed by mass spectrometry via electrospray mass
analysis (ESMS). Assignment of the acylation site was based
either on a chromatographic analysis ("HPLC"), or on an N-
terminal analysis ("N-terminal"), or both.
Table 10. Summary of synthesis of various derivatized
proteins.
ar ng pro em uman nsu~in human ~nsumn human ~nsuiin
pro a n mass mg . ,'
__
. Z5:9
acy c in n- exanoy n-oc ahoy n-aoaecanoyl
ss o mg
o ume o . .
o ume o . ~_ . .
solution added (mL)
eac on ime ma,n
Ethanotamine volumecu
(NL)
o a yie
o . . eory
o .
r y
cy a on si a a E E
( HPLC)
cy a on s e- NE Ne Ne
(N-terminal)
ar ng pro em uman insu in uman insu n uman ins in
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7299
-102-
pro a n mass mg y
TMCi y,tL) 91 . y g41 443
acy chain n- n- a yry n- a oy
tetradecanoyl
ass o mg . .
o ume o a .v . .
o ume o o. . ,
solution added
(mL)
eac on ame man
estnanoiamane volume5
( EtL )
o a yae
o . . eory o s. . ,
O . U 8. .
.. .
.
ur y
acytataon sate Ne NE
(HPLC)
Acytataon sate Ns - -
(N-terminal)
* purification involved first reversed-phase HPLC, then
cation exchange HPLC, then reversed-phase HPLC
The following is an outline of the synthesis of
additional derivatized proteins. The outline is to be read
together with the data in Table 11, below, to provide full
synthetic schemes.
A measured mass of purified insulin or of an
insulin analog was dissolved by adding to it a measured
volume of 50 mM boric acid, pH 2.57. A measured volume of
acetonitrile, equal to the volume of boric acid solution,
was then added slowly with stirring. The "solvent" volume
is the sum of the volumes of the boric acid and
acetonitrile. The pH of the solution was adjusted to
between 10.2 and 10.5 using NaOH. In a separate container,
a measured mass of an N-acyl-succinimide ("NAS") was
dissolved in a measured volume of DMSO. A measured volume
of the second solution was added to the first solution. The
reaction was carried out at room temperature, the pH was
maintained above 10.2 as necessary, and the progress of the
reaction was monitored by analyzing samples of the reaction
mixture using HPLC. The reaction was quenched by acidifying
to pH 2-3. The reaction mixture was then subjected to
purification using a reversed-phase chromatography system as
described above.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-103-
Table 11 provides experimental data, according to
the outline above, for the synthesis of the derivatized
proteins that were used to prepare various embodiments of
the present invention. Molecular weight of the purified
derivatives was confirmed by mass spectrometry via
electrospray mass analysis (ESMS). Assignment of the
acylation site was based either on a chromatographic
analysis ("HPLC"), or on an N-terminal analysis ("N-
terminal"), or both.
Table 11. Summary of synthesis of various derivatized
proteins.
ar ing protein human insulW riuman insulinIZUman -insui3n
pro a n massTT" -~l.;'J:T~" ~"6-- ,
8olVeriL l~) ~UU
acy c n n- a yry n-pen ahoy n-oc anoy
ss o -acy -
succinimide (mg)
o ume o
o ume o .y . o.s
solution added
(mL)
eac on me n v
a yie
o . . eory
o .
Y
cy a ion s a E s E
(HPLC)
ar ng pro em omen nsu omen nsu in omen insu
in in
pro a n mass mg , , ,
so ven m
acy c a.n n-nonanoyi--n=do~canoy n-
tetradecanoyl
r2ass of N-acyi- ig5.s iy.y zoz.a
succinimide (mg)
o ume o
o ume o ~ 887 0.771
..
~
(mL)
solution added
eac ion a m n
o a yie
o . . eory y . v.u o s.
o .
r y
cy a on si a Ns Ns E
(HPLC)
ar ing pro ein s eep ee nsu in por insu n
insulin
pro a n mass ,
so ven
acy c n n- exanoy n- exanoy n-oc anoy
ass o -acy -
succinimide (mg)
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-104-
o ume o a
o ume o .
solution added
(mL)
eac on ime mm s
o a y a
o . . eory a .
o . . ms su . . U .y
r y
cy a i on s a NE Ns Ns
(HPLC)
ar ing pro ein -- rya bit 3esCB3-oT=- sp - omen
insulin human insulin insulin
ro ein mass mg ,
o ven _.
acy c in n-oc anoy n-oc anoy n-oc anoy
ass o -aryl-- - ~s : 8 _ ~r3 _.
succinimide (mg)
o ume o a . . .u
o ume o . . o o.
solution added
(mL)
eac on ime n v
o a y a
o . . eory y y.y s
O . . m8 9 U.U
r y ~~-
cy a on s a Ns s E
(HPLC)
-starting protein Gtym, numan insulinc~es($a~)-
Arg831, human insulin
ArgB32-human analog
insulin
analog
ro ein mass mg a . . ~s . s
o ven
acy c n n-oc anoy -me y - n-oc anoy
hexanoyl
MESS OI N-8Cy1- 11.4 -I4J 3.b
succinimide (mg)
o ume o r~
o ume o , . .
solution added
(mL)
eac ion me min U
o a y a
o . . eory sy. y .y
o . . ms . y. s .y
r y y
cy a on s a NE E E
(HPLC) .
* Dissolved in acetonitrile instead of DMSO.
ar ing pro a n omen insu omen nsu in omen insu in
in
ro em mass mg ,uaU
o ven m _~__ __.
acy c n -me y - -me y - ri=oc anoy
octanoyl decanoyl
Mdss OI N-8Cy1- ~/15 1L.5 196.-/
succinimide (mg)
o ume o r~
o ume o
CA 02315300 2000-06-20
WO 99132116 PCT/US981Z7299
-105-
- so a ion a a
sac ion m n U
.o a yie
O . . eOry 9 . 9
O . . m8 y . 9
ri y y
cy a on s a a NE A1=Na, Ne
(HPLC)
* Dissolved in acetonitrile instead of DM80.
** Yield of the A1-Na,B29-NS-diacyl-human insulin derivative
*** Determined by Matrix-Assisted Laser Desorption Ionization (MALDI)
mass spectroscopy instead of electrospray mass spectroscopy
ar mg protein c~esI83~T human msu uman insu m
- m
human insulin
analog
ro em mass mg v . , ,
O Ven UU
acy c n n-oc anoy n-nonanoy -n- ecanoy
ass o -acyt- _~~~ .
succinimide (mg)
o ume o ~ . .u
o ume o U.v o. s .
solution added (mL)
sac ion ime m~.n
o a yie
o . . eory y y. _ .
o . . ms y y. . .
r y __ _
cy a on si a Al- a, s Al- a, Ns A1- a, a
(HPLC)
The following is a general outline of a synthetic
scheme to produce additional derivatized proteins. In a
specific instance, the outline is to be read together with
the data in Table 12, below, to a provide full synthetic
scheme for a particular derivatized protein. A measured
mass of purified insulin or insulin analog was dissolved by
adding to it a measured volume DMSO. The pH of the solution
was adjusted with 10 equivalents of tetramethylguanidine.
In a separate container, a measured mass of an N-acyl-
succinimide {~NAS") was dissolved in a measured volume of
DMSO. A measured volume of the second solution was added to
the first solution to provide a 1.9 fold molar excess of N-
acyl-succinimide. The reaction was carried out at room
temperature and the progress of the reaction was monitored
by analyzing samples of the reaction mixture using HPLC.
The reaction was quenched with 20 microliters of
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-106-
ethanolamine, chilled in ice/water bath and diluted 2.1
times with O.1N HC1. The reaction mixture was then
subjected to desalting on reversed phase chromatography
column using the following protocol: 1) the column was
wetted with 100% acetonitrile, then was washed using three
to four column volumes of 0.1% TFA/70% acetonitrile (Buffer
B); and finally was washed using four to five column volumes
of 0.1% TFA/10% acetonitrile (Buffer A); 2) diluted reaction
mixtures were loaded, and the column was again washed with
five to six column volumes of Buffer A; and 3) the
derivatized protein was eluted by passing five to six column
volumes of Buffer B through the column. The fluid collected
during elution was frozen, then lyophilized. The
lyophilized crude product (86.1 mg) was then subjected to
re-purification using a reversed-phase chromatography system
as described above.
Table 12 provides experimental data, according to
the outline above, for the synthesis of the derivatized
proteins that were used to prepare various embodiments of
the present invention. Molecular weight of the purified
derivatives was confirmed by mass spectrometry via
electrospray mass analysis (ESMS). Assignment of the
acylation site was based either on a chromatographic
analysis (°HPLCp).
Table 12. Summary of ayathesis of various derivatized
proteias.
ar ing pro ein uman nsu in
pro ein mass mg
-
~sv zo aissolve zo
human insulin
(mL )
r~S acyl cnain 1; ~-
dichlorophenylthio-
acetyl
mass o -acy -
succinimide (mg)
-
volume oz asv 1.0
(mL)
volume oz NAS 0.412
solution added
CA 02315300 2000-06-20
WO 99/32116 PCT/US98l27299
-107-
eac ion ime
(min)
o a yie
o . . eory
o .
ri y
Acyiazion site NE
(HPLC)
* Yield ca cu a a ized
ase on a esa a an
yop i
crude product weight.
Experiment l
Time Actioa of Co-crystsl8 is Doga
The time-action of three co-crystal compositions
of the present invention was determined in normal dogs that
received a constant infusion of somatostatin to create a
transient diabetic state. The first co-crystal formulation,
comprising human insulin and B29-Ns-octanoyl-human insulin,
was prepared essentially as described for Formulation D in
Preparation 16 above, and was administered subcutaneously at
a dose of 3 nmol/kg ("8753"). The second co-crystal
formulation, comprising human insulin and B29-Ng-octanoyl-
human insulin, was prepared as described for Formulation D
in Preparation 16 above, and was administered subcutaneously
at a dose of 2.5 nmol/kg ("8752.5"). Finally, a third co-
crystal formulation, comprising human insulin and B29-Ns-
decanoyl-human insulin, was prepared as described in
Preparation 14 above, and was administered subcutaneously at
a dose of 2.5 nmol/kg ("10252.5"). The data were compared
to that observed in the same model after administration of
Humulin N (2.0 nmol/kg "NPH"), Beef/Pork Ultratlente insulin
(3 nmol/kg, "BP-UL"), and saline.
Experiments were conducted in overnight-fasted,
chronically cannulated, conscious male and female beagles
weighing 10-17 kg (Marshall Farms, North Rose, NY). At
least ten days prior to the study, animals were anesthetized
with isoflurane (Anaquest, Madison, WI), and silicone
catheters attached to vascular access ports (V-A-P''M, Access
Technologies, Norfolk Medical, Skokie, IL) were inserted
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-108-
- into the femoral artery and femoral vein. The catheters
were filled with a glycerol/heparin solution (3:1, v/v;
final heparin concentration of 250 KIU/ml; glycerol from
Sigma Chemical Co., St. Louis, MO, and heparin from Elkins-
Sinn, Inc., Cherry Hill, NJ) to prevent catheter occlusion,
and the wounds were closed. Kefzol (Eli Lilly & Co.,
Indianapolis, IN) was administered pre-operatively (20
mg/kg, IV and 20 mg/kg, I.M.), and Reflex was administered
post-operatively (250 mg, p.o. once daily for seven days) to
prevent infections. Torbugesic (1.5 mg/kg, I.M.) was
administered post-operatively to control pain.
Blood was drawn just prior to the study day to
determine the health of the animal. Only animals with
hematocrits above 38% and leukocyte counts below 16,000/mm3
were used (hematology analyzer: Cell-Dyn 900, Sequoia-
Turner, Mountain View, CA).
The morning of the e~eriment, the ports were
accessed (Access Technologies, Norfolk Medical, Skokie, IL);
the contents of the catheters were aspirated; the catheters
were flushed with saline (Baxter Healthcare Corp.,
Deerfield, IL); the dog was placed in a cage; and extension
lines (protected by a stainless steel tether and attached to
a swivel system [Instech Laboratories, Plymouth Meeting,
PA]) were attached to the port access lines.
Dogs were allowed at least 10 minutes to acclimate
to the cage environment before an arterial blood sample was
drawn for determination of fasting insulin, glucose, and
glucagon concentrations (time = -30 minutes). At this time,
a continuous, IV infusion of cyclic somatostatin (0.65
~g/kg/min; BACHEM California, Torrance, CA) was initiated
and continued for the next 30.5 hours. Thirty minutes after
the start of infusion (time = 0 minutes), an arterial blood
sample was drawn, and a subcutaneous bolus of test
substance, or vehicle, was injected in the dorsal aspect of
the neck. Arterial blood samples were taken every 3 hours
thereafter for the determination of plasma glucose and
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/Z7299
-109-
- insulin concentrations and every 6 hours for determination
of plasma glucagon concentrations. The entire study lasted
30 hours.
Arterial blood samples were collected in vacuum
blood collection tubes containing disodium EDTA (Terumo
Medical Corp., Elkton, MD) and immediately placed on ice. A
portion of the blood sample (1.5 ml) was transferred to a
polypropylene tube containing 40 ~l of aprotinin (10,000
KIU/ml; Trasylol, Miles, Inc., Diagnostics Division,
Kankakee, IL) in preparation for the determination of the
plasma glucagon concentration. The samples were
centrifuged, and the resulting plasma was transferred to
polypropylene test tubes and stored on ice for the duration
of the study.
Plasma glucose concentrations were determined the
day of the study using a glucose oxidase with a commercial
glucose analyzer. Samples for other assays were stored at -
80° C until time for analysis. Insulin concentrations were
determined using a double antibody radioimmunoassay.
Glucagon concentrations were determined using a
radioimmunoassay kit (LINGO Research, Inc., St. Charles,
MO ) .
At the conclusion of the experiment, the catheters
were flushed with fresh saline, treated with Kefzol (20
mg/kg), and filled with the glycerol/heparin mixture;
antibiotic (Keflex; 250 mg) was administered p.o. To
minimize the number of animals being used and to allow
pairing of the data base when possible, animals were studied
multiple times. Experiments in animals being restudied were
carried out a minimum of one week apart.
The 1:3 co-crystal of human insulin and B29-NE-
octanoyl-human insulin had a time-action 9 hours longer than
NPH human insulin (24 hours vs. 15 hours) for the higher
dose (8753), and a time-action 6 hours longer than NPH human
insulin (21 hours vs. 15 hours) for the lower dose (8752.5).
The time-action was determined by statistically comparing
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-110-
the mean glucose levels with those of the control group
(saline). The glucose profiles for the 1:3 co-crystal
formulations of human insulin and B29-Ns-octanoyl-human
insulin were more like that expected of a basal insulin than
was the profile for NPH-human insulin. The 1:3 co-crystals
also had greater activity and a more desirable glucose
profile than did Beef/Pork Ultralente insulin. The
reduction in blood glucose, compared with the control
(saline), that the co-crystal formulations caused persisted
longer than that caused by this Beef/Pork Ultralente
insulin.
The 3:1 co-crystal formulation of human insulin
and B29-NE-decanoyl-human insulin (10252.5) had a time-
action 9 hours longer than NPH human insulin (24 hours vs.
15 hours). The difference was significant statistically
(p<0.05). In the same animals, the 3:1 co-crystal
formulation of human insulin and B29-Ns-decanoyl-human
insulin (2.5 nmol/kg, SC) had a time-action 6 hours longer
than either Humulin U or Beef U preparations (24 hours vs.
18 hours). The differences were also significant
statistically (p<0.05). The glucose profile for the co-
crystal formulations was more like that expected of a basal
insulin than was the profile for NPH-human insulin.
Furthermore, the variability in time-action among the dogs
was the least when the 3:1 co-crystal was administered.
In conclusion, these data demonstrate that the co-
crystals of the present invention are effective for
controlling glucose levels for protracted periods of time in
dogs. They also support a conclusion that the co-crystals
of the present invention will be effective for overnight
glucose control of patients with type 2 diabetes or as the
basal arm of basal/bolus insulin therapy for patients with
type 1 or type 2 diabetes. They also suggest that these
preparations may produce less variable responses than
commercially available insulin preparations.
Bacperimeat 2
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-111-
- Time Actioa of Co-crystals fn 8igs
Studies were performed on normal, conscious female
pigs weighing 17-25 kg. An arterial (carotid or femoral)
catheter was surgically pre-implanted for sampling along
with jugular venous lines for the administration of
somatostatin. Prior to experiments, the cannulated pigs
were fasted 22-24 hours. Subcutaneous insulin injections
were given in the soft skin behind the ear at a dosage of
3.0 nmol/kg (0.5 unit/kg). Somatostatin was administered
concurrently at 0.3 ug/kg/min (dissolved in 0.9% NaCl
containing 1% human serum albumin, Miles Canada, Etobicoke,
ON) to suppress endogenous insulin secretion. Near
normoglycemia was maintained by infusing 20% dextrose at a
variable rate, with frequent monitoring of glucose
concentrations. The plasma glucose levels were determined
on fresh plasma samples the day of the study using a glucose
oxidase method with a commercial glucose analyzer.
In a euglycemic clamp study, a formulation of the
present microcrystals comprised of 1:3 insulin:B29-Ne-
octanoyl-human insulin was administered subcutaneously at a
dose of 0.5 U/kg (equivalent to about 3 nmol/kg) at the
start of the study (time 0) to five pigs. The rate of
glucose infusion required to maintain euglycemia (set point
= about 90 mg/dL) was determined continuously. A control
group received Humulin N (U100) by subcutaneous
administration at the same dose (n=6). A concomitant
infusion of somatostatin (0.3 ~g/kg/min) was maintained for
the entire duration of the experiment. For the
microcrystals of the present invention, the glucose infusion
rate increased steadily over the first two hours, reaching a
maximum of about 7 mg/kg/min. From then, until about 17.5
hours, the glucose infusion rate decreased fairly steadily
to about 0.5 mg/kg/min. For most of the time between 17.5
hours and the end of the study at 24 hours, the glucose
infusion rate remained between about 0.5 and about 2
mg/kg/min.
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-17.2-
By contrast, the mean glucose infusion rate in the
control group (Humulin NPH) increased steadily, reaching a
maximum of about 14 mg/kg/min at about 3 hours after
administration. Thereafter, the infusion rate decreased to
about 7 mg/kg/min by about 4.5 hours, and to about 5
mg/kg/min by 13 hours after administration. No further data
were taken for the control group. These results are
consistent with a conclusion that the microcrystalline
formulation comprised of insulin and B29-NE-octanoyl-human
insulin in a 1:3 molar ratio has a flatter glucodynamic
profile than does insulin NPH.
Sxperimeat 3
Time Action of Co-crystals is Rats
A formulation of the present microcrystals
comprised of 1:3 insulin:829-Ns-octanoyl-human insulin was
tested in BBDP/Wor rats, a genetically-characterized animal
model, maintained by, and available from, the University of
Massachusetts Medical Center (Worchester, MA) in connection
with Biomedical Research Models, Inc. (Rutland, MA). The
DPBB/Wor rat line is diabetes-prone, and exhibits insulin-
dependent (autoimmune) diabetes mellitus. All preparations
were administered subcutaneously at a dose of 0.9 U/100 g
body weight.
Male BBDP/Wor rats, aged 4-5 months and maintained
on a long-acting insulin (PZI), were randomly assigned to
five experimental groups, A, B, C, D and E. Group A (n=22)
was treated for three days with a U40 human insulin
ultralente (Humulin UL); group B (n=18) was treated for 3
days with a U40 preparation of Iletin Ultralente (65% beef
insulin, 35% pork insulin); group C (n=10) was treated for
three days with a formulation of microcrystals comprised of
1:3 insulin:B29-Ns-octanoyl-human insulin, prepared as
described above; group D (n=21) was treated with a
formulation of microcrystals comprised of 100% B29-NE-
octanoyl-human insulin; and group E received U40 beef-pork
PZI insulin (PZI). Each rat was given daily injections of
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-113-
- its group's formulation for the two days before blood
glucose was determined, and on the day that the blood
glucose was determined.
Blood was obtained half an hour before
administering the test formulations. Samples of the
formulations were injected at 11:30 A.M. Blood was obtained
by nicking the tail (not anaesthetized). The samples were
stored briefly on ice, then were centrifuged, and glucose
determined using a Beckman II glucose analyzer. Blood
samples were obtained just prior to administering the test
formulations, and at 2, 4, 6, 8, 12, 16, 20, and 24 hours
after administration. Considering adequate control to be
indicated by blood glucose levels less than 200 mg/dL, the
preparations provided about 9.5 hours (Humulin UL), about 12
hours (Iletin U), about 15.5 hours (the present invention),
about 20.5 hours (100% B29-NE-octanoyl-human insulin), and
about 21.5 hours (PZI) of control. Therefore, the
microcrystal formulation of the present invention controlled
blood glucose longer than both Humulin UL and Iletin U and
for a shorter period of time than did either the 100% B29-
Ns-octanoyl-human insulin microcrystal preparation or the
PZI preparation.
>sxperimeat 4
Time 7~ctioas of Amorphous Precipitates is Bats
Formulations of amorphous precipitates comprised
of 1:3 insulin:B29-NE-octanoyl-human insulin, 1:3
insulin:B28-NE-octanoyl-Lys(B28),Pro(B29)-human insulin, and
1:3 insulin:B29-Ns-nonanoyl-human insulin, prepared as
described in Preparation 19, were tested in BBDP/Wor rats.
All preparations were administered subcutaneously at a dose
of 0.9 U/100 g body weight.
Male BBDP/Wor rats, aged 4-5 months and maintained
on a long-acting insulin (PZI), were randomly assigned to
five experimental groups, A, B, C, D, and E. Group A (n=7)
was treated with a preparation of U40 NPH (Humulin N).
Group B (n=8) was treated with a U42.4 preparation of 1:3
CA 02315300 2000-06-20
WO 99/32116 PCT/US98/27299
-114-
insulin:B29-Ne-octanoyl-human insulin. Group C (n=8) was
treated with a U42.6 preparation of 1:3 insulin:B28-Ns-
octanoyl-Lys(B28),Pro(B29)-human insulin. Group D(n=8) was
treated with a U42.7 preparation of 1:3 insulin:B29-N8-
nonanoyl-human insulin. Group E was treated with U40 beef-
pork PZI insulin (PZI).
Blood was obtained half an hour before
administering the test formulations. Animals were injected
subcutaneously (0.9 U/100 g body weight) at 11:30 A.M.
Blood was obtained by nicking the tail (not anaesthetized).
The samples were stored briefly on ice, then centrifuged,
and glucose was determined using a commercial glucose
analyzer. Blood samples were obtained just prior to
administering the test formulations, and at 2, 4, 6, 8, 10,
12, 14, 16, 18, 20, 22, and 24 hours after administration.
Considering adequate control to be indicated by blood
glucose levels less than 200 mg/dL, the preparations
provided about 7.5 hours (1:3 insulin:B28-Ns-octanoyl-
Lys(B28),Pro(B29)-human insulin), about 9 hours (NPH), about
15.5 hours (1:3 insulin:B29-NE-octanoyl-human insulin),
about 16 hours (1:3 insulin:B29-NE-nonanoyl-human insulin)
and about 22.5 hours (PZI) of control.
The principles, preferred embodiments and modes of
operation of the present invention have been described in
the foregoing specification. The invention which is
intended to be protected herein, however, is not to be
construed as limited to the particular forms disclosed,
since they are to be regarded as illustrative rather than
restrictive. Variations and changes may be made by those
skilled in the art without departing from the spirit of the
invention.
